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Summary 
 
Description of technology 
This report reviews the evidence of the clinical and cost-effectiveness of anakinra, an 
interleukin-1 receptor antagonist (IL-1Ra), for the treatment of rheumatoid arthritis in adults. 
Anakinra is licensed in Europe for use in combination with methotrexate, for patients with an 
inadequate response to methotrexate alone. 
 
Anakinra acts in the same way as naturally occurring IL-1Ra, transiently binding to the IL-1 
receptor, augmenting the natural regulation of the pro-inflammatory effects of IL-1. 
 
Epidemiology and background 
RA is a chronic illness characterised by inflammation of the synovial tissues in joints, which 
can lead to joint destruction. Key aims of treatment include: 
• To control symptoms of joint pain and inflammation 
• To minimise loss of function and to maintain or improve quality of life 
• To reduce the risk of joint damage and disability 
• To treat extra-articular complications of RA 
• To have well-informed and satisfied patients and carers  
 
RA affects around 0.5% to 1% of the population with approximately 421,330 patients 
affected in England & Wales.  Prevalence increases with age so that prevalence at age 65 is 
six times the prevalence at age 25.  Peak age of onset is in the sixth decade and RA is more 
common in women by a ratio of 2.5 to 1. 
 
Corticosteroids, NSAIDs and analgesics are used to control symptoms, but early use of 
DMARDs is key, with the aim of slowing disease progression.  There are approximately 8 
DMARDs currently in common use in the UK. Variable effectiveness or loss of effectiveness 
over time, and toxicity hampers their use, with low continuation rates seen over time. New 
DMARDs are therefore of great importance. Several new agents have appeared in recent 
years including the biologic modifiers the TNF inhibitors, infliximab and etanercept.   
 
Number and quality of studies, and direction of evidence 
Five randomised controlled trials of anakinra in adult patients with RA, involving a total of 
2,905 patients, of whom 2,146 received anakinra, were identified. All compared anakinra to 
placebo and all but one presented outcome data at 24 weeks. In three trials anakinra was 
administered in combination with methotrexate/other DMARDs and in two as monotherapy. 
Only two trials evaluated the licensed dose of 100mg daily. 
 
All five trials were identified as high quality.  
 
Summary of benefits 
The results of the clinical trials are consistent with clinical benefit (compared to placebo) as 
measured by ACR composite response rate at 6 months. Variation in response rate was seen 
across the trials which is likely to be a reflection of size of the trials and the wide range of 
doses evaluated. Consistent benefit was seen at the higher dose evaluated (NNT to achieve an 
ACR20 response of 7 [95%CI 5 to 11] at licensed dose).  Benefit was evident with both 
monotherapy and when used in combination with methotrexate.  
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Data on the efficacy endpoints evaluated in a large pragmatic safety study have not been 
made available. This is of concern. Given the nature and scale of this study such data has the 
potential to alter the overall findings of this review. In the absence of data we made an 
educated guess about the result of trial 0757. Assuming that this trial failed to reach 
conventional levels of statistical significance with a p-value of treatment difference of the 
order of p< 0.1 to p<0.2, we derived an estimate of effectiveness for trial 0757. The derived 
estimate has been combined with the data from the earlier trials, using a random effects 
model, to give our best estimate about anakinra’s effectiveness for ACR 20 response: RR 
1.43 (95% CI 1.16 to 1.76), RD 0.11 (95% CI 0.04 to 0.18), NNT 9 (95% CI 6 to 25) 
 
Anakinra can be considered modestly effective in the treatment of RA based on ACR 
response. Reduction in HAQ scores, a measure of disability, were small. Robust data on 
radiologically assessed joint damage is not currently available. No conclusion can therefore 
be made on the effect of treatment on disease progression. 
 
Direct comparisons with other biologic modifiers are not available. Adjusted indirect 
comparison suggests that anakinra may be significantly less effective at relieving the clinical 
signs and symptoms of RA, as measured by the ACR response criteria, than TNF inhibitors 
all used in combination with methotrexate. Such indirect results should of course be 
interpreted with caution but can be useful in guiding clinical practice in the absence of direct 
comparisons between agents. 
 
Anakinra treatment was associated with a high incidence of injection site reactions. Serious 
adverse events were infrequent, but longer term follow up is required. 
 
Economic Evaluation 
 
Existing economic evaluations 
 
• No fully published economic evaluations of anakinra in patients with RA were identified. 
Two abstract reports presented limited data. 
 
Commentary on submitted model 
 
• This is a Markov model with a six month cycle time 
• There are problems associated with the structure of this model which makes its 
conclusion, that the ICER for anakinra is £16,545/QALY, unreliable 
 
Summary of the economic analysis 
 
The Birmingham Rheumatoid Arthritis Model (BRAM) was used to compare DMARD 
sequences of drugs, chosen to reflect current clinical practice, with and without the addition 
of anakinra at different points in the DMARD sequence. 
The BRAM gives a base-case estimate of the ICER of anakinra of between £106,000/QALY 
to £604,000/QALY.   
 
This model uses data from public domain trial results only.  These trials recruited a highly 
selective patient population and may well overestimate the cost-effectiveness that anakinra 
would achieve in an average clinic population. 
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In the sensitivity analyses quite substantial variations were made in key parameters and 
ICERs were shown to be responsive. However, ICERs did not drop below £50,000/QALY in 
any univariate sensitivity analysis. 
 
The BRAM produces an ICER for anakinra substantially higher than those for infliximab and 
etanercept.  However, patients may respond to anakinra when they have not responded to 
other biologics, as these agents have a different mechanism of action.  Thus anakinra may 
produce a clinically significant and important improvement in some patients that they could 
not otherwise have achieved. 
 
Need for further research 
• Current clinical trials with anakinra are of limited duration. RCTs are required to evaluate 
the efficacy, safety and cost of anakinra over the longer term in patients with such a 
chronic disease.  
• Comparative trials of anakinra with other DMARDs and biologic modifiers are required 
to identify the comparative efficacy of these drugs and to guide clinical practice to 
optimise patient care. 
• Trials are required to assess the role of anakinra in the treatment of patients who have 
failed to achieve a benefit whilst taking infliximab or etanercept. 
• Further research is required to assess the impact of DMARDs and anakinra on joint 
replacement, mortality and quality of life.  Also, continued pharmacovigilance and 
analysis of potential adverse effects of new and old DMARDs is essential. 
• Optimal treatment of RA in the future may require combinations of therapeutic 
compounds that inhibit different mediators. Controlled clinical trials of combination 
therapy with two anti-cytokines is required to inform clinical practice, before such an 
approach is widely adopted.  
• Suggestions that newer biologic therapies reduce radiographic damage without 
necessarily improving clinical outcomes need to be confirmed if treatments in the absence 
of a clinical response are to be justified. 
• Further research is needed to improve the utility of radiographic outcomes in clinical 
trials of RA either by building on existing efforts with plain radiographs or through the 
use of newer imaging methods. 
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DEFINITIONS OF TERMS  
 
Severe Adverse Events (SAE) 
An event suggesting significant hazard including fatal or life-threatening events, those 
requiring or prolonging hospitalisation, events resulting in persistent or significant 
disability/incapacity, congenital abnormality or birth defect. 
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1 AIM OF THE REVIEW 
• To provide a background on rheumatoid arthritis including epidemiology, current 
therapeutic options, and impact of disease on individuals and health services.  
• To conduct a systematic review and meta-analysis of the clinical benefits and hazards of 
using anakinra in rheumatoid arthritis. 
• To review the economic evidence about the cost-effectiveness of anakinra compared with 
other treatment options. 
• To describe other agents being developed for the treatment of RA, and outline areas for 
research. 
 
2 BACKGROUND 
2.1 Description of underlying health problem 
2.1.1 Clinical features of rheumatoid arthritis 
 
Rheumatoid arthritis (RA) is a systemic inflammatory disorder that mainly affects synovial 
joints. The pathological hallmarks of RA are an inflammatory reaction, increased cellularity 
of synovial tissue and joint damage. RA is characterised by pain, swelling and stiffness of 
synovial joints.  These symptoms are often worse in the morning and after periods of 
inactivity. RA may also affect other organ systems with a potential for severe disability and 
life-threatening complications.  For example patients may develop lymph node enlargement, 
anaemia, a raised platelet count, pulmonary disease such as pleurisy or interstitial lung 
disease, pericarditis, vascular inflammation (vasculitis), skin nodules, and eye diseases such 
as reduced tear production or inflammation.  Patients commonly also experience lethargy and 
occasionally experience weight loss, and fever.   
 
The severity of disease can be very variable. In a community cohort 18% of RA patients were 
in ‘remission off treatment’ after 3 years follow-up.  By contrast 47% of patients were 
classified as having moderate disability as rated by a Health Assessment Questionnaire 
(HAQ) score of greater than 1.0, and 25% of patients have a joint replaced within 22 years of 
disease onset.1,2  (For details of the HAQ see Appendix 1, page 87).  Symptoms of RA may 
have a rapid onset (overnight in some cases) or evolve over weeks, months or years.3 
Common patterns of disease are: 
1. Disease of small or medium joints particularly metacarpophalangeal (MCP) and proximal 
interphalangeal (PIP) joints of the hands, metatarsophalangeal joints of the feet, wrists 
and ankles.  There may also be variable large joint disease. 
2. Predominantly large joint disease. 
3. Disease involving only a few joints, or sometimes only one joint.   
4. Less common presentations: pain and stiffness affecting the shoulder and hip girdles 
(polymyalgic presentation); systemic symptoms such as weight loss and joint pain 
without a true arthritis; intermittent short-lived attacks of arthritis (‘palindromic 
rheumatism’). 
 
The clinical course of RA and the responses of any one individual to disease are also 
variable.  Pain and disability of early RA is linked to disease severity and to measures of 
psychological distress.4  The course of RA may follow three broad patterns: progressive 
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disease with significant functional limitations in time, intermittent disease (where disease is 
punctuated by partial, or complete, remissions), and disease with long clinical remissions.5  
2.1.2 Diagnosis of rheumatoid arthritis 
 
Rheumatoid arthritis is diagnosed from a constellation of clinical and laboratory or 
radiographic abnormalities.  Diagnosis may be obvious in some but in others it may be more 
difficult and require a period of clinical observation.  Classification criteria for RA have been 
devised to aid research.  Most contemporary research studies of RA include patients who 
satisfy such criteria.  The most recent criteria, formulated by the American Rheumatism 
Association (ARA) in 1987, are shown in Table 1 (page 15).6  These criteria were derived 
from a group of typical patients who had been diagnosed with RA and had well-established 
disease.  They have limited utility in routine practice and most clinicians diagnose RA 
without formal reference to such criteria, with many patients not meeting formal criteria at 
least early in their disease.7;8  Criteria were also developed as an algorithm. These are more 
readily met in clinical practice.9  
 
2.1.3 Radiographic features of rheumatoid arthritis 
 
Early in disease radiographs may show soft tissue swelling and reduced bone density around 
affected joints.  Later there may be evidence of joint damage such as joint erosions. ‘Erosion’ 
refers to focal loss of bone and cartilage that occurs near the joint margin.   More diffuse loss 
of cartilage results in a reduced joint space. As joint damage progresses joint deformity or 
instability may occur and at a late stage bony ankylosis or fusion may occur.  With advanced 
joint damage surgical intervention such as joint replacement arthroplasty, joint fusion or 
osteotomy may be necessary.  At an earlier stage other surgeries such as removal of synovial 
tissues (synovectomy) or soft tissue procedures such as tendon release or repair may be 
necessary. 
 
Anakinra for the treatment of RA- TAR  WMHTAC 
Confidential Page 15 07/04/2003 
Version for website publication 
Table 1: 1987 Revised ARA Criteria for Classification of Rheumatoid Arthritis 
 
Criteria 
 
Definition 
 
Morning stiffness Morning stiffness in and around the joints lasting at least 1 hour 
before maximal improvement 
Arthritis of three or more 
joints 
At least 3 joint areas have simultaneously had soft tissue swelling or 
fluid (not bony overgrowth alone) observed by a physician.  The 14 
possible joint areas are (right or left): PIP, MCP, wrist, elbow, knee, 
ankle and MTP joints. 
Arthritis of hand joints At least one joint area swollen as above in wrist, MCP or PIP joint 
Symmetrical arthritis Simultaneous involvement of the same joint areas on both sides of the 
body (bilateral involvement of PIP, MCP, or MTP joints is acceptable 
without absolute symmetry). 
Rheumatoid nodules Subcutaneous nodules, over a bony prominence, or extensor surface or 
in juxta-articular regions, observed by a physician. 
Serum rheumatoid factor Demonstration of abnormal amounts of serum ‘rheumatoid factor’ by 
any method that has been positive in less than 5% of control subjects. 
Radiographic changes Radiographic changes typical of RA on postero-anterior hand and 
wrist radiographs, which must include erosions or unequivocal bony 
decalcification localised to or most marked adjacent to the involved 
joints (osteoarthritis changes alone do not qualify). 
A patient is said to have RA if he or she satisfies at least 4 of the above 7 criteria.  Criteria 1 through 4 
must be present for at least 6 weeks.  Patients with two clinical diagnoses are not excluded. 
Adapted from Arnett et al (1988)6  
2.1.4 Epidemiology 
 
RA is the most common form of inflammatory arthritis. It affects around 0.5% to 1% of the 
population. Recent estimates from England and Wales show an annual incidence of 31 per 
100,000 women and 13 per 100,000 men and a prevalence of 1.2% in women and 0.4% in 
men.10  Therefore there are approximately 476,170, patients with RA in the UK,  and 421,330 
(309,890 women and 111,440 men) in England & Wales (population 52,041,916).11 This 
means that an average Health Authority with a population of half a million has 4,000 patients 
with RA.  The incidence of RA in the UK appears to have declined in recent decades.12 
Prevalence increases with age so that prevalence at age 65 is six times the prevalence at age 
25.  Peak age of onset is in the sixth decade and RA is more common in women by a ratio of 
2.5 to 1.13 
2.1.5 Aetiology 
 
No single cause of RA has been identified.  It appears to be a multi-factorial disease in which 
there are important genetic and environmental influences: 
• Genetic influence is estimated at 50 to 60%.14  Much of this contribution comes from the 
human leukocyte antigen (HLA) region of chromosome 6, particularly HLA-DR4.  HLA 
plays a key role in immune function and regulation. The only known function of DR is in 
presentation of peptides to T cells for mounting an immune response to particular 
antigens. The occurrence of RA in both monozygotic twins is 12%-15%.12;13  A family 
history of RA gives an individual a risk ratio of 1.6 compared with the expected 
population rate.15 
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• Infectious agents have been suspected as causal agents but without any conclusive or 
convincing evidence.16;17 
• Lifestyle factors such as diet, occupation, or smoking are not causally linked to RA.      
• Sex hormones are implicated since there is an increased incidence in women and, in 
general, improvement during pregnancy.12  
• Rheumatoid factor, an autoimmune response to IgG is a key feature of RA.  High levels 
are relatively specific for RA but rheumatoid factor may also occur in other chronic 
diseases and is absent in around 30% of patients with established RA.  
2.1.6 Pathology 
 
The pathological hallmark of RA is synovial hyperplasia and an inflammatory reaction of 
synovial tissues.  This is accompanied by an inflammatory exudate into the joint cavity.  
Synovial fluid in RA is highly cellular and contains predominantly polymorphonuclear cells 
with lesser numbers of T cells and macrophages. In disease, the synovial lining layer is 
increased to up to a 10-cell layer thickness.  There are more blood vessels and populations of 
activated cells such as fibroblasts, T lymphocytes, plasma cells (antibody producing cells) 
and cells resembling macrophages.  
 
Cytokines, small peptides that mediate signals between cells, primarily in a localised 
environment, and their receptors are produced in greater quantities in inflamed synovial 
tissues.  Erosion, or destruction, of cartilage and bone commonly occurs where synovial 
tissue meets cartilage and bone.  This occurs through the combined actions of ‘invasive’ 
synovial tissue (pannus) and resident cartilage and bone cells.  Erosions may be seen on X-
rays and are useful in diagnosis.  Erosions, and loss of cartilage in a synovial joint, are rarely 
reversible.  Such damage therefore compromises the structure and function of a normal joint. 
2.1.7 Role of cytokines in RA 
 
Almost all biological processes involve cytokines.  This includes normal development, 
immunity and inflammation.  Cytokines are multifunctional and are highly expressed in RA 
tissues.18-20 They function in a network of overlapping, synergistic, antagonistic and 
inhibitory activities. The net biological response appears to depend on the balance of counter-
acting factors.21  Tumour necrosis factor (TNF) and interleukin-1 (IL-1) are two of the key  
proinflammatory cytokines in RA. In early disease (< 6months) both cytokines are expressed 
in abundance.22 
 
IL-1 and TNFα have both local and systemic effects in RA. Locally they enhance the 
migration of leukocytes from the circulation into the inflamed joint. They also contribute to 
the growth of new blood vessels, which characterises rheumatoid synovitis. Most 
importantly, IL-1 and TNFα are key mediators of the tissue destruction and osteopenia seen 
in a rheumatoid joint.  
 
The relationship between cytokines is complex. TNFα appears to regulate production of a 
variety of pro-inflammatory agents including IL-1.20  IL-1 itself can induce expression of 
TNFα and also uniquely up-regulate its own expression.22  IL-1 and TNFα have overlapping 
effects but IL-1 is recognised as a primary inducer of acute-phase proteins,23 and appears to 
have a more important role in promoting cartilage and bone destruction. 
Anakinra for the treatment of RA- TAR  WMHTAC 
Confidential Page 17 07/04/2003 
Version for website publication 
2.1.8 Role of Interleukin-1 and interleukin-1 receptor antagonist in RA 
 
There are three members of the IL-1 gene family: IL-1α, IL-1β and IL-1Ra. IL-1α and IL-1β 
are secreted by immune cells in response to infectious or inflammatory challenge. IL-1Ra 
(IL-1 receptor antagonist) regulates IL-1α and IL-1β activity by blocking their actions.   
 
Each member of this family binds to two receptors, designated type 1 (IL-1RI) and type 2 
(IL-1RII), that are present on a variety of cells. The binding of IL-1α and IL-1β to  type 1 
receptors  leads to cellular signalling and biological effects.  By contrast binding of IL-1α 
and IL-1β to the type 2 receptor (IL-1RII) does not cause cellular signalling.  IL-1RII is a 
‘decoy’ receptor that functions by scavenging IL-1α and IL-1β. IL-1Ra competes with IL-1α 
and IL-1β for binding to type 1 receptors.  Binding of IL-1Ra to IL-1R1 does not lead to 
cellular signalling.   
 
Both receptors (IL-1RI and IL-1RII) may be cleaved from cell surfaces and circulate as 
soluble proteins (sIL-1RI and sIL-1RII).  Soluble receptors may also bind to all members of 
the IL-1 family.  However sIL-1RII preferentially binds to IL-1α and IL-1β, further 
inhibiting the activity of these cytokines.  Binding of sIL-1RI to IL-1Ra reduces the amount 
of IL-1Ra that is available to inhibit the actions of IL-1α and IL-1β.24 23,25,26;27 
 
Mice in whom the gene for IL-1Ra has been knocked-out develop either an inflammatory 
arthritis resembling RA or a lethal arterial inflammation.28;29  These data support the concept 
that an imbalance in IL-1 regulation can lead to destructive tissue inflammation.   
 
IL-1Ra is found in large amounts in the synovial fluid and tissues of patients with RA, but 
local production appears to be insufficient to effectively inhibit IL-1. Fewer than 5% of type 
1 receptors need to be occupied by IL-1 in order to induce biological responses.25  High local 
tissue concentrations of IL-1Ra must  therefore be achieved to be physiologically inhibitory, 
a 10 to 1000 fold excess of IL-1Ra being required to block the effects of IL-1 in vivo.25 
2.1.9 Goals of management  
 
The goals of treating RA are:30,31 
 
• To control symptoms of joint pain and inflammation 
• To minimise loss of function and to maintain or improve quality of life 
• To reduce the risk of joint damage and disability 
• To treat extra-articular complications of RA 
• To have well-informed and satisfied patients and carers  
 
As with any chronic incurable disease a long-term treatment plan is required that is 
repeatedly re-examined in the light of clinical parameters and patient preferences.32 
Clinicians recognise that many factors need to be considered during this interaction with 
patients.33 These include: 
 
• Discussion of drug and non-drug therapeutic options.  An open discussion about the 
benefits and risks of these options including an awareness of the hazards of untreated 
disease and also of rare potentially life-threatening adverse events with some drugs 
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• Modes of drug administration and monitoring needs to ensure safe use of particular drugs 
• Assessment of psychosocial factors such as available social support, adjustment to 
disease, needs of dependants and effect on employment and employability 
• Educational needs of patients and carers 
• Co-morbidity that may influence drug use and prognosis 
• Drug costs 
2.1.10 Current drug therapy for rheumatoid arthritis 
 
Conventional drug therapy for rheumatoid arthritis relies on varying combinations of the 
following four classes of drugs: 
 
• Non-steroidal anti-inflammatory drugs (NSAIDs) 
• Analgesics 
• Corticosteroids such as prednisolone and methylprednisolone 
• Disease modifying anti-rheumatic drugs (DMARDs) including sulfasalazine, 
methotrexate, gold preparations, penicillamine, azathioprine, hydroxychloroquine, 
leflunomide, ciclosporin A and biologic modifiers (e.g. TNF inhibitors) 
 
Daily pain control and stiffness are managed by NSAIDs, low dose prednisolone (for 
example prednisolone 10 mg or less), analgesics or a combination of these.  The risks and 
benefits of NSAIDs are well recognised and have been reviewed extensively elsewhere.31;34 
Corticosteroids may be given in varying doses by mouth, or as intra-articular, intramuscular 
or intravenous injections.  They are often used as short-term treatment for acute relapses, as 
‘bridge therapy’ or ‘step down therapy’ to allow rapid control of disease whilst awaiting the 
effects of DMARDs.35 The benefit of corticosteroids on symptoms of RA does not appear to 
be sustained in randomised trials.  However, in clinical practice, a significant proportion of 
patients are maintained on corticosteroids long-term, indicating sustained benefit for some 
patients.35;36  Long-term therapy may also be justified on the grounds that low-dose 
prednisolone prevents joint damage.37  
 
DMARDs are slow acting drugs that provide symptomatic relief and reduce the risk of 
progressive joint damage. Most DMARDs take several weeks or months to work.  The mode 
of action of many DMARDs is not fully understood but many appear to act by immune 
suppression. For example methotrexate (MTX) and leflunomide, a newly available DMARD, 
are anti-metabolites.38 Inhibitors of TNFα, etanercept and infliximab, are very effective 
agents in RA and are being widely used.39 
  
It is generally accepted that patients with RA should be treated with DMARDs soon after 
diagnosis.  Delayed use of DMARDs leads to worse outcomes.31;40;41  DMARDs are usually 
given with NSAIDs, analgesics, corticosteroids, or a combination, at least initially.  As 
disease control is achieved doses of other drugs may be reduced, or drugs discontinued, while 
maintaining therapy with DMARDs.  Comparisons between DMARDs indicate that oral 
gold, azathioprine and hydroxychloroquine are less effective than other agents.31;38;42  The 
remaining drugs appear to have comparable efficacy.  A meta-analysis of treatment 
termination rates showed that continued drug use 5 years after starting a DMARD was 36% 
for methotrexate, 23% for i.m. gold, and 22% for sulfasalazine.  Median time for drug use for 
these agents was 41 months, 24 months and 18 months respectively, underlining a key 
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limitation of DMARDs.43 That is relatively short-term use, or drug survival, of a DMARD for 
a disease with a life-long course.   
 
DMARDs may be discontinued because of toxicity, inadequate disease control, disease 
relapse, patient or physician preference, complicating co-morbidity or a combination of 
these.44 DMARD toxicity varies from relatively minor adverse reactions to life-threatening 
events such as bone marrow suppression. Antimalarial drugs and methotrexate appear to have 
the most favourable risk-benefit profile.45 Methotrexate is widely regarded as the standard 
against which other drugs should be judged especially because of its lower propensity for 
treatment termination.  Effective disease control may also lead to other benefits such as 
reduced cardiovascular mortality.46 
 
DMARDs are used in a variety of ways.  Some use several agents at once in patients with 
severe disease (‘combination therapy’), others use DMARDs in sequence and either add one 
DMARD to another or replace one DMARD with another in an effort to attain disease 
control.47 Increasingly, combinations of DMARDs are used although evidence in favour of 
combining DMARDs is limited.48-50  Preferred DMARD combinations include methotrexate 
combined with hydroxychloroquine or ciclosporin A. 47 Of the newer biological modifiers, 
infliximab is only currently licensed for use in combination with methotrexate. An analysis of 
sequential use of DMARDs suggests that there may be reduced likelihood of sustained 
therapy with each successive DMARD.51 It  appears that the prospect of prolonged therapy 
for a DMARD is greatest if that DMARD is the drug first used in a sequence of DMARDs.52 
The choice of initial DMARD does not seem to be relevant suggesting that failure to respond 
to methotrexate, or any other specific DMARD, is not a marker for a resistant form of RA.51  
 
Patients whose disease is well controlled, or in remission, whilst taking DMARDs often seek 
to reduce their medication.  Discontinuing treatment increases the risk of relapse and 
guidelines advocate sustained long-term therapy.53;54 However it is not widely acknowledged 
that only around 60% of patients are fully compliant with DMARD therapy and that nearly a 
quarter are consistently non-compliant.55   
 
Disease in some patients appears to be resistant to conventional approaches but there is no 
clear definition of ‘resistant RA’.  Criteria for ‘refractory’ RA have been proposed recently. 56 
The following demands must be met, according to the criteria described: 
That patients have used at least 3 DMARDs including methotrexate (> 15 mg/week) and 
sulfasalazine (dose >2 g / day) for a minimum of 6 months unless there was toxicity. 
• Lack of efficacy is defined by failure to improve the Disease Activity Score, (DAS), by 
>0.6 (discussed below) 
• That patients have persistently active disease (DAS>3.7) despite therapy  
 
2.1.1.1 Toxicity of DMARDs 
The high rate for discontinuation of DMARDs is a key concern in rheumatology.  In general, 
drug toxicity arises during the first months of therapy.  After 24 months drug cessation is as 
likely to be a result of loss of efficacy as toxicity.52  Treatment cessation because of toxicity 
is more likely with i.m. gold than with sulfasalazine or methotrexate.43 Adverse reactions to 
commonly used DMARDs are listed in, Table 2, page 21. 
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2.1.1.2 Assessment of response to DMARDs 
 
The ultimate goal of treating any disease is complete remission.  For RA this is not usually 
achieved, using current criteria for remission, but very effective disease control is possible in 
many patients. Modern clinical trials assess the response of a patient to therapy by using a 
composite measure that combines several measures of disease activity (Appendix 2, page 89). 
The ACR definition of improvement and the disease activity score (DAS) are two of the most 
commonly used measures.  The ACR response, for example, requires an improvement in:57  
 
• Tender joint count 
• Swollen joint count 
• At least 3 of : 
- global disease activity assessed by observer 
- global disease activity assessed by patient 
- patient assessment of pain 
- physical disability score (e.g. HAQ) 
- acute phase response (e.g. ESR or CRP) 
 
Response is defined as ACR20, ACR50 or ACR70 where figures refer to %age improvement 
of the clinical measures shown above.  This creates a dichotomous outcome of responders 
and non-responders.  Achieving an ACR20 response has been regarded as a low hurdle but in 
clinical practice patients who achieve this hurdle may still gain a worthwhile clinical 
response, especially in early RA.58;59  The perspective of regulatory agencies in approving 
new drugs for RA was summarised in our review of anti-TNF therapies.39 
 
Radiographic outcomes are believed by many to be the most important outcome measure in 
RA.  A variety of schemes have been developed to assess joint damage in RA using 
radiographs.  The most commonly used measures are the Sharp and Larsen methods and 
modifications of these methods (Appendix 3, page 90).  Plain radiographs, however, are 
insensitive to change but are cheap and widely available.  A majority of patients show only 
mild or no progression on plain radiographs over periods of 1 to 2 years.60  In addition there 
are significant problems of measurement error between 2 independent observers viewing the 
same set of radiographs.  For example the smallest detectable deterioration in the hands and 
feet radiographs of an individual over 12 months is estimated to be 15 Sharp units and 8 
Larsen units, if 95% agreement between observers is required.61  The group mean change in 
the Sharp score for anti-TNF agents over 1 or 2 years was in the range 0 to 7 Sharp units.39  
Others have reported that the median annual change in Larsen units was 6.5 units in patients 
with high levels of clinical disease.62  Therefore whilst radiographic outcomes are important 
in RA there are obvious challenges in improving the reliability and utility of radiological 
outcomes for clinical trials. 
 
Anakinra for the treatment of RA- TAR  WMHTAC 
Confidential Page 21 07/04/2003 
Version for website publication 
Table 2: Toxicity of commonly used DMARDs 
Drug Common Uncommon 
 
Rare or very rare 
Azathioprine Nausea, rash, hypersensitivity, 
mouth ulcers 
Leucopenia, 
infection 
Lymphoma (long-term 
use) 
Ciclosporin A Headaches, hypertension, renal 
impairment, depression, nausea 
paraesthesia, tremor, 
hypertrichosis 
gingival hyperplasia, depression 
Incipient renal failure, gout Malignancy 
Etanercept Injection site reactions, pruritus, 
fever, infections, allergic 
reactions, autoantibody formation  
Serious infections, 
thrombocytopenia, angioedema, 
urticaria 
Anaemia, leucopenia, 
pancytopenia, aplastic 
anaemia, serious 
allergic/anaphylactic 
reactions, seizures, CNS 
demyelinating disorders, 
malignancy 
Gold  Rash and pruritus, diarrhoea 
(especially oral gold), mouth 
ulcers, thrombocytopenia, 
proteinuria 
IgA deficiency, reduced Igs, 
neutropenia, cholestatic 
jaundice 
 
Marrow aplasia, 
pneumonitis, exfoliative 
dermatitis 
Hydroxy-
chloroquine 
Nausea, diarrhoea, rash, 
headache, dizziness, blurred 
vision 
Muscle weakness  
 
Retinal toxicity 
Infliximab Infusion related reactions 
(dyspnoea, urticartia headache), 
rash, pruritus, increased sweating, 
dry skin, fatigue, chest pain, viral 
infection, respiratory tract 
infections, sinusitis, flushing, 
vertigo/dizziness,  nausea, 
diarrhoea, abdominal pain, 
dyspepsia, abnormal hepatic 
function 
Fungal and bacterial infections, 
autoantibodies, anaphylactic 
reactions, anaemia, leucopenia, 
neutropenia, thrombocytopenia, 
lymphadenopathy, 
conjunctivitis, cardiovascular 
symptoms/disease, GI 
symptoms, abnormal skin 
pigmentation, alopecia, myalgia, 
arthralgia, injection site 
reactions 
CNS demyelinating 
disorders, pancytopenia, 
anaphylactic shock, 
opportunistic infections, 
malignancy 
Leflunomide Hypertension, nausea, diarrhoea, 
mouth ulcers, abnormal LFTs, 
headache, dizziness, hair loss, 
rash 
Hypocalcaemia, taste 
disturbance, tendon rupture, 
anxiety  
Severe abnormality of 
LFTs, Stevens-Johnson 
syndrome, leucopenia 
(<2.0), pancytopenia, 
agranulocytosis (very rare) 
Methotrexate Abdominal pain, nausea, 
diarrhoea, abnormal LFTs, 
neutropenia, macrocytosis, 
subcutaneous nodules, altered 
mood 
Pancytopenia, pneumonitis, 
herpes zoster 
Lymphoma, liver failure, 
unusual and severe 
infections 
Penicillamine Altered taste or loss of taste, 
nausea, mouth ulcers, rash or 
pruritus, proteinuria, 
thrombocytopenia (dose related) 
Glomerulo-nephritis Myasthenia, polymyositis, 
systemic lupus 
erythematosus, aplasia, 
neutropenia 
Sulfasalazine Nausea, rash, discoloured urine, 
leucopenia, fever, mouth ulcers, 
dizziness, oligospermia, raised 
MCV 
Neutropenia, agranulocytosis, 
abnormal LFTs, reduced Igs  
Pneumonitis 
Data are collated from a variety of sources, primarily Denman AM.63 The term common indicates occurrence in 
approximately 1-10% of patients; uncommon 0.1-1%; rare 0.01-0.1%; very rare 0.01% or less. BP = Blood pressure.  
MCV = mean red blood cell volume.  LFTs = liver function tests.  FBC = full blood count.  Igs = immunoglobulins. 
Adapted from and reproduced with permission from NCCHTA39  
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2.1.11 Non-drug therapy 
 
Management of severe RA often requires input from a multidisciplinary team of health 
professionals.31;64 This includes assessment, education and advice from an occupational 
therapist, physiotherapist, podiatrists, specialist nurses and many others.  Hospitalisation 
occurs less often than it used to but is still sometimes needed for those with severe disease or 
life-threatening complications.65 
2.1.12 Prognosis  
 
The impact of RA on an individual can be viewed from a variety of perspectives including 
employment status, economic costs to the individual or society, quality of life, physical 
disability, life expectancy, medical complications such as radiographic damage or the need 
for surgery, and so on.  Understandably, factors that can predict longer term outcomes at 
diagnosis are of great interest to patients and doctors.  In general, persistent disease activity is 
associated with poorer outcomes but studies show an inconsistent relationship with specific 
markers.   This probably reflects differences in settings and in selection of patients.  Inception 
cohorts of patients with RA provide the most robust assessment of prognosis.  A few well-
studied outcomes and their predictors are discussed briefly below.   
• Disability can be difficult to predict within 5 years of diagnosis, as the functional status of 
individuals is labile.66At 5 years disability (HAQ >1) is predicted by age at symptom 
onset, a high disability score at presentation (i.e. disability at presentation predicts itself), 
rheumatoid nodules, female sex, psychological status and joint tenderness.67-69 Accuracy 
of 76% is reported for a combination of these factors (excluding female sex).67 Physical 
function of patients followed soon after disease onset, and defined by ACR classification 
for function (Appendix 4, page 91) is normal in up to 40% of patients at 5 years.  
Moderate or severe disability occurs in 15.4%.68 
• Loss of employment is related to type of employment, and other aspects of the workplace 
such as pace of work, physical environment, physical function, education and 
psychological status.70;71 Work disability is not necessarily linked to measures of disease 
activity such as tender or swollen joint count.  It occurs in 40% of patients 5 or more 
years after diagnosis and, in as many a third, 2 years after diagnosis.  Rates of work 
disability are substantially greater than in controls in some studies, but not all.72 Manual 
workers, not surprisingly, suffer most limitations.68 
• Serial measures of disease activity and severity may predict radiographic damage.  
Markers linked to greater radiographic damage include positive rheumatoid factor, age, 
disease duration and extent of disease.73 The predictive value of such factors for erosions 
on X-rays approaches 80% in some studies although there is considerable variation 
between studies.1 Genetic markers have been shown in some studies to predict 
radiographic damage, however, others suggest that this may not be the case.74 Clinical 
trials of DMARDs usually measure radiographic damage in the small joints of hands and 
feet.  The degree of small joint damage correlates with extent of large joint damage and 
both correlate with physical function.75;76 
• Major joint replacement surgery (including hip, knee, shoulder, and elbow replacements) 
was required in 8% of RA patients 5 years after diagnosis.68 With longer follow-up 25% 
of patients had total joint arthroplasty within 22 years of disease onset.2 Hospitalisation 
for medical treatment of RA shows considerable variation between centres due to 
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availability of in-patient facilities.68 However medical treatment of severe RA in hospital 
can lead to better outcomes up to 2-years after hospitalisation, compared with routine out-
patient care.77 
• Mortality, especially due to cardiovascular disease, may be increased in RA.  Studies of 
inception cohorts (defined as those with disease duration of less than 2 years) show a  
standardised mortality ratio (SMR) of between 0.87 and 1.38 (mean 1.22).  Skin nodules, 
greater physical disability rheumatoid factor and treatment with steroids were associated 
with increased mortality.70;78  Deaths from infection, lymphoma or leukaemia, and deaths 
related to the digestive system appear to occur in greater than expected proportions.  The 
death rate at 5 years in a large British cohort of patients seen in hospital was 10.7%, 
whereas the rate for an inception cohort of primary care patients with RA was 13% after 
median follow-up of 6.9 years.68;79  
2.1.13 Burden of illness 
 
RA is associated with a substantial economic burden in some studies.  Medication costs 
account for between 8 and 24% of medical costs, physician visits 8 to 21% and 
hospitalisation 17 to 88%.  It is unclear whether indirect costs exceed direct medical costs  
but patients and families, rather than health care services, incur a majority of the economic 
costs early in disease.80 Mean annual direct and indirect costs, for the year 1996, are reported 
at £3,575 and £3,638 per patient respectively.81 Inevitably, in a disease characterised by 
lifelong pain, discomfort and physical impairment, the burden on individuals and families is 
increased.  Economic disadvantage, for example because of work disability, or limited access 
to resources, such as aids and appliances, can have a substantial impact on the ability of an 
individual to function. 
2.2 Current service provision 
 
Most patients with RA are referred to hospital services but up to a quarter of patients with 
early inflammatory arthritis (not necessarily RA) are managed in primary care without 
specialist referral.1  Joint pain is the leading reason for referral to hospital outpatient services 
with an annual rate of referral exceeding 40 per 1000 population.82 The BSR and other 
organisations recognise a significant shortfall in rheumatology service provision (estimated at 
approx 300 whole-time Consultant Rheumatologists in the UK).83;84 Prolonged waiting times 
for patients to be seen in hospitals, and opinions of general practitioners and patient groups, 
provide support for the view that rheumatology provision is insufficient.85;86 
 
The majority of patients followed up in a hospital rheumatology department have RA or 
another type of inflammatory arthritis or connective tissue disease.  A proportion of such 
patients may also require in-patient treatment. There are considerable variations in in-patient 
facilities for patients with rheumatic disease.  This may account for variations in 
hospitalisation rates seen for RA.83 
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2.3 Description of the new intervention 
2.3.1 Identification of patients and criteria for treatment 
 
The limitations of current therapies for RA were described earlier.  These limitations provide 
a context in which new treatments for RA should be viewed.  Rigid criteria for use of any 
specific treatment in any one individual are inappropriate.87;88 This is especially true for RA 
where, in addition to considering a patient’s perspective, significant co-morbidity is likely to 
influence therapeutic choices.   
 
Anakinra is only licensed in Europe for use in combination with methotrexate in those 
patients who have not responded sufficiently to methotrexate alone. A BSR committee has  
issued guidelines on the appropriate use of anakinra in RA.89 The guidance is similar to that 
issued on the use of etanercept and infliximab in RA.90 It is recommended that anakinra 
should only be used if the following criteria are met: 
 
• Patients satisfy the 1987 ACR classification criteria for RA.  
• Patients have highly active RA based on a DAS score of >5.1 (using DAS28, Appendix 2, 
page 89). 
• Patients must have failed treatment with methotrexate and at least one other DMARD 
(from a list including i.m. gold, hydroxychloroquine, sulfasalazine, penicillamine, 
azathioprine, methotrexate, and leflunomide).  Treatment with each DMARD should be 
for at least 6 months.  A ‘standard target dose’ for a minimum of 2 months is stipulated 
unless toxicity requires discontinuation.  
• Clinicians must register treated patients, with consent, in a central registry and provide 
data on drug dose, outcome and toxicity on a six-monthly basis.91  
 
The BSR biologics registry is a prospective cohort study designed to compare the risk, over 5 
years, of developing malignancy, lymphoproliferative malignancy, infection requiring 
hospitalisation, serious co-morbidity and death in two cohorts. The first cohort is a group of 
patients with rheumatic disorders newly exposed to a biologic drug. The comparison cohort is 
a group of patients with similar disease characteristics newly exposed to other non-biologic 
drugs.  It is proposed that patients are monitored for at least 5 years and the goal is to recruit 
all patients treated with anti-TNF agents and anakinra. All UK hospitals are obliged to collect 
data on patients treated with anti-TNF agents92 and 7 centres across the UK are recruiting the 
comparison cohort.  The BSR and the manufacturers of etanercept, infliximab and anakinra 
have funded the study.  Physicians contributing patient data do not receive support or 
reimbursement for data gathering.  It seems likely that smaller units and those with less 
support from professions allied to medicine will have difficulty meeting the demands of the 
patient registry. It is unclear how complete participation can be ensured by NICE and BSR 
guidance nor is it apparent how standards for data recording are maintained and audited.  All 
data collected in the registry are owned by the BSR. 93 (personal communication Kath 
Watson, BSRBR Study Co-ordinator, October 2002) 
2.3.2 Description of the technology 
 
Anakinra (TN Kineret) is a recombinant, non-glycosylated form of human IL-1Ra with a 
single methionine residue added at the amino terminus.94;95 It is the first biologic agent of this 
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type designed specifically to modify the biological  response of IL-1.  Amgen launched it in 
the UK in April 2002. It has been available in the US since November 2001. 
 
Anakinra is administered by the patient, or carer, as a single daily subcutaneous injection. It 
should be administered at approximately the same time each day, with rotation of the 
injection site. It is supplied in pre-filled syringes containing the recommended fixed daily 
dose of 100mg. Pre-filled syringes of anakinra need to stored in a refrigerator (2-80C) and 
protected from light. Each syringe should be allowed to reach room temperature before it is 
administered. Anakinra pre-filled syringes should not be removed from a refrigerator for 
more than a single period of 12 hours (at temperatures up to 250C). 
 
Training may be needed for administration of injections and in some cases injections may 
have to be administered by a healthcare professional. Patients need access to a refrigerator for 
storage of syringes and a sharps bin for disposal of used syringes. No other equipment is 
required. 
 
The bioavailability of anakinra was 95% after a 70mg s.c. injection in healthy volunteers.96 
Peak plasma concentrations are seen within 3 to 7 hours in patients with RA. Anakinra is 
excreted in the urine, less than 10% unchanged, with a terminal half-life of about 6 hours. 
The site of metabolism is not known. Absorption of anakinra is the rate-limiting factor for 
clearance of the drug from plasma following s.c. injection.97  Accumulation of anakinra does 
not occur after daily s.c. injections (of up to 2 mg/kg/day) for 24 weeks in RA.  Plasma 
clearance of the drug is reduced by 70-75% in patients with severe or end stage renal 
disease.94  Use in such patients is contra-indicated.96 
 
Anakinra acts in the same way as naturally occurring IL-1Ra, transiently binding to the IL-1 
receptor, augmenting the natural regulation of IL-1. 
 
Anakinra is licensed in Europe ‘for the treatment of the signs and symptoms of RA in 
combination with methotrexate, in patients with an inadequate response to methotrexate 
alone’.96  The summary of product characteristics further recommends that ‘treatment should 
be initiated and supervised by specialist physicians experienced in the treatment and 
diagnosis of RA.’96 Anakinra is not recommended for use in children and adolescents under 
18 years of age. 
 
The European licence is more restrictive than the US licence which allows use ‘for the 
reduction in signs and symptoms of moderately to severely active rheumatoid arthritis, in 
patients 18 years of age and older who have failed 1 or more disease modifying antirheumatic 
drug.’ Prescribers are advised not to use anakinra in combination with TNF inhibitors.98 
 
Anakinra is contra-indicated in patients with severe renal impairment and in those with 
hypersensitivity to the active substance, any of the excipients or to E. coli derived proteins. 
Anakinra is not recommended for use in patients with neutropenia, those with pre-existing 
malignancies, pregnant or breast feeding women.96  Women of childbearing potential are 
advised to use effective contraception during treatment.  Caution is advised in moderate renal 
impairment and in those with a history of recurring infections or with underlying conditions 
that may pre-dispose them to infections.96  It is recommended that neutrophil counts are 
assessed prior to initiating anakinra treatment, monthly during the first 6 months of treatment 
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and quarterly thereafter. If neutropenia develops anakinra should be discontinued and 
neutrophil counts monitored closely.96 
2.3.3 Degree of Diffusion 
 
Currently data on the usage of anakinra in the NHS is limited. Amgen were unwilling to 
provide data on the use of anakinra in the UK since they viewed this as commercially 
sensitive. CONFIDENTIAL INFORMATION REMOVED. 
2.3.4 Anticipated costs  
 
The acquisition cost of one year’s treatment with anakinra (100mg daily by s.c. injection) is 
£7471.99  Anakinra is currently being supplied by one of two routes both of which incur 
additional expense: Directly by Hospital Trusts which incurs additional cost of 17.5% or by a 
home care company at an additional cost of 8% of the drug acquisition cost.  
 
Additional costs associated with supervision, training, safety and efficacy monitoring, and 
collection of data for the BSR registry also need to be taken into account.  
 
It is not possible to give any reliable estimate of how many RA patients are likely to be 
eligible for anakinra since anti-TNF agents are only now being widely used in the UK.  If we 
assume that 30% of patients do not respond to anti-TNF agents (based on clinical trials of 
anti-TNF agents), and, if we assume that 10% of RA patients known to hospital departments 
are eligible for anti-TNF, then 3% of RA patients might be eligible for anakinra (9480 
patients in England and Wales currently).39 
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3 EFFECTIVENESS 
3.1 Methods for reviewing effectiveness  
3.1.1 Search Strategy 
 
The following electronic bibliographic databases were searched with a stop date of 1st 
November 2002: 
 
Cochrane Library, Medline, Embase, Science Citation Index (SCI), National Research 
Register (NRR), NHS Database of Reviews of Effectiveness (DARE), Index to Scientific and 
Technical Proceedings (ISTP), NHS Economic Evaluation Database (NHS EED), Health 
Economic Evaluation Database (HEED). 
 
Search terms included the text words: anakinra; kineret; interleukin-1 receptor antagonist; IL-
1ra; rhu-IL-1Ra; and the index terms; arthritis, rheumatoid; receptors, interleukin-1; 
interleukin-1.  
 
Studies were limited to humans. No language, date or age restrictions were applied. A meta-
search engine was used to search the Internet, and links followed up.  Proceedings from the 
American College of Rheumatology and European Congress of Rheumatology meetings were 
searched electronically for the years 2001 and 2002. 
 
Scrip, FDA submissions for new drug applications, EMEA reports and the pharmaceutical 
company submission to the National Institute for Clinical Excellence (NICE) were hand 
searched. The reference lists of identified publications were reviewed to identify any 
additional studies and/or citations. 
3.1.2 Inclusion and exclusion criteria 
 
Two reviewers independently applied the following inclusion/exclusion criteria to all 
potential studies. Disagreements were resolved by discussion, referring to a third party when 
necessary. Reviewers were not blinded to any features of the report including authorship 
however inclusion/exclusion decisions were made prior to detailed scrutiny of the results. 
 
3.1.2.1 Inclusion criteria 
 
The criteria for inclusion related to the population, intervention and comparator considered 
and the publication status of the report were applicable to both the clinical effectiveness and 
cost-effectiveness parts of the review. 
 
Population Adults aged 18 years and above with rheumatoid arthritis  
Intervention: Anakinra (Kineret) alone or in combination with other drugs  
Comparator: Placebo, or other drug treatments for RA 
Publication All data to be included irrespective of publication status. 
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Studies were included in the final analysis of the review if they met the above criteria and the 
additional criteria for study design and outcomes as specified below for the clinical and cost-
effectiveness parts of the review. 
 
Clinical effectiveness review 
Study design: Randomised or quasi-randomised controlled trials 
Outcomes: To include: mortality, morbidity (e.g. disability/mobility, disease 
progression, joint damage, pain, adverse events), response rates and 
quality of life. 
 
Cost-effectiveness review 
Study design: Economic evaluation studies: cost analysis, cost-effectiveness, cost-
utility and cost-benefit studies. Existing health economic reviews were 
also assessed. 
Outcomes: To include: quality of life, costs, and incremental cost-effectiveness 
ratio.  
  
3.1.2.2 Exclusion criteria 
• Trials only recruiting children with juvenile idiopathic arthritis. 
• Trials with no comparator arm. 
• Trials which were not randomised. (clinical effectiveness part of review only) 
• Articles reporting solely on laboratory measures aimed at investigating disease or 
treatment mechanisms. 
3.1.3 Data extraction strategy 
 
Two reviewers independently extracted data using pre-designed data extraction forms. 
Disagreements were resolved by discussion. Data from studies with multiple publications 
were extracted and reported as a single study.  
 
Clinical effectiveness review 
The following data were extracted: 
• Details of the study population and baseline characteristics of the intervention and control 
groups, with particular reference to disease characteristics and previous treatment history. 
• Details of the intervention, such as dose, mode of administration, frequency of 
administration and duration of treatment 
• Details of completion rates across the groups, reasons for withdrawal, loss to follow up. 
• Details of individual outcomes measured such as: 
- Changes in disease activity e.g. ACR improvement criteria, swollen joint count, pain, 
joint space narrowing and erosion. 
• Changes in quality of life 
• Adverse events reported 
Results were extracted, where possible for the intention to treat population, as raw numbers, 
plus any summary measures with standard deviations, confidence intervals and p-values 
where given. 
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Cost-effectiveness review 
The following data were extracted: 
• Details of the study characteristics, including type of economic analysis, intervention and 
comparator, perspective, time frame, modelling used. 
• Details of the data used to populate the evaluation and the key assumptions made such as 
effectiveness data, cost data, health state valuations, discounting rate. 
• Details of the results and sensitivity analysis 
3.1.4 Quality assessment strategy 
 
Two reviewers undertook quality assessments independently, using a structured approach. 
Disagreements were resolved by discussion, with reference to a third party where necessary. 
 
Clinical effectiveness review 
The validity of included studies were assessed by looking at the method of randomisation, the 
concealment of allocation, the comparability of baseline characteristics between the different 
arms, blinding, withdrawals and losses to follow-up for each patient group.  Based on these 
criteria a Jadad score was calculated. (The Jadad score ranges from 0 to 5, with a score of 5 
representing trials of highest quality). 
 
Cost-effectiveness review 
The criteria of Drummond et al served as an a priori standard for the assessment of economic 
evaluations.100  These evaluate the study question, selection of alternatives, form of 
evaluation, effectiveness data, costs, benefit measurement and valuation, decision modelling, 
discounting, allowance for uncertainty and presentation of results.  
 
3.2 Results 
3.2.1 Quantity and quality of research available  
 
Sensitive rather than specific search strategies were used. The considerable interest in the 
potential role of biological therapies in the management of RA, particularly following the 
positive research data on anti-TNF therapy has generated a large number of publications. 
Identified reports included many reviews, news articles, observational studies and studies 
investigating IL-1 related disease mechanisms as well as a small number of clinical trials of 
IL-1Ra therapy. Results of Medline and Embase Searches are shown in Appendix 5, page 92. 
3.2.2 Identified studies, inclusions and exclusions 
 
Fifty eight publications that potentially reported relevant trials were identified; 13 published 
reports, 45 abstracts.  All were identified from searches of electronic databases.  
 
A number of duplicate publications were identified which included; abstracts for trials 
subsequently published in full, abstracts on the same data presented at more than one 
meeting, full reports of the same trial published in more than one journal. Where identical 
data were presented in different publications then, if available, the fully published report was 
included. Where there were duplicate abstracts the most recent report was included. In the 
case of duplicates of fully reported trials the original report was included.  
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In other cases several abstracts and full papers presented sub-sets of data or details of a 
specific outcome.  These were included if pertinent outcome data, not found in other sources, 
were presented.   
 
Efficacy data from the open-label extension phase of blinded studies, or studies that were 
unblinded for safety or ethical reasons, were excluded. 
 
The FDA NDA application and EMEA EPAR were available from the internet and provided 
detailed information on the trials considered in the licensing application for anakinra in the 
US and Europe respectively. Clinical trial reports on four trials were provided in Amgen’s 
submission to NICE. These were considered in conjunction with the RCT reports. 
 
Five RCTs of anakinra were included in the review, two as monotherapy, and three in 
combination with DMARDs, one of which was principally a safety study. Only one efficacy 
trial and the safety study specifically evaluated anakinra at a dose of 100mg/day (licensed 
dose).  
 
CONFIDENTIAL INFORMATION REMOVED. 
 
A flow diagram illustrating the volume of literature identified and the selection of relevant 
reports is shown in Figure 1. A list of included and excluded reports, with a brief comment 
and reasons for exclusion, is shown in Appendix 6, page 94. Additional trials of anakinra in 
RA are currently in progress. 
 
In evaluating adverse events with anakinra data from the included studies, post-marketing 
surveillance and other experiences are evaluated and discussed. 
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Figure 1 Flow diagram for identified reports. 
 
 
 
 
 
 
 
 
Excluded reports, not 
relevant (n=195). 
Excluded reports: review articles 
(n=10), pharmacokinetic study 
(n=2), single centre experience 
(n=1), technology evaluated not 
anakinra (n=1). 
Excluded reports: data duplication or 
superseded data (n=17), sub-group or 
post-hoc analyses (n=4), studies 
lacking suitable control (n=8), meta-
analysis (n=1), juvenile RA (n=1).
Potentially relevant reports screened 
for retrieval including abstracts 
(n=253). 
Reports retrieved for more detailed 
evaluation (n=58) 
Potentially relevant reports of RCTs 
(n=44) 
Included reports with potentially 
relevant data (n=13). 
Four RCTs were identified.  The remaining 9 items were reports that provided more 
detailed information on the 4 included RCTs.  These reports were therefore considered 
in conjunction with the full RCTs report. 
The FDA NDA and EMEA EPAR were printed from the Internet. Amgens submssion 
to NICE was used as a data source. These reports contained detailed information on the 
included RCTs. An additional RCT which fully met the inclusion criteria was identified 
from these reports. These reports were considered in conjunction with published 
reports.  (Final tally of five RCTs.) 
Unique reports identified by searching 
(n=1003). 
Medline – 95 
EMBASE – 478 
Cochrane CCT – 12 
ACR & EULAR 
conferences 2001/2 
– 42 
ISTP –10 
NRR – 4 
SCI – 362 
Duplicates (n=159)
Excluded reports, not 
relevant (n=591) 
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3.2.3 Quality and Efficacy 
Five trials, which met the inclusion criteria, were identified; four efficacy trials (two 
monotherapy [0560,102 0182 103], two in combination with MTX [0180,104 0145105 103]) and 
one safety study (combined therapy [0757]106,103. Four were identified from electronic 
searches and one from the FDA and EMEA licensing submissions.  A description of the 
included studies is given in Table 4, page 47.  
The four efficacy trials have all been completed but fully published data are only available 
for two. The low dose ranging trial (2.5 - 30mg/day), 0182, has never been published and the 
largest efficacy trial, 0145 has just been completed. Currently only interim and preliminary 
endpoint data are available. The safety study (0757) is still ongoing, interim data are currently 
available. The large efficacy trial (0145) and the safety study (0757) both evaluated anakinra 
at a dose of 100mg/day, the other studies considered ranges of doses.  
 
All included trials were of high quality.  
Table 3: Summary of JADAD scores for included studies  
Was treatment allocation 
masked from: 
Study Truly 
random 
allocation 
Was 
concealment 
adequate? 
Participants Investigators  Assessors 
Significant 
difference in 
completion 
rates between 
groups 
JADAD 
score 
560102;107 Yes Yes Yes Yes Yes No 5 
0182103 
108 
Yes Yes Yes Yes Yes No 5 
0180 104 
103;109 
Yes Yes Yes Yes Yes No 5 
0145 
105;110 
Yes Yes Yes Yes Yes No 5 
0757106 
103;111 
Yes Yes Yes Yes Yes No 5 
All trials were described as double-blind with active and control medication having similar 
appearance. There is however the potential that unblinding occurred due to differences in 
adverse event profiles of the treatments, particularly injection site reactions. This is discussed 
in more detail later in the report. 
A description of the study characteristics and key data are given below for each trial. Results 
from all trials are tabulated.  
 
3.2.3.1 Anakinra monotherapy 
Two short-term dose ranging placebo controlled trials have evaluated the efficacy of anakinra 
monotherapy in the treatment of RA. The study by Bresnihan and colleagues is published in 
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full. 102 Data on the smaller dose ranging study are only available in the FDA NDA 
submission and European centralised marketing authorisation application. 101;103 
Study 0560 - Bresnihan and colleagues 1998102;103;107 
Population: 
This phase II dose ranging study enrolled adult patients with active RA as defined by ACR 
criteria. Patients did not have to have failed, or been intolerant of, prior DMARD treatment. 
For those who were on DMARD treatment prior to enrolment, this treatment had to be 
withdrawn at least 6 weeks before entry.  
 
A total of 473 patients from 41 centres across 11 European countries were enrolled. Patients 
were aged between 18-75 years (mean 53.1 years) were almost exclusively white (99%) and 
predominantly women (75%). Patients had active disease with a median of 32 to 35 tender 
and 25 to 26 swollen joints, median HAQ of 1.5 or 1.6, median CRP of 2.7 to 3.2 mg/dl and a 
mean ESR above 45mm/hr at baseline. Median disease duration was 3.3 years for placebo 
and 3.9 years for anakinra.  Patients had received a median of 1 previous DMARD, and 36% 
had previously received methotrexate. Nearly a quarter of all patients had not received any 
previous DMARD (116 of the 473 patients; 19-34% across the treatment groups). Patients 
were permitted to continue treatment with NSAIDs and low dose oral corticosteroids (taken 
by 83.5 % and 42.6% respectively) provided that drug doses remained constant during the 
trial. Approximately 70% of patients were rheumatoid factor positive and 73% had erosions 
on baseline radiographs. 
 
At baseline notable differences across the treatment groups were fewer men, lower previous 
DMARD use and fewer erosions in the highest anakinra dose group. 
 
Interventions: 
All interventions were given as a single daily subcutaneous injection administered by the 
patient or caregiver. Patients were randomised to one of 4 treatment groups: 
• Placebo  n= 121 
• Anakinra 30mg/day n=119 
• Anakinra 75mg/day n=116 
• Anakinra 150mg/day n=116 
One patient withdrew before receiving study medication.  
 
Study duration and key outcomes: 
24 weeks – the primary outcome measure was ACR composite score & Paulus criteria. Nine 
secondary efficacy outcome measures were pre-specified. The Larsens score and erosive joint 
count were also evaluated. 
 
Main efficacy results: 
With modified intention to treat analysis 27%, 39%, 34% and 43% patients met the ACR20 
response criteria at week 24 when treated with placebo and anakinra 30mg, 75mg, 150mg 
respectively (p=0.047, 0.276, 0.014 for each dose versus placebo). Similar responses were 
documented using Paulus criteria with 20% response in 21%, 39%, 37% and 44% patients 
respectively.  
 
Sustained ACR20 response, defined as ACR20 response for 4 of the 6 study months, one of 
which must be observed at week 12 or 24, was achieved by 11% patients treated with 
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placebo, 28%, 28% and 24% of patients treated with anakinra 30mg, 75mg and 150mg 
respectively (p= 0.0009, 0.0005, 0.0083 vs placebo). ACR50 responses occurred in 8% of 
placebo patients, 13%, 10% and 18% with increasing doses of anakinra (LOCF method).  
ACR70 responses occurred in less than 1% of cases except for the group treated with 
anakinra 30 mg (4%). 
 
The mean change from baseline in the components of the ACR were all significantly reduced 
with the highest dose of anakinra. Consistent changes across all these criteria were not 
evident for the other two doses of anakinra evaluated. Refer to Table 6, page 50. 
 
The duration of EMS was only significantly reduced with 75mg anakinra vs placebo 
(p=0.006). Hand radiographs were available for 74% of the patients at baseline and 24 weeks.  
The mean Larsen score increased by 6.4 (from a baseline of 15.4) with placebo compared 
with increases of 3.8, 3.9 and 4.0 respectively with increasing doses of anakinra (p=0.04, 
p=0.09 and p=0.11 comparing anakinra with placebo).  The number of joints with erosions 
increased by 2.6 with placebo (5.0 at baseline) compared with increases of 1.5, 1.0 and 1.7 
respectively with increasing doses of anakinra (p=0.02, p=0.004 and p=0.074 comparing 
anakinra with placebo). 
 
Twenty seven % of patients dropped out of this trial prior to the 6 month primary endpoint 
with the highest drop out occurring in the placebo group (26% placebo vs 20%, 19% & 24% 
anakinra 30mg, 75mg & 150mg respectively). Of the completers 37% of placebo patients 
achieved ACR20 response at 24 weeks compared with 49.5%, 42% and 52% with increasing 
doses of anakinra (p = 0.12, 0.56 and 0.04 respectively).  One patient allocated to anakinra 
withdrew before receiving study medication. Of the remaining withdrawals 20% patients on 
placebo and 12% on anakinra (all doses) withdrew due to lack of efficacy and 4% vs 9% 
respectively for adverse effects. 
 
Adverse events: 
These were reported in detail in an internal company report. Severe adverse events, as 
defined by the FDA, occurred in 12% of placebo treated patients compared with 8%, 15% 
and 16% with increasing doses of anakinra.  
 
The most frequent adverse event was injection site reactions (ISRs: 25% placebo, 50%, 73%, 
81% respectively with increasing anakinra). Most ISRs were graded ‘mild’ or ‘moderate’ but 
some took 2-3 weeks to resolve.  Symptoms of ISRs included local irritation, pain or 
urticaria.  Patients experiencing ISRs usually reported them within 28 days of starting 
treatment.  No ISR was recorded as a serious adverse event but ISRs led to study withdrawal 
in 2% of placebo treated patients, and 1%, 3% and 5% of anakinra patients with increasing 
dose of anakinra. Worsening of joint pain was reported by 50% of placebo treated patients 
and, 48%, 42%, and 38% respectively for anakinra 30mg, 75mg and 150mg doses. 
Headaches were reported in 6% patients on anakinra 150mg compared to 1% with placebo 
(no further details given).  
 
Infections occurred in 38% patients treated with placebo and 37% treated with anakinra (all 
doses). The most common infections were upper respiratory tract infections (URTI), 
influenza like symptoms and urinary tract infections (UTIs). Infections resulting in antibiotic 
therapy occurred in 12% placebo treated and 15-17% anakinra treated patients. Six patients 
were hospitalised for infections, 4 in the 150mg anakinra group. Serious infections were 
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reported in 7 patients ; placebo (1 URTI), 75mg (2; URTI and bursitis), 150mg (4; 
UTI/URTI, Herpes Zoster and 2 bursitis) anakinra.  
 
Three patients given anakinra were withdrawn due to neutropenia (<2.0 x 103/µl; as required 
by study protocol). Clinical symptoms were not seen and neutrophils recovered on drug 
withdrawal. In three patients, one in each anakinra arm, anti-IL1-Ra antibodies were detected 
at two or more follow up visit (titres of between 1:50 to 1:800).  
 
Four patients on anakinra [30mg (2), 150mg (2), none receiving placebo or 75 mg] developed 
a malignancy during treatment (lung cancer, oral squamous cell cancer, basal cell carcinoma, 
thyroid cancer). A further patient who received 30mg anakinra was diagnosed with small cell 
lung cancer 3 weeks after completing the study. These were all considered unrelated to the 
study drug. 
 
Comments 
Patients were enrolled if they had had RA for > 6 months but less than 8 years. Thus patients 
were at an early stage of disease and 59% of patients had received fewer than 2 DMARDs at 
inclusion.  Patients who had failed to respond to 3 or more previous DMARDs were excluded 
however 4 patients were reported as having received 4 previous DMARDs at baseline. 
Differences between groups at baseline in terms of DMARD use did not  predict response to 
anakinra. 
 
It seems likely that unmasking to treatment allocation occurred during the study due to the 
high rate of ISRs in patients receiving anakinra, particularly the 150mg dose. 
 
The modified intention to treat analysis included all patients who had taken at least one dose 
of study drug and had at least one post-baseline evaluation. No adjustment for multiple 
comparisons was undertaken in the reporting of the trial results. P values quoted in the papers 
are thus nominal values. If a Bonferroni adjustment for multiple comparisons were applied p 
values would have to be less than 0.017 for significance at the 0.05 level to be retained.  
 
Sensitivity analyses were reported, in an internal company report, by assuming that subjects 
with missing data or unusable data at week 24 had not responded.  Reported p values 
comparing anakinra with placebo were 0.033, 0.186 and 0.033 for anakinra 30, 75 and 150 
mg respectively.   
 
The trial protocol specified that radiological progression of the disease would be assessed by 
the Larsens score and erosive joint count (EJC) following defined methodology. A post-hoc 
analysis re-reading the data using different methodology was undertaken to calculate a 
modified Sharp score. The results from this re-analysis suggested that anakinra may have 
activity in inhibiting radiological progression. However data from 133 patients was not 
included in this re-analysis. Caution is therefore advised in the interpretation of this post-hoc 
analysis. The FDA state ‘ the lack of statistical significance of the primary analysis and large 
amount of missing data (26%) limit the conclusions that can be based on this data.’  The re-
analysis using Sharp score is not therefore considered in this evaluation. 
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Study 0182 – unpublished 101;103;108 
This European randomised controlled trial was a phase 1 pilot study, conducted in 15 centres 
across 6 European countries in 1997. It was undertaken to evaluate the efficacy of lower 
doses of anakinra. 
 
Population: 
Adult patients (≥ 18 years of age) with active RA for at least 6 months but less than 8 years 
were enrolled into this trial. Patients had to have ≥ 10 swollen joints and were not permitted 
to use DMARDs during the study. DMARDs were discontinued at least 6 weeks before study 
entry with the exception of ciclosporin, which had to be stopped 6 months before the trial 
commenced. Treatment with NSAIDs and/or low doses of oral corticosteroids could be 
continued provided doses were stable for at least 4 weeks before entry. 
 
A total of 141 patients were randomised to treatment for 12 weeks. Of 141 patients 108 
(77%) were female.  Patients had a mean age of 52 years (range 25-80) and all were white. 
The majority (79% to 93%) of patients were using NSAIDs at baseline and 38% to 50% were 
receiving corticosteroids. Patients had active disease with an average of 32 to 36 
tender/painful joints and 23 to 25 swollen joints, mean HAQ of 1.5 to 1.7, and mean ESR of 
40 to 47 mm/hr. Mean CRP concentrations were higher in the placebo group (4.2mg/dl) than 
in the anakinra groups (2.7 to 3.1 mg/dl). Mean disease duration was also higher in the 
placebo group (4.9 years) than in the anakinra treatment groups (2.7 to 3.7 years) as was the 
median number of previous DMARDs ( 2.0 vs 1.0). Of placebo treated patients, 53% had 
previously used methotrexate compared with 29-40% anakinra treated patients. At baseline 
59% to 76% patients across the treatment groups were positive for RF.  
 
At baseline notable differences in baseline characteristics were longer mean duration of RA, 
higher proportion of methotrexate use, lower proportion of DMARD-naïve subjects, higher 
mean CRP concentration, higher RF titres in the placebo group.  
 
Interventions: 
All treatments were given by subcutaneous injection, once daily. Patients were randomised 
to: 
• Placebo n= 30 
• Anakinra 2.5mg/day n=42 
• Anakinra 10mg/day n= 40 
• Anakinra 30mg/day n=29 
 
Study duration and key outcomes: 
12 weeks – Primary endpoint ACR 20 response at week 12 
 
Secondary endpoints included change from baseline in ACR components at week 12, ACR50 
ACR70, duration of morning stiffness and ESR. 
 
Main efficacy results: 
No statistically significant effects of anakinra on primary or secondary endpoints were 
documented. 
 
ACR 20 response was seen in 43% placebo treated and 26%, 28% and 34% patients treated 
with anakinra 2.5mg, 10mg, and 30mg respectively.   
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Twelve % of patients withdrew prematurely; 10% placebo, 19%, 7.5%, 10% anakinra 2.5mg, 
10mg and 30mg respectively. 
 
Adverse events: 
Anakinra was well tolerated with 5.4%  patients withdrawing from treatment due to an 
adverse reaction. Adverse events occurred at comparable rates across the treatment groups 
(including infections). The most frequent event was RA flare; 17% on placebo and 14% on 
anakinra. ISRs were reported in 3% placebo and 12%, 18% and 35% of patients treated with 
anakinra 2.5mg, 10mg, 30mg/day. 
 
No changes in WBC counts were documented. Antibodies to anakinra were seen in 5% of 
anakinra treated patients. 
 
Comments: 
Intention-to-treat (ITT) analysis was undertaken for all randomised patients who received at 
least one dose of study drug with non-responder imputation. 
 
Despite the placebo response rate in this trial being higher than that seen in the other efficacy 
trials with anakinra, the ACR response seen with the low doses of anakinra was low and 
cannot be considered different to that achieved with placebo. 
 
3.2.3.2 Anakinra in combination with DMARDs/ MTX 
Two trials have evaluated use in combination with MTX, only one of these is completed and 
published in full.104 The second trial is a one year study which focuses on the effect of 
treatment on disease progression. Whilst this trial is now completed, full data on the one year 
endpoint are not yet available. Data to 6 months (for a sub-set of patients) on the effect of 
treatment on ACR responses is reported in an abstract105, the FDA and EMEA submission 
documents and the clinical study report provided by Amgen in confidence. A third trial, a 
pragmatic safety study, evaluated use in combination with DMARDs.106 
 
Study 0180 – Cohen and colleagues 2002104;109  
 
Population: 
Patients enrolled in this trial had active RA despite treatment with methotrexate for at least 6 
months (15-25mg/week). The dose of methotrexate had to have remained stable for at least 3 
months before study entry and was maintained at this level throughout the trial.  Patients 
received folic acid to reduce methotrexate toxicity.  
 
Concomitant treatment with other DMARDs was not permitted. These were discontinued at 
least 12 weeks before study entry with the exception of hydroxychloroquine and sulfasalazine 
which were discontinued at least 8 weeks before entry. Treatment with NSAIDs and low dose 
oral corticosteroids (≤ 10mg/day of prednisolone or equivalent) was permitted provided doses 
were stabilised for 4 weeks before study entry and for the duration of the trial.  
 
Active disease was defined as at least 6 swollen joints and the presence of at least two of the 
following: 
• At least 9 tender and painful joints 
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• Morning stiffness lasting at least 45 minutes 
• CRP of greater than 1.5mg/dl 
 
A total of 419 patients participated in this study across 36 centres in the US, Canada and 
Australia. The design was however complicated by a change to the original trial protocol (see 
comments below). 419 patients were evaluated at the 12 week endpoint of whom 317 were 
also evaluated at the 24 week endpoint.  
 
The mean age of patients enrolled in the trial was 52.5 years and mean disease duration 7.5 
years. Over 80% of patients were white and 66.5% female. Excluding methotrexate the  
median number of previous DMARDs was 2.0 for all groups except for patients treated with 
0.4 and 2.0 mg/kg/day who had received a median of 1.0 previous DMARD.  Twenty % of 
placebo patients and 14%, 19%, 31%, 27%, and 23% of anakinra patients (in increasing 
doses) had not received any other DMARD previously.  NSAID use (68.9%) and oral 
corticosteroid use (64.1%) varied across the groups but was generally comparable between 
control and the higher anakinra doses evaluated (1.0 & 2.0mg/kg/day). 70-80% patients were 
rheumatoid factor positive at baseline.  
 
The median dose of methotrexate at baseline was 15 mg/week for all groups except patients 
on 0.04 and 0.1 mg/kg/day of anakinra who received 17.5 mg and 15.6 mg per week 
respectively. Patients had a mean of 18 swollen and 25 tender joints at baseline. The mean 
tender joint count varied across the treatment groups with the highest level seen in the control 
group (28) and the lowest in patients treated with anakinra 1.0mg/kg/day (22 joints). Mean 
baseline ESR ranged from 35.1 to 37.9 mm/hr across treatment groups. Refer to Table 5: 
Disease activity at baseline across the treatment groups (mean (SEM) or ± SD), page 49.  
Median HAQ scores for all groups were either 1.4 or 1.5 at baseline.  
 
Intervention: 
Study drugs were all administered by subcutaneous injection once daily by the patient or 
caregiver. Rotation of the injection site was advised. Patients were randomised to: 
• Control (MTX alone) n=74 12 weeks, n= 48 24 weeks 
• Anakinra 0.04mg/kg/day n= 63, 12 & 24 weeks   
• Anakinra 0.1mg/kg/day n= 74 12 weeks, n= 46 ,24 weeks 
• Anakinra 0.4mg/kg/day n= 77 12 weeks, n= 55 24 weeks 
• Anakinra 1.0mg/kg/day n= 59 12 & 24 weeks 
• Anakinra 2.0mg/kg/day n= 72 12 weeks, n= 46 24 weeks 
 
Study duration and key outcomes: 
12 weeks subsequently amended to 24 weeks – primary efficacy endpoint was ACR 20 at 
week 12. 
 
In addition to ACR 20 response at week 24, 11 secondary efficacy endpoints were specified 
including ACR50 and ACR70. All but one (sustained ACR 20 response) were assessed at 
both 12 and 24 weeks.  A sustained ACR20 response was defined as an ACR20 response for 
at least 4 out of the 6 months of therapy (not necessarily consecutive), one of which was at 
weeks 12 or 24. 
 
Main Results: 
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ACR 20 response at 12 weeks was 19% with control and 25%, 35%, 25%, 46% and 38% with 
anakinra 0.04-2.0mg/kg/day respectively. A significant dose response was seen (p=0.001) 
across the anakinra groups. The proportions of patients showing ACR20 responses were 
significantly greater for 0.1, 1.0 & 2.0mg/kg/day of anakinra compared with control 
(p=0.014, 0.001 & 0.007 respectively).  Similar results were apparent for ACR20 at 24 weeks 
but a significantly improved response was only apparent with the 1.0mg/kg/day dosage group 
(p=0.018 vs control). ACR20 responses were evident from week 2 but statistically significant 
differences between active and control treatment did not appear before week 4.  
 
A sustained ACR20 response (see above for definition) was seen more frequently for 
anakinra 0.1,1.0 & 2.0mg/kg/day compared to control (30%, 31%, 35% respectively vs 15% 
with control; p<0.05 for all).  
 
The proportion of patients achieving ACR50 and ACR70 was higher at all doses of anakinra 
evaluated (with a significant dose response) compared to control at both time points. ACR50 
responses at week 24 were 4% for control and 8%, 13%, 9%, 14% and 11% for anakinra 
groups with increasing dose.  ACR70 responses at 24 weeks were 0% for control and 5%, 
6.5%, 2%, 10% and 6.5% for anakinra groups with increasing dose.  Statistical tests to assess 
the significance of these improvements compared to control are not reported but only 16 
patients of 345 treated with anakinra showed ACR70 responses at weeks 12 or 24.  
 
The ‘adjusted’ mean change from baseline in the components of the ACR criteria are 
presented for control versus anakinra (refer to Table 6, page 50).  At week 24 statistically 
significant changes from baseline compared to control were apparent for swollen joint count 
(2.0mg/kg/day only), pain (0.1, 1.0 & 2.0mg/kg/day only), physicians global assessment 
(1.0mg/kg/day & 2.0mg/kg/day), patients global assessment (0.1, 1.0 & 2.0mg/kg/day), HAQ 
(1.0 & 2.0mg/kg/day) and ESR (0.4, 1.0 & 2,0mg/kg/day). The improvements in tender joint 
count, CRP and duration of morning stiffness did not reach statistical significance.  
 
Eighty eight patients (21%) withdrew from the study; 19% control and 21%, 16%, 22%, 22% 
& 26% across the anakinra dose groups. Withdrawals were due to lack of efficacy in 7%, 
14%, 10%, 8%, 7% & 6% of patients respectively. 
 
Adverse events: 
Across the dosage groups 4% patients on control, 3%, 1%, 7%, 14% and 15% patients on 
anakinra 0.04-2.0mg/kg/day withdrew from the study as a result of adverse events. ISRs were 
the most common adverse reaction encountered and increased in frequency with increasing 
anakinra dose; 28% control, 19%, 38%, 56%, 64%, 63% anakinra 0.04-2.0mg/kg/dose. These 
were generally mild to moderate and diminished with time. ISRs led to withdrawal from 
treatment in 3%, 0%, 0%, 1%, 7% and 10% respectively across the groups. 
 
The second most frequently reported side effect, potentially related to anakinra, was headache 
seen in 15% placebo, 24%, 20%, 17%, 34% and 14% patients in the 0.04-, 0.1-, 0.4-, 1.0-, 
and 2.0-mg/kg/day anakinra groups respectively. 
 
Severe adverse events were reported in 19% patients treated with placebo compared with 8-
18% treated with any dose of anakinra studied. No deaths were reported during the study. 
Two patients (1 control, 1 anakinra 2.0mg/kg/day) were diagnosed with a new malignancy 
during the study (lung cancer, breast cancer) neither was considered related to the study drug. 
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Other adverse drug reactions (ADRs) were not reported in detail. URTI was documented in 
22% patients treated with control compared with 14-24% treated with anakinra, sinusitis 
(15% vs 5-14%) abdominal pain (1% vs 6%), arthralgia (7% vs 6%) and worsening of RA 
(11% vs 6%). Serious infections occurred in 7 patients in total; 1 control, 2 anakinra 
0.04mg/kg/day, 1 anakinra 0.1mg/kg/day, 1 anakinra 0.4mg/kg/day and 2 anakinra 
1.0mg/kg/day. 
 
Five cases of neutropenia (one in each anakinra dose group) occurred during the course of the 
study. In all cases patients were withdrawn from treatment and white blood cell (WBC) levels 
returned to normal. 
 
Antibodies to IL-1Ra were detected in 9 of the 354 patients screened; 1 control, 8 anakinra. 
Seven of the 8 patients who developed these antibodies suffered with injection site reactions. 
 
Comments 
This trial represents the first study to explore anakinra in combination with methotrexate.  
 
The design of this study was complicated by a change to the initial protocol. The study was 
originally designed to evaluate the 12 week efficacy of anakinra across 3 doses (0.1,0.4, 
2.0mg/kg/day). It was subsequently amended to a 24 week study and included two additional 
doses of anakinra (0.04 & 1.0mg/kg/day). Of the 105 patients originally enrolled in the 12 
week trial only 3 re-consented and remained in the trial to 24 weeks. The impact of this self 
selection is unlikely to significantly undermine the results of this study due to the small 
numbers of patients involved.   
 
Results were analysed by intention to treat with non-responder imputation. Adjusted mean 
changes were reported adjusted for study centre and baseline value. 
 
Again there is the potential for unblinding due to the high frequency of injection site 
reactions with anakinra.  
 
Study 0145 – Cohen and colleagues 2001 103;105;112 
 
Population: 
Patients enrolled in this trial had active RA despite treatment with methotrexate for at least 24 
weeks (10-25mg/week) at a stable dose for at least 8 weeks before study entry. Patients also 
took folic acid at a dose of approximately 1mg/day. At baseline evidence of at least one bony 
erosion was required. 
 
Active disease was defined as at least 6 swollen and 9 tender joints and a CRP level ≥ 1.5 
mg/dl or ESR ≥ 28mm/hr. 
 
Concomitant treatment with DMARDs other than MTX had to be discontinued at least 60 
days before study entry. Treatment with NSAIDs and low dose oral corticosteroids (≤ 
10mg/day of prednisolone or equivalent) was permitted provided patients were on a stable 
dose for at least 4 weeks before study entry. Rescue analgesics were allowed up to 12 hours 
before a scheduled study evaluation and intra-articular corticosteroids could be administered 
to 2 joints on two separate occasions (doses not specified) provided that injections were at 
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least 2 weeks prior to the next assessment visit. The treated joint was thereafter classified as a 
‘failed’ joint in the joint assessment.  The protocol permitted use of NSAIDs or oral steroids 
(or increases in dose), temporarily, for flare of RA symptoms.  However written permission 
was required for changes in steroid doses. 
 
A total of 906 patients were recruited into this trial across 106 centres in the US, Canada and 
Australia. 506 were included in the interim analysis. 
 
The mean age of patients enrolled in the trial was 56.3 years, mean disease duration 10.8 
years. 87% of patients were white and 77% female. Patients had a mean of 20 swollen and 26 
tender joints at baseline. The number of previous DMARDs used was not stated. NSAID use 
(76.4%) and oral corticosteroid use (52.7%) were comparable in both groups. 76.8% patients 
were rheumatoid factor positive at baseline. The median dose of methotrexate at baseline was 
15mg/week and median HAQ scores 1.38 in both groups. Mean baseline ESR was 42 mm/hr 
and CRP 2.6 mg/dl. 
 
Intervention: 
Study drugs were all administered by subcutaneous injection once daily by the patient. 
Patients were randomised to: 
• Control (MTX alone) n=253 24 weeks (453 for 52 weeks) 
• Anakinra 100mg n= 253 24 weeks  (453 for 52 weeks) 
 
Study duration and key outcomes: 
The primary endpoint was radiographic progression measured by modified Sharp score at 1 
year.  However a 6 month interim analysis was undertaken on the 506 patients enrolled in the 
trial as of 18th May 2000 with ACR20 as a primary endpoint. Sustained ACR20 response, 
ACR50, ACR70 and other components of disease were secondary endpoints. Sustained 
ACR20 response was defined as an ACR20 response for at least 4 out of the 6 months of 
therapy (not necessarily consecutive), and one of which was at weeks 12 or 24. 
 
The study blind, for the primary outcome of radiographic progression, was maintained during 
the interim analysis.   
 
Main Results: 
ACR 20 response at 24 weeks was 22% with MTX and placebo (control) vs 38% for  
anakinra 100mg + MTX, p<0.001. It was assumed that where ACR responses could not be 
calculated because of missing data ACR response did not occur (‘non-responder imputation’).  
Similarly patients who increased their baseline dose of methotrexate or corticosteroids were 
classified as non-responders from the time of dose increase.  A significant difference in 
ACR20 response between the groups was apparent from week 4. The ACR response 
increased to week 12 in patients on control and then plateaued. For patients on anakinra + 
MTX ACR 20 response continued to increase to at least week 20.  
 
Sustained ACR20 response was reported in 12% patients treated with control and 27% 
treated with anakinra +MTX, p<0.001. 
 
The proportion of patients who achieved ACR50 and ACR70 was 17% and 5.6%, 
respectively, with anakinra + MTX compared with 8% and 2% with control (p=0.001 and 
p=0.024).  
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The mean reduction in swollen joints for patients treated with control was 6.5 joints (total 
assessed 66) compared with 6.8 for anakinra + MTX (p=0.686) at 24 weeks.  This result is 
surprising since an ACR20 response requires a 20% improvement in swollen and tender 
joints as well as three other disease components (from physician and patient global, patient’s 
assessment of pain, disability score and ESR or CRP). These other disease parameters 
showed significant differences when comparing anakinra + MTX and control (Refer to Table 
6, page 50).  
 
Over 6 months, 67 (26.5%) patients on control and 56 (22.1%) on anakinra withdrew from 
the study. Two patients randomised to control and 3 to anakinra did not receive study drug 
and were excluded from the ITT analysis. Of the other withdrawals 29 (12%) patients on 
control and 12 (5%) on anakinra withdrew at the subjects request and 10 (4%) vs 3 (1%) 
because of disease progression. Lack of efficacy per se was not specified as a reason. 
 
Adverse events: 
Withdrawals due to adverse events are reported to have occurred in 9% of patients on control 
and 13% on anakinra. Injection site reactions were the most common adverse event and 
occurred  in 24% control and 65% anakinra treated patients, leading to withdrawal from the 
study in 0.8% and 8.4% respectively. These reactions were generally mild to moderate and 
transient.  
 
Infectious episodes occurred in 26% of control treated patients compared with 33% for 
anakinra, but there were similar numbers of serious infections (0.8%).  Serious adverse 
events, affecting a variety of body systems, occurred in 8 (3.2%) of control patients and 11 
(4.4%) anakinra patients. No patients died whilst receiving study drug, though one patient 
died of congestive heart failure 37 days after discontinuing study drug (anakinra). 
 
Comments: 
This trial was complicated by allowing a ‘Lack of Efficacy’ (LOE) designation after 16 
weeks. LOE designation was defined as a failure to achieve ACR 20 response on 3 
consecutive visits spanning 8 weeks. These patients continued with study drug and had their 
regimen optimised by changing their methotrexate, corticosteroid and/or NSAID doses. If 
patients continued to meet the LOE criteria after these dosage changes then 
hydroxychloroquine, sulfasalazine, gold, minocycline, leflunomide or ciclosporin could be 
added.  Nineteen patients (7.6%) in each arm increased corticosteroid or DMARD usage (8 
patients on control because of failure to meet efficacy criteria and five patients on anakinra). 
Subjects who required a change in their base-line medication due to LOE were classified as 
non-responders for the ACR20. 
  
In order to prevent assessors becoming aware of treatment allocation due to ISRs independent 
assessors were used to evaluate swollen and tender joint counts. 
 
Results, for the interim analysis, were analysed by intention to treat for all randomised 
subjects who received at least one dose of study drug (n=251 control, n=250 anakinra + 
MTX), with non-responder imputation. Sensitivity analysis around the primary endpoint 
conducted by the FDA identified that the difference in ACR20 response rates between control 
and anakinra remained statistically significant when the analysis was adjusted to: 
• a completer analysis 
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• consider only patients with no injection site reaction 
• count patients who responded after a change to their treatment regimen as responders not 
failures. 
 
Subset analysis by the FDA found no evidence that the benefit from anakinra was limited to 
any identifiable subset of RA patients in terms of age, sex, ethnicity, disease duration, RF 
status & acute phase reactants at baseline, and baseline level of disease activity. 
 
This one-year trial, with a planned recruitment of 990 patients, was designed to evaluate 
radiographic outcome using the modified Sharp total score at 12 months.  Only limited data 
are currently available. Preliminary analysis suggests that anakinra + MTX inhibits joint 
destruction compared to MTX alone (change from baseline to week 52 in total modified 
Sharp score; p=0.002). This effect on disease progression was also apparent in patients who 
failed to achieve an ACR20 response at week 24.  
 
Study 0757 – Fleischman and colleagues 2001106 
This large randomised placebo controlled international study was undertaken to evaluate the 
safety of anakinra in the “usual RA patient seen in clinical practice”. 
 
Population 
Adult patients (age ≥18 years) with RA for at least 3 months were enrolled.  Those on 
DMARDs either as monotherapy or combination therapy had to be on stable doses for at least 
2 months. Concomitant treatment with NSAIDs and/ or low dose oral corticosteroids (doses 
stabilised for at least 1 month) was also permitted. A minimum of 3 swollen and 3 
tender/painful joints or morning stiffness of at least 45 minutes were required for entry. 
 
Changes in NSAIDs, corticosteroids or DMARDs were permitted during the study as 
clinically needed. The following drugs however were not permitted; etanercept, infliximab, 
mycophenolate mofetil, cyclophosphamide, ciclosporin and prosorba column. 
 
A total of 1414 patients in Australia, Belgium, Canada, Germany, Ireland, Sweden, UK and 
the US were enrolled. Over 80% patients were enrolled in the US. The trial was double 
blinded and controlled for the first 6 months with an open label extension to 3 years (still 
ongoing). 
 
The mean age of patients enrolled in this trial was 55 with 23.0% patients aged 65 or over. 
Mean disease duration was 10.2 years (median 7.5 years), 88% patients were white and 75% 
were female. Patients had a mean of 19 swollen and 23 tender joints at baseline.  Mean 
baseline CRP was 2.7 mg/dl (median 1.7).  
 
DMARDs were taken by 82% of patients on control and 78% of patients randomised to 
anakinra.  Figures for MTX were 59% and 52% respectively with a mean (and median) dose 
of MTX of 15mg/wk in both groups. After MTX the most common DMARDs were 
hydroxychloroquine (22% patients) sulfasalazine (14%) and leflunomide (10%). 
Combinations of DMARDs were being given to 30% on control and 28% on anakinra.  
 
At baseline a high proportion of patients were on NSAIDs (87%) and  corticosteroids (58%) 
with similar usage in both groups. 
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Intervention: 
Study drugs were administered by subcutaneous injection once daily. Patients were 
randomised to treatment in a 1:4 ratio. 
• Control (placebo + current DMARD regimen) n= 284 
• Anakinra 100mg/day n= 1130 
 
Study duration and key outcomes 
3 years – the primary endpoint for this ongoing study is safety, evaluated by death, serious 
and severe adverse events and discontinuation from the study due to adverse events. 
 
This study was controlled and blinded to 6 months with open label anakinra planned for  3 
years. Safety data for the 6 month controlled trial are available. The open-label phase will 
complete at the end of 2002.  No efficacy endpoints have been reported and none are 
currently available from Amgen. 
 
Results were analysed by intention to treat for all randomised subjects who received at least 
one dose of study drug (n= 283 control, n=1116 anakinra). 
Main results 
By 6 months 54 of 284 (19%) of the patients allocated control and 255 of the 1130 (23%) 
patients allocated anakinra had withdrawn prematurely.  Withdrawal because of an adverse 
event occurred in 6% and 11.5% respectively. Consent was withdrawn by approximately 6% 
of patients in each group before completing 6 months.   
 
ISRs in particular were more common with anakinra and occurred in 73% vs 33% control 
patients.  ISRs led to withdrawal in 7% vs 1% patients respectively. Anakinra caused ISRs 
that were described as erythema, pruritus or rash whereas control caused ISRs reported as 
pain or ecchymoses.  Most ISRs occurred within one month but the duration of each ISR was 
not determined.   
 
Respiratory events were experienced by 34.6% control treated and 35.0% anakinra treated 
patients, and consisted primarily of URTI and sinusitis. Pneumonia or bronchopneumonia 
occurred in 2 control (0.7%) patients and 15 (1.4%) anakinra patients, leading to withdrawal 
in 5 of these 15.  Musculoskeletal pain and worsening of RA occurred more commonly in 
control treated patients and led to withdrawal in 3.5% of patients compared with  2.1% for 
anakinra treated patients. 
 
Five patients died during the 6 month study; 1 on control (0.4%) and 4 on anakinra (0.4%). 
Causes of death were MI (control), pulmonary fibrosis, suicide, melanoma and upper 
gastrointestinal bleed (anakinra). 
 
Serious adverse events were reported in 7.8% control treated and 7.7% anakinra treated 
patients. By body system a higher proportion of serious adverse events was seen with 
anakinra for the gastrointestinal (2% vs 0.4%) and respiratory (2% vs 0.4%) systems. Severe 
adverse events were reported in 13.1% control and 15.5% anakinra treated patients. 
 
The overall incidence of infections was similar for control and anakinra: 43.5% vs 41.2%. 
However severe infections were more common with anakinra:  2.1% vs 0.4% . None were 
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fatal.  The most common severe infections seen with anakinra were pneumonia (10 patients), 
cellulitis (3 patients ) and osteomyelitis (3 patients). Patients who developed infections 
tended to be male and older.  
 
A total of 9 malignancies were reported during the 6 month study; 4 (0.4%) anakinra vs 5 
(2%) control.  
 
Comments 
This large pragmatic trial was concerned with safety but it also provides effectiveness data 
for anakinra, in a typical clinical population of patients with RA. The first six months of the 
trial when efficacy data were collected, was blinded.  ACR assessments were undertaken at 
screening and at month six.  All data collection for the 6-month endpoints was completed by 
26th July 2000.  The effectiveness data from this trial was requested from Amgen.  The 
pharmaceutical company declined to make it available.  They issued the following statement: 
 
“Study 990757 was designed to evaluate the overall safety of anakinra in 
1,414 patients with rheumatoid arthritis (RA) in the average clinical 
practice to contrast against the more controlled patient populations 
enrolled in previous studies.  The primary safety endpoints assessed the 
incidence of: adverse events, deaths, serious adverse events, and adverse events 
leading to withdrawal, and infections.  No efficacy endpoints were planned 
for the study.  This study included patients receiving a variety of 
concurrent RA medications including multiple DMARD therapies, as well as 
patients who were DMARD-free. Concurrent DMARDs included MTX, 
sulfasalazine, hydroxychloroquine, gold, penicillamine, leflunomide, and 
azathioprine.   The study population also included patients predisposed to 
infection due to a history of underlying disease such as pneumonia, asthma, 
controlled diabetes, and chronic obstructive pulmonary disease.  Patients 
with co-morbidities such as hypertension, coronary artery disease and 
congestive heart failure were also included. 
 
Given the study was not designed to assess efficacy, and the varied patient 
population defined above, it would be inappropriate and misleading to draw 
any conclusions from any efficacy assessments taken from this study. 
Confounding factors such as disease duration, concomitant medications and 
co-morbid conditions make it difficult to define discreet patient 
populations in whom efficacy could be assessed and even where this is 
possible, the low numbers of patients in such analyses renders any clinical 
or statistical assessment invalid.” 
 
It is not true that no efficacy endpoints were planned for the study.  Table 7-1 of the study 
report shows that ACR scores (at the screening assessment and at six months) were collected 
prospectively.  That this was planned from the start of the trial is confirmed in Table 7-2 of 
the study report, Summary of Protocol Amendments, which shows that making an ACR score 
assessment was not a later amendment. 
 
Whilst the primary endpoint of this study was safety the non-disclosure of efficacy data is of 
concern, due to both the large size of this trial and its ‘real life’ design.  
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Concomitant diseases were present in 5-10% patients; COPD 5%, history of pneumonia 
(9%), asthma 9%, CAD 10%, DM 6%. 
 
The study had 63% probability of observing ≥ 1 case of an adverse event occurring with an 
incidence of ≥ 0.1% over two and half years. At the 6 month endpoint there was a > 99% 
chance of detecting an adverse event occurring at a rate of 1%. 
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Table 4 : Description of Included Studies 
Intervention & patient characteristics Study & Description 
Interventions 
 
Anakinra and placebo were administered 
as once daily subcutaneous injections 
Patient 
nos. 
Mean Age 
(years) 
Disease 
duration 
(mean 
years)  
No. of 
previous 
DMARDs 
(mean) 
% On 
steroids 
 
% on 
NSAIDs 
Monotherapy- DMARDs not permitted 
Bresnihan, et al. 1998. 102;107 (0560)  
Study duration – 24 weeks. 
Placebo controlled RCT in 31 European centres of a 
range of doses of anakinra.   
 
 
Placebo 
Anakinra 30mg/day 
Anakinra 75mg/day 
Anakinra 150mg/day 
 
121 
119 
116 
116 
 
52 
53 
53 
54 
 
3.7 
4.3 
4.2 
3.9 
 
1.3 
1.3 
1.3 
1.2 
 
40.5 
48.7 
40.5 
41.4 
 
89.3 
82.4 
87.9 
85.3 
Study 960182101;103 108 
Study duration - 12 weeks 
Placebo controlled RCT conducted in multiple 
centres in Europe to evaluate the efficacy of lower 
doses of anakinra 
 
Placebo 
Anakinra 2.5mg/day 
Anakinra 10mg/day 
Anakinra 30mg/day 
 
30 
42 
40 
29 
 
51.7 
54.2 
52.3 
49.8 
 
4.9 
2.8 
3.7 
2.7 
 
2.1 
1.4 
1.6 
1.4 
 
50.0 
38.1 
47.5 
41.4 
 
93.3 
78.6 
90.0 
82.8 
Combination therapy with DMARDs 
Cohen, et al. 2002 104;109 (0180) 
Study duration – 24 weeks 
Methotrexate controlled RCT in 36 centres across 
America, Canada & Australia to evaluate the efficacy 
of anakinra in combination with methotrexate 
 
Placebo + MTX alone 
Anakinra 0.04mg/kg/day + MTX 
Anakinra 0.1mg/kg/day + MTX 
Anakinra 0.4mg/kg/day + MTX 
Anakinra 1.0mg/kg/day + MTX 
Anakinra 2.0mg/kg/day + MTX 
(12 wk) 
74 
63 
74 
77 
59 
72 
 
53.0 
52.6 
53.0 
52.8 
49.0 
54.1 
 
7.8 
6.3 
8.8 
7.0 
6.5 
8.0 
(Excl MTX) 
2.1 
2.0 
1.9 
1.4 
1.8 
1.9 
 
66.2 
68.5 
64.9 
58.4 
62.7 
65.3 
 
67.6 
79.4 
70.3 
67.5 
64.4 
65.3 
Cohen, et al. 2001 105;110 (0145) 
Study duration – 12 months (interim data to 6 
months) 
Methotrexate controlled RCT in 106 centres across 
America, Canada & Australia to evaluate the effect 
of anakinra in combination with methotrexate on 
disease progression 
 
 
 
Placebo+ MTX 
Anakinra 100mg/day + MTX 
(interim 
analysis) 
 
251a 
250a 
 
 
 
57.0 
55.7 
 
 
 
10.4 
11.1 
 
 
Not 
reported 
 
 
 
52.2 
53.2 
 
 
 
77.3 
75.6 
Fleischman, et al. 2001106;111 (0757) 
Study duration – 3 years (6 months double blind + 
remainder open label) 
International placebo controlled RCT in 169 centres 
to evaluate the safety of anakinra in clinical practice. 
Patients were permitted to continue with their current 
stable DMARD treatment 
 
 
Placebo + current DMARD regimen 
Anakinra 100mg/day + current DMARD 
treatment 
 
 
283b 
1116b 
 
 
56 
55 
 
 
11 
10 
 
 
Not 
specified 
 
 
61 
57 
 
 
86 
87 
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a 253 patients were randomised into each treatment arm, baseline characteristics are only provided for the 501 patients who were randomised and received at least one dose of 
study drug 
b 284 patients were randomised to control and 1130 to anakinra treatment, baseline characterises are only provided for patients who received at least one dose of study drug  
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Table 5: Disease activity at baseline across the treatment groups (mean (SEM) or ± SD) 
Global score STUDY SJC 
(0-66) 
 
TJC 
(0-68) 
 
 
Pain score 
patient Patient Physician 
CRP 
(mg/dl) 
 
ESR 
(mm/hr) 
 
HAQ 
(0-3) 
EMS 
(min) 
 
Bresnihan, et al. 1998. 102;107 (0560) 
24 week data.a (unadjusted) 
Placebo 
Anakinra 30mg/day 
Anakinra 75mg/day 
Anakinra 150mg/day 
 
 
 
25.6 ± 10.3 
26.2 ± 9.9  
26.2 ± 10.2 
26.6 ± 9.5 
 
 
 
32.8 ± 14.1 
33.4± 13.5 
35.7± 14.4 
35.2± 13.5 
(0-1) 
 
0.62 ± 0.2  
0.62 ± 0.2  
0.65 ± 0.2 
0.63± 0.2 
(0-4) 
 
3.0 ± 0.5 
3.1± 0.5 
3.1 ± 0.5  
3.1 ± 0.5  
(0-4) 
 
3.0 ± 0.4 
3.1 ± 0.4 
3.1 ± 0.5 
3.1 ± 0.4 
 
 
4.2 ± 4.2 
4.1 ± 3.7  
4.2 ± 3.8 
4.0 ± 4.0 
 
 
47 ± 30 
49 ± 27 
53 ± 31 
49 ± 30 
 
 
1.5 ± 0.6 
1.5± 0.6 
1.6 ± 0.7 
1.6 ± 0.7 
 
 
 
127 ± 92  
138 ± 102 
138 ± 109 
133 ± 101 
Study 960182 103;108 
12 week data. 
Placebo 
Anakinra 2.5mg/day 
Anakinra 10mg/day 
Anakinra 30mg/day 
 
 
25.1 ± 10.2 
22.6 ± 10.1 
24.0 ± 10.2 
23.7 ± 9.6 
 
 
35.8 ± 13.0 
32.4 ± 13.4 
32.1 ± 11.6 
32.4 ± 12.7 
(0-100) 
 
65.6 ± 16.0 
62.5 ± 18.5 
56.3 ± 18.5 
55.4 ± 18.8 
(0-4) 
 
3.2 ± 0.5 
3.1 ± 0.5 
3.0 ± 0.5 
3.1 ± 0.4 
(0-4) 
 
3.3 ± 0.5 
3.0 ± 0.4 
3.1 ± 0.4 
3.1 ± 0.4 
 
 
4.2 ± 3.9 
3.1 ± 3.3 
2.7 ± 2.9 
2.8 ± 4.3 
 
 
47 ± 27 
45 ± 26 
40 ± 21 
41 ± 27 
 
 
1.6 ± 0.7 
1.7 ± 0.5 
1.6 ± 0.6 
1.5 ±0.7 
 
 
136 ± 84 
124 ± 92 
132 ± 94 
117 ±83 
Cohen, et al. 2002 104;109(0180)  
24 week data 
Placebo + MTX alone 
Anakinra 0.04mg/kg/day + MTX 
Anakinra 0.1mg/kg/day + MTX 
Anakinra 0.4mg/kg/day + MTX 
Anakinra 1.0mg/kg/day + MTX 
Anakinra 2.0mg/kg/day + MTX 
 
 
18.4 ± 9.8 
18.8 ± 8.7 
18.3 ± 9.2 
19.1 ± 9.2 
17.6 ± 8.8 
17.4 ± 8.1 
 
 
28.1 ± 13.9 
23.9 ± 11.4 
25.9 ± 14.8 
27.1 ± 13.0 
22.0 ± 12.9 
24.6 ± 12.8 
(0-100 
scale) 
52.5 ± 22.2 
46.4 ± 20.9 
51.6 ± 22.4 
51.2 ± 21.3 
47.5 ± 22.8 
54.6 ± 21.4 
(0-100 
scale) 
52.6 ± 21.5 
47.6 ± 21.2 
51.1 ± 21.5 
50.4 ± 19.3 
47.5 ± 21.5 
51.2 ± 21.7 
(0-100 scale) 
56.7 ± 18.5 
55.7 ± 19.2 
61.2 ± 17.6 
60.1 ± 18.5 
53.6 ± 17.0 
55.8 ± 18.5 
 
 
2.0 ± 2.6 
2.2 ± 3.46 
1.6 ± 1.6 
2.1 ± 2.5 
1.6 ± 2.3 
2.0± 2.6 
 
 
36 ± 28 
37 ± 23 
38 ± 25 
37 ± 26 
37 ± 25 
35 ± 21 
 
 
1.4 ± 0.6 
1.4 ± 0.6 
1.5 ± 0.7 
1.5 ± 0.6 
1.3 ± 0.6 
1.3 ± 0.6 
 
 
140 ± 113 
129 ± 90 
117 ± 91 
120 ± 91 
134 ± 99 
143 ± 98 
Cohen, et al. 2001 105;110(0145) 
24 week data 
Placebo + MTX 
Anakinra 100mg/day + MTX 
 
 
 
20 ± 10.2 
20.1 ± 11.7 
 
 
24.5 ± 13.1 
26.8 ± 15.7 
(0-100) 
 
55.7 ± 20.4 
59.2 ± 21.6 
(0-100) 
 
52.3 ± 19.8 
53.2 ± 22.1 
(0-100) 
 
57.0 ± 18.4 
57.4 ± 18.7 
 
 
2.6 ± 2.6 
2.7 ± 2.6 
 
 
43 ± 22 
42 ± 22 
 
 
1.32 ± 0.6 
1.36 ± 0.6 
 
 
111 ± 99 
102 ± 84 
Fleischman, et al. 2001 106;111 (0757) 
24 week data 
Placebo + current DMARD regimen 
Anakinra 100mg/day + current 
DMARD treatment 
 
 
18.3 ± 11.7 
18.8± 11.9 
 
 
22.6 ± 14.5 
22.6 ± 14.7 
 
 
Not 
reported 
 
 
 
Not 
reported 
 
 
Not reported 
 
 
2.7± 3.3 
2.7± 3.3 
 
 
Not reported 
 
 
Not 
reported 
 
 
Not reported 
a  Based on modified ITT population n= 468. Four patients (2 placebo, 1 anakinra 75mg/day, 1 anakinra 150mg/day) had no post baseline assessment and were excluded form the analysis  
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Table 6 : Mean (SEM) change in measures of disease activity from baseline 
Global score STUDY SJC 
0-66 
TJC 
0-68 
Pain score 
patient Patient Physician 
CRP 
(mg/dl) 
 
ESR 
(mm/hr) 
HAQ 
(0-3) 
 
EMS 
 
Bresnihan, et al. 1998102;107 (0560) 
24 week data.a (unadjusted) 
Placebo 
Anakinra 30mg/day 
Anakinra 75mg/day 
Anakinra 150mg/day 
 
 
-5.7 (0.9) 
-7.9 (1.2) 
-6.8 (1.0) 
-9.5 (0.9)# 
 
 
-5.2 (1.4) 
-8.6 (1.3) 
-9.3 (1.3) 
-11.9 (1.2) τ 
(0-1cm) 
 
-0.05 (0.03) 
-0.13 (0.03)* 
-0.12 (0.03) 
-0.17 (0.03)τ 
(0-4) 
 
-0.5 (0.09) 
-0.7 (0.09)  
-0.8 (0.09)  
-0.9 (0.09) * 
(0-4) 
 
-0.6 (0.08) 
-0.9 (0.08) * 
-0.9 (0.09) * 
-1.0 (0.08) τ 
 
 
-0.4 (0.28) 
-1.3 (0.25) # 
-1.0 (0.31) # 
-1.0 (0.49) # 
 
 
+1 (2)  
-9 (2) τ 
-8 (2) τ 
-10 (3) τ 
 
 
0.0 (0.04) 
-0.2 (0.05) * 
-0.2 (0.04) * 
-0.3 (0.06) τ 
 
 
-14 (10) 
-36 (10) 
-55 (11) # 
-48 (10) 
Study 960182103;108 
12 week data.b 
Placebo 
Anakinra 2.5mg/day 
Anakinra 10mg/day 
Anakinra 30mg/day 
 
 
-6.8 (1.7) 
-3.0 (1.5) 
-6.3 (1.5) 
-6.4 (1.7) 
 
 
-11.4 (2.4) 
-7.2 (2.1) 
-9.7 (2.1) 
-12.0 (2.4) 
 
 
-21.5 (4.3) 
-14.7 (3.8) 
-11.9 (3.8) 
-12.9 (4.4) 
 
 
-1.0 (0.15) 
-0.8 (0.14) 
-0.9 (0.14) 
-0.9 (0.16) 
 
 
-1.20 (0.13) 
-0.72 (0.12) 
-0.92 (0.12) 
-0.82 (0.14) 
 
 
0.02 (0.19) 
-0.01 (0.17) 
-0.06 (0.17) 
0.01 (0.19) 
 
 
-2 (3) 
1 (3) 
-5 (3) 
-2 (3) 
 
 
-0.33 (0.09) 
-0.30 (0.08) 
-0.09 (0.08) 
-0.21 (0.09) 
 
 
-55 (14) 
-26 (13) 
-25 (13) 
-32 (15) 
Cohen, et al. 2002104;109(0180) 
24 week data c 
Placebo + MTX alone 
Anakinra 0.04mg/kg/day + MTX 
Anakinra 0.1mg/kg/day + MTX 
Anakinra 0.4mg/kg/day + MTX 
Anakinra 1.0mg/kg/day + MTX 
Anakinra 2.0mg/kg/day + MTX 
 
 
-4.2 (1.0) 
-5.0 (0.9) 
-5.7 (1.0) 
-6.7 (0.9) 
-6.3 (0.9) 
-7.6 (1.0)* 
 
 
-8.3 (1.5) 
-6.9 (1.4) 
-7.9 (1.5) 
-9.7 (1.4) 
-8.3 (1.4) 
-11.2 (1.6) 
(0-100) 
 
-2.6 (3.1)  
-3.8 (2.9) 
-12.3 (3.1) 
-8.9 (3.0) * 
-12.9 (3.0)* 
-22.8(3.3)τ 
(0-100) 
 
-3.6 (3.0) 
- 5.3 (2.8) 
-12.4 (3.0) 
-8.1 (2.9) * 
-13.8 (2.9)* 
-20.4 (3.2)τ 
(0-100) 
 
-14.1 (2.9) 
-11.5 (2.6) 
-20.3 (2.9) 
-20.4 (2.8) 
-22.3 (2.8)* 
-24.5 (3.1)* 
 
 
-0.19 (0.34) 
0.15 (0.30) 
-0.06 (0.35) 
-0.74 (0.33) 
-0.77 (0.32) 
-0.77 (0.38) 
 
 
-4 (2) 
-4 (2) 
-10 (2) 
-12 (2) # 
-12 (2)# 
-15 (3)# 
 
 
-0.15 (0.07) 
-0.25 (0.07) 
-0.33 (0.07) 
-0.24 (0.07) 
-0.37(0.07) * 
-0.51 (0.07)τ 
 
 
-50 (12) 
-45 (11) 
-63 (12) 
-41 (11) 
-74 (11) 
-82 (13) 
Cohen, et al. 2001 105;110(0145) 
24 week datad 
Placebo + MTX 
Anakinra 100mg/day + MTX 
 
 
-6.5 (0.6) 
-6.8 (0.6) 
 
 
-8.7 (0.9) 
-12.0 (0.9)# 
(0-100) 
 
-11.7 (1.8) 
-19.0 (1.7)# 
(0-100) 
 
-8.9 (1.7) 
-17.7 (1.6)τ 
(0-100) 
 
-20.1 (1.5) 
-25.2 (1.5)* 
 
 
-0.10 (0.04) 
-0.51 (0.03)τ 
 
 
-6 (1) 
-16 (1)τ 
 
 
-0.18 (0.03) 
-0.29 (0.03)* 
 
 
-36 (6) 
-48 (6) 
Fleischman, et al. 2001106;111 
(0757)24 week data 
Placebo + DMARD  
Anakinra 100mg/day + DMARD  
 
Not 
reported 
 
Not reported 
 
Not reported 
 
Not reported 
 
Not reported 
 
Not reported 
 
Not reported 
 
Not reported 
 
Not reported 
a  Based on modified ITT population n= 468. Four patients (2 placebo, 1 anakinra 75mg/day, 1 anakinra 150mg/day)had no post baseline assessment and were excluded from the analysis  
b ITT analysis using least squares mean obtained from repeated measures mixed model adjusted for centre and baseline value, with the exception of HAQ outcome data which are provided for the completer subset only. 
c Least squares mean obtained from repeated measures mixed model adjusted for study centre and baseline variable  
d Adjusted mean and SE estimated by EMEA based on repeated measures mixed model adjusted for study week, treatment by study week interaction, centre and baseline value 
 
* p<0.05 vs placebo      # p≤ 0.01 vs placebo     τ p≤0.001 vs placebo  
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Table 7: Percentage of patients showing ACR response and %age discontinuing therapy 
DRUG CESSATION  
Study & Intervention 
ACR20  ACR50  ACR70  
Any reason Lack of efficacy Toxicity 
Bresnihan, et al. 1998. 102;107 (0560) 24 week data.a 
Placebo 
Anakinra, 30mg/day 
Anakinra 75mg/day 
Anakinra 150mg/day 
 
27 
39* 
34 
43* 
 
7 
17* 
11 
17* 
 
1 
4 
1 
1 
 
26 
20 
19 
24 
 
20 
13 
12 
9 
 
4 
4 
6 
9 
Study 960182101;103;10812 week data. 
Placebo 
Anakinra 2.5mg/day 
Anakinra 10mg/day 
Anakinra 30mg/day 
 
43 
26 
28 
34 
 
13 
2.4 
7.5 
6.9 
 
6.7 
0 
0 
0 
 
10 
19 
7.5 
10 
 
0 
7 
2.5 
3 
 
7 
7 
2.5 
7 
Cohen, et al. 2002104;109(0180)  24 week data 
Placebo + MTX alone 
Anakinra 0.04mg/kg/day + MTX 
Anakinra 0.1mg/kg/day + MTX 
Anakinra 0.4mg/kg/day + MTX 
Anakinra 1.0mg/kg/day + MTX 
Anakinra 2.0mg/kg/day + MTX 
 
23 
19 
30 
36 
42* 
35 
 
4 
13 
20 
11 
24 
17 
 
0 
5 
7 
2 
10 
7 
 
19 
21 
16 
22 
22 
26 
 
7 
14 
10 
8 
7 
6 
 
4 
3 
1 
7 
14 
15 
Cohen, et al. 2001 105;110(0145) 24 week data 
Placebo + MTX 
Anakinra 100mg/day + MTX 
 
22 
38τ 
 
8 
17τ 
 
2 
6* 
 
27 
22 
 
Not reported 
 
9 
13 
Fleischman, et al. 2001106;111 (0757)24 week data 
Placebo + current DMARD regimen 
Anakinra 100mg/day + current DMARD treatment 
 
Not 
reported 
 
Not 
reported 
 
Not 
reported 
 
19 
23 
 
Not reported 
 
 
6 
12 
 
* p<0.05      τp≤0.001 
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3.2.4 Meta-analysis 
 
Treatment with anakinra at doses in line with the licensed dose of 100mg/day showed a 
consistent clinical benefit in the trials included in this report.  In order to get a summary 
measure of treatment effect data were pooled.  We describe the methods and key findings 
below. 
 
3.2.4.1 Methods 
 
As this is a rapid review we restricted meta-analyses to six important measures of treatment. 
Three outcomes HAQ, patient global assessment, and swollen joint counts, which reflect 
physical disability, patient-centred outcomes and physician assessment of joint disease 
respectively, were reported as continuous data.  Three other outcomes, the ACR20, ACR50 
and ACR70, which are presented as binary data and which represent an overall measure of 
treatment effect were also analysed. The primary analysis pooled results from the latest 
follow up data available for the blinded, randomised, controlled period of each trial (24 
weeks for all studies with the exception of 0182 where data are presented at week 12).  
 
We pooled results for trials where anakinra (with or without methotrexate) was compared to 
placebo. Pooled results for use in combination with methotrexate (licensed indication) are 
also presented. For the dose ranging trials (0560, 0180) a chi-squared test for trend was 
undertaken for the ACR endpoint based on the aggregated data. Since individual patient data 
were not available for the disease activity endpoints a test for trend could not be undertaken 
since group data may be subject to the ecological fallacy*. Given that the test for trend on the 
ACR 20, 50 and 70 endpoints suggested that there may be a dose response, the doses closest 
to the licensed dose were pooled (75mg and 150mg for study 0560, 1.0 and 2.0mg/kg/day for 
study 0180). However all data should be considered relevant.  A sensitivity analysis including 
all data is therefore also reported. 
 
Where possible, the SD was taken directly from the reported results or derived from the SEM 
where used. Where an outcome was reported on the same scale the results are presented as a 
weighted mean difference (WMD).  
 
A fixed effects model was used since statistical heterogeneity was not demonstrated across 
the trials. 
 
To pool outcomes which use continuous data we used the final result not %age change from 
baseline. More estimates of variability were available in this way. 
 
3.2.4.2 ACR Improvements 
 
Licensed dose analysis 
Pooled analyses for ACR improvements, (at or around the licensed dose of anakinra, based 
on n=1007) are shown in Figure 2, page 54, Figure 3, page 55 and Figure 4, page 56 as both 
                                                 
*The ecological fallacy is the attribution of group level associations (e.g. from aggregated 
trial data or countries) to the individuals that constitute the group. 
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relative risk (RR) and risk difference (RD). A clear treatment effect is evident for ACR20 but 
effect on the more rigorous endpoints of ACR50 and ACR70 is much smaller.  
 
Clinical effectiveness, when expressed in terms of RR of achieving an improvement in ACR, 
increases with a higher hurdle, such that RR of achieving an ACR20 with anakinra was 1.6, 
whilst RR of achieving ACR70 was around 3, consistent with treatment effect.  However, 
effectiveness expressed as a risk difference decreases, reflecting the much lower prospect of 
achieving an ACR50 or ACR70 with placebo.  The number needed to treat (NNT) to achieve 
an ACR20 response was 7 (95%CI 5 to 11), NNT for ACR50 was 11 (95% CI 8 to 20) and 
the NNT for ACR70 was 33 (95% CI 20 to 100).  Both the ACR50 and ACR70 are believed 
to be clinically very significant.  
 
For the subset of patients enrolled in trials who received anakinra (at or around the licensed 
dose) in combination with methotrexate (based on n=654), the NNT to achieve an ACR 20 
response was 6, ACR 50 was 9 and ACR 70 was 20 .  
 
All dose analysis 
When ACR endpoint data for all doses of anakinra evaluated in clinical trials are pooled 
(based on n=1429), the NNT to achieve an ACR20 response increases to 9 (95% CI 6 to 17) 
and for ACR 50 increases to 13 (95% CI 9 to 25). A statistical benefit in terms of ACR 70 
response is no longer apparent. 
 
Anakinra for the treatment of RA- TAR  WMHTAC 
Confidential Page 54 07/04/2003 
Version for website publication 
Figure 2 : Anakinra (licensed dose) vs placebo result at end of trial - ACR20 
Relative Risk  
 
 
Risk difference 
Anakinra for the treatment of RA- TAR  WMHTAC 
Confidential Page 55 07/04/2003 
Version for website publication 
Figure 3 Anakinra (licensed dose) vs placebo result at end of trial - ACR50 
 
Relative Risk 
 
 
 
Risk difference 
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Figure 4 Anakinra (licensed dose) vs placebo result at end of trial - ACR70 
 
Relative Risk 
 
 
Risk difference 
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Sensitivity analysis considering study 0757  
For any decision we make there will always remain some uncertainty and variability in the 
data that inform the decision.  A key role of decision analytic modelling is, not only to obtain 
the best estimate based on current knowledge, but importantly, to investigate the 
consequences of plausible estimates concerning the uncertainties. 
 
Trial 0757 had less restrictive inclusion criteria, to reflect the characteristics of people with 
RA, than the other trials (which use a more controlled patient population not representative of 
average clinical practice) and is therefore probably the most generalisable of all the trials to 
real life practice.  Thus the findings of study 0757 are highly relevant to the Health 
Technology Assessment.  Moreover over half the people who have received anakinra (1116 
out of the 2146) were in this trial (of whom 77.4% completed the first six months) so a 
significant amount of trial data is missing.  For these reasons trial 0757 should not be ignored.   
 
The fact that the pharmaceutical company has declined to allow the effectiveness data for this 
trial into the public domain and their assertion that any statistical assessment of efficacy 
would be invalid, suggests to the authors of this report that the effectiveness in this pragmatic 
trial may have been less than in the earlier trials and probably did not reach conventional 
levels of statistical significance.    
 
If the assumption were made that the withheld data showed no difference in effectiveness 
between the anakinra and placebo recipients, this would give the following combined 
estimate of effect for ACR 20 response: RR 1.39 (95% CI 1.03 to 1.87),  RD 0.10 (95% CI 
0.01 to 0.19).  However, this figure almost certainly underestimates the effectiveness of 
anakinra seen in this trial as it is unlikely that, given the positive results from earlier trials, the 
result from 0757 would be completely null or negative.   
 
However we think that the result was probably suggestive of benefit but failed to reach 
conventional levels of statistical significance.  Based on the assumption that the results from 
this trial favour anakinra over placebo but the p-value of treatment difference was possibly of 
the order of p< 0.1 to p<0.2, we worked backwards to derive a plausible estimate of 
effectiveness for trial 0757.  Of the 283 placebo patients, 66 were assumed to have an ACR20 
response (paralleling the 23% response rate seen in the combined results for the placebo 
groups in earlier trials).  We worked backward and calculated that a response rate of 
303/1116 in the anakinra group would have given a two-sided p<0.2 or one-sided p<0.1. 
 
We combine this figure for trial 0757 with the data from the earlier trials to give our best 
summary estimate about anakinra’s effectiveness (Figure 5, page 58).  Given the fact that 
there is clinical heterogeneity in terms of different population characteristics, co-morbidities 
and co-medications in trial 0757 compared to earlier trials we combined 0757 with previous 
trials using a random effects model.  This gives the following as the best summary estimate 
of effectiveness for the ACR 20 response; RR 1.43 (95% CI 1.16 to 1.76), RD 0.11 (95% CI 
0.04 to 0.18), NNT 9 (95% CI 6 to 25). 
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Figure 5 Anakinra (licensed dose including study 0757) vs placebo, result at end of trial 
- ACR20 
 
Relative Risk 
Risk difference 
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3.2.4.3 HAQ Scores, patient global assessment, and swollen joint counts 
 
The pooled result at the end of trials for HAQ scores for anakinra versus placebo gave a 
weighted mean difference of  -0.18 (95% CI –0.12 to –0.24) with licensed doses (Figure 6, 
page 59) and –0.16 (95% CI –0.11 to –0.22) for all doses.  The HAQ scale scores 0 for 
normal function and 3 for greatest disability, thus a reduction indicates improved function. 
Improvement in function was slightly less in the pooled analysis of trials which evaluated 
anakinra (licensed dose) in combination with methotrexate (WMD –0.14 95% CI –0.07 to –
0.22) 
 
Patient global assessment of disease activity, which indicates the patient’s view of how the 
arthritis is doing, was scored in most trials on a scale of 0 (best) to 100 (worst).  The 
weighted mean difference for anakinra at licensed dose compared to placebo was –10.4 (95% 
CI –6.3 to –14.4) at the end of the studies (Figure 7, page 60).  This also represents the 
improvement seen with use in combination with methotrexate.  The monotherapy trials 0560 
and 0182 used a scale of 0 to 4 for patient assessment of disease activity and were not 
included in this meta-analysis.  Whilst no effect was evident in the low dose study 0182, in 
study 0560 the direction of effect on patients global assessment of disease activity was 
consistent with the other trials, although the size of benefit is much smaller.  
 
The swollen joint count at the end of studies was reduced by 1.5 (95% CI –0.38 to –2.68) in 
the anakinra (licensed dose) arms compared to placebo (Figure 8, page 60) and by 1.2 (95% 
CI –0.11 to –2.2) for all doses. Similar but slightly smaller benefit which was no longer 
statistically significant was evident with use in combination with methotrexate, reduction of 
1.2 (95% CI 0.15 to –2.54). 
Figure 6 HAQ: Anakinra (licensed dose) versus placebo 
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Figure 7 Patient global assessment: Anakinra (licensed dose) versus placebo 
 
Figure 8 Swollen joint counts: Anakinra (licensed dose) versus placebo 
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3.2.5 Anakinra compared to other agents 
 
The trial data clearly demonstrate that anakinra at the higher doses evaluated has a 
statistically significant effect, compared to placebo, on ACR 20% response rates in patients 
with RA.  However, no trials have directly compared anakinra head-to-head with another 
DMARD or more specifically another biological modifier. In trials where patients continued 
with methotrexate but were given additional treatment with anakinra or placebo, these were 
not regarded as a direct comparison of DMARD against anakinra. 
 
In Europe anakinra is only licensed for use in combination with methotrexate. A number of 
trials with TNF inhibitors have evaluated use in combination with methotrexate. Direct 
comparisons between these classes of drugs have not been undertaken. When there is no 
direct comparison it has been demonstrated that the adjusted indirect method (which makes 
some adjustment for variability in prognostic factors at baseline across trials) may be used to 
obtain some evidence about the relative efficacy of competing interventions. Such indirect 
results should of course be interpreted with caution, since the estimate provided may differ 
from that obtained by direct comparison within randomised controlled trials.  Nevertheless 
the adjusted indirect method can be useful in guiding clinical practice in the absence of direct 
comparisons between agents.113 
 
Results from 4 clinical trials that evaluated different biological modifiers in combination with 
effective doses of methotrexate have now been published; two with anakinra 104;105, one with 
etanercept114 and one with infliximab.115  Table 8 compares the clinical responses in terms of 
ACR across these trials, for all treatment doses combined for the etanercept and infliximab 
studies and the ‘licensed dose’ for anakinra. This differentiation was made since for anakinra 
a dose response appeared to be evident across the doses evaluated. The response was 
measured at endpoint, 24 weeks for anakinra and etanercept and 54 weeks for infliximab. 
 
Table 8: Adjusted Indirect comparison of anakinra with TNF inhibitors 
Intervention Risk Difference for ACR 20 response 
TNF + MTX vs MTX alone39 0.37 (0.28 to 0.45) 
Anakinra + MTX vs MTX alone 104 0.16 (0.09 to 0.23) 
Anakinra + MTX vs TNF + MTX -0.21 (-0.32 to -0.10) 
 
This indirect comparison suggests that anakinra may be significantly less effective at 
relieving the clinical signs and symptoms of RA, as measured by the ACR response criteria, 
than TNF inhibitors all used in combination with methotrexate. The divergence in benefit is 
particularly evident at the higher levels of ACR response, 50% & 70%.  
 
For the adjusted indirect comparison to be valid, the key underlying assumption is that the 
relative efficacy of an intervention is consistent in patients included in different trials i.e. that 
the estimated relative efficacy is generalisable. For both TNF inhibitors and anakinra 
consistent benefit was seen across clinical trials, trials were of similar design, conducted in 
similar settings with similar sorts of patients and were of high quality. Diagnostic criteria are 
standard in most contemporary trials and inclusion and exclusion criteria can also be 
considered sufficiently similar. We therefore have no reason to ignore the finding of such an 
indirect comparison. 
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3.2.6 Adverse Effects – Summary and additional data 
 
The safety data for anakinra are derived from 2,606 subjects with RA who have been exposed 
to anakinra in clinical trials, including 1,812 (1,379 ≥100mg/d) exposed for at least 6 months 
and 570 (237 ≥ 100mg/d) exposed for at least 1 year.96  Safety for up to 4.5 years has been 
evaluated in 67 patients in the open label extension study of 0560. No new safety concerns 
arose over this time. 
 
Published data on adverse effects are available from the American prescribing information, 
the SPC, the 4 clinical efficacy studies and the 6 month, double-blind safety study. Amgen 
also have safety data from over 12,000 patients in the post marketing setting. Adverse events 
reported in the trial programme are summarised in Table 9 below. 
 
Table 9: Summary of Adverse Events reported in Clinical Trials with Anakinra (all 
doses)  
Adverse event       
 Treatment 0560 0182 0180 0145 0757 
% withdrawing due to 
AE 
Control 4.1% 7% 4.1% 9% 6% 
 Anakinra 6.6% 5% 7.8% 13% 11.5%
Individual events       
Deaths Control 0% 0% 0% 0% 0.4% 
 Anakinra 0% 0% 0% 0% 0.4% 
Serious adverse events Control 11.6% 6.7% 4.1% 3.2% 7.8% 
 Anakinra 12.8% 6.3% 6.7% 4.4% 7.7% 
Malignancy Control 0 0% 1.4% NR 1.8% 
 Anakinra 1.1% 0% 0.3% NR 0.4% 
Injection site reactions Control 25% 3% 28% 24% 33% 
 Anakinra 54.5% 19.8% 48% 65% 73% 
Any infection Control 38% 13.3% 50% 25.9% 43.5%
 Anakinra 37% 13.5 48.4% 33.3% 41.2%
Serious infection Control 0.8% NR 1.4% 0.8% 0.4% 
 Anakinra 1.7% NR 1.7% 0.8% 2.1% 
Neutropenia Control 4% 0% 0% NR NR 
 Anakinra 9% 0% 1.4% NR NR 
Antibodies to Il-1Ra Control 0% 0% 1.8% NR NR 
 Anakinra 0.9% 5% 2.7% NR NR 
Trial 0145  - interim data whilst the trial was ongoing. AE data are limited to avoid breaking the blinding of the 
trial. 
 
Across the five randomised controlled trials, adverse events led to withdrawal from treatment 
in 6.7% control and 10.1% anakinra treated patients. The difference in withdrawal rates 
between control and anakinra were primarily the result of ISRs.  
 
Deaths 
Eighteen patients died whilst taking study medication (5 during double blind treatment and 
13 during open label extension studies); 4 cancer, 3 infections, 5 cardiovascular events, 6 
other. All but one of these deaths occurred in patients taking anakinra. A further patient died 
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37 days after discontinuing study drug (anakinra) from a condition which developed whilst 
on study medication.103 
 
Serious adverse events (SAEs) 
Serious adverse events were essentially defined as any event that represented a significant 
hazard to health. This encompassed events that were life threatening, permanently disabling, 
required or prolonged hospitalisation, resulted in death, or constituted cancer, congenital 
abnormality or overdose. The incidence of serious adverse events in each of the four trials 
presenting results was similar with control and active treatment; 6.5% vs 8% respectively 
across all four trials. 
 
For trials 0560, 0182, 0180 and 0145 the number of SAEs was small and no meaningful 
conclusions can be drawn. No treatment specific trends were noted. 
 
In trial 0757 whilst the incidence of SAEs was similar between the study groups, when 
analysed by body systems compared to control a higher proportion of anakinra treated 
patients suffered GI (<0.4% vs 1.8%) and respiratory (0.4% vs1.6%) events. No predominant 
GI event was evident, however the higher incidence of respiratory events could in part be 
accounted for by higher incidence of pneumonia. In contrast more patients on control 
suffered a serious musculoskeletal event 2.8% vs 2.5% with anakinra, predominantly RA. 
 
Malignancies 
Twenty two malignancies were reported across studies 0560, 0180 (and their open label 
extensions) and study 0757; 16 with anakinra treatment and 6 with control. No predominant 
type of malignancy was observed. A single malignancy, prostate cancer, was reported during 
the 6 month interim analysis of study 0145. Due to maintenance of the blind it is not known 
which medication this patient was receiving.  
 
The incidence of malignancies within clinical trials was within the expected range. Follow up 
over the longer term is however required to fully evaluate the effects of anakinra on 
malignancy. 
 
Injection site reactions (ISR) 
These represent the most common and consistently reported treatment related adverse event 
associated with anakinra in clinical trials, being seen in over 60% patients who received 
therapeutic doses vs < 34% with control. Such ISRs resulted in withdrawal from treatment in 
up to 10% patients treated with anakinra and up to 3% treated with control. 
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Table 10 Reports of and withdrawals due to injection site reactions across clinical trials 
Anakinra Trial Control 
30mg 75mg 150mg 0.04 
mg/kg 
0.1 
mg/kg 
0.4 
mg/kg 
1.0 
mg/kg 
2.0 
mg/kg 
100mg 
0560 ISR 
withdrawals 
25% 
2% 
50% 
0.8% 
73% 
3% 
81% 
5% 
      
0182 ISR 
withdrawals 
3% 
0% 
35% 
0% 
        
0180 ISR 
withdrawals 
28% 
2.7% 
   19% 
0% 
38% 
0% 
56% 
1.3% 
64% 
6.8% 
63% 
9.7% 
 
0145 ISR 
withdrawals 
24% 
0.8% 
        65% 
8.4% 
0757 ISR 
withdrawals 
33% 
1.4% 
        73% 
7.1% 
 
These reactions were characterised by erythema, ecchymosis, inflammation and pain. Such 
reactions were usually reported as mild to moderate occurred within the first 4 weeks of 
treatment and typically lasted for 14-28 days. The frequency of ISRs was seen to increase 
with increasing doses of anakinra across the trials.  
 
Infections 
The overall incidence of infections in each trial was comparable across the control and active 
treatment groups ranging from 26% to 50% (refer to Table 9, page 62). 
 
URTIs, bronchitis, influenza-like symptoms and UTIs were the most commonly reported 
infections in trials 0560, 0180 and 0757 (Table 11, page 64). Sinusitis was also documented 
as a common event in all but trial 0560. These data are not available for studies 0182 and 
0145. For the interim analysis of 0145 it is stated in the trial report that respiratory infections 
were most common (15.5% with control vs 21.2% with anakinra, no further details given).  
 
Table 11: Incidence of commonly occurring infections for studies 0560, 0180 & 0757 
Infection CLINICAL TRIAL 
 0560 0180 0757 
 Control Anakinra Control Anakinra Control Anakinra 
URTI 6.6% 7.1% 21.6% 17.1% 18.4% 13.3% 
Sinusitis 1.7% 0.9% 14.9% 8.4% 6.0% 6.7% 
Bronchitis 4.1% 2.6% 0% 3.2% 4.6% 3.4% 
Influenza like 
symptoms 
5.8% 5.7% 5.4% 6.1% 6.4% 5.8% 
UTI 5.8% 3.4% 5.4% 5.2% 5.3% 4.6% 
 
In the large safety study (0757) whilst the incidence of infections was similar across the two 
groups, when analysed by body system, the GI system showed a higher proportion of subjects 
with infections in the anakinra arm compared to control (5.0% vs 2.8%). 103 No individual 
type of infection or group of infections accounted for this difference. 
 
Considering the subset of infections defined as serious. The incidence in study 0757 was 
increased with anakinra compared to control (2% vs 0.4%). The most common infections 
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were pneumonia, cellulitis and osteomyelitis. None of the 23 infections in patients on 
anakinra were fatal. All resolved with the exception of one case of osteomyelitis. The 
potential risk factors identified for the higher incidence of serious infections were 
corticosteroid use and possibly asthma. 103 
 
In studies 0560, 0180, 0182 & 0145 only small numbers of patients developed serious 
infections.  
 
Neutropenia 
Treatment with anakinra is associated with small reductions in the mean values for WBC 
count and absolute neutrophil count (ANC). The incidence of neutropenia surprisingly is not 
reported for all trials. Trial protocols however required treatment to be withdrawn when 
WBC or ANC levels fell below pre-defined values.116 
 
Across studies 0560 and 0180, 85 of 696 patients treated with anakinra (12%) developed 
neutropenia compared to 10 out of 195 treated with control (4%). For these figures 
neutropenia is defined as an increase of at least one grade of the neutropenia. Most of this 
neutropenia was mild.103 
 
Withdrawal due to neutropenia was reported for 8 patients (1.1%) receiving anakinra and 
none receiving control in these trials.  Time since initiation of anakinra treatment varied with 
about one third developing in the first 100 days and one third after 200 days of treatment. In 
all cases the ANC recovered on withdrawal of the drug. Only 1 case was associated with an 
infection.103 
 
No data on neutropenia are provided for the large pragmatic safety study.  
 
Antibodies to IL-1Ra 
Limited data are available. In study 0560 of 454 patients who had baseline and follow up 
serum samples available 3 patients on anakinra developed positive reactions for anti-IL-1Ra 
antibody reactivity, at 2 or more follow up visits. None were observed in the control group. In 
study 0180 one of 57 screened patients administered control and 8 of 297 administered 
anakinra were seropositive for antibodies to IL-1Ra at some time during the study. Injection 
site reaction occurred in 7/8 seropositive patients given anakinra. No evidence of neutralising 
antibodies was detected. 
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4 ECONOMIC ANALYSIS 
 
4.1 Introduction 
This section of the report has three components: 
• a review of existing economic evaluations of the use of anakinra in RA 
• a technical commentary on the decision-analytic models used in the economic analyses 
reported in the Amgen’s submissions to NICE 
• a description of the modelling and economic analyses of anakinra use in RA patients, 
undertaken by the authors. 
4.2 Existing economic evaluations 
There is extensive literature on the burden of illness and general costs associated with RA, 
which provides an indication of the substantial cost burden imposed on individuals and 
society as a result of the condition.81;117-125  In addition, a number of published economic 
Summary of existing economic evaluations 
 
• No fully published economic evaluations of anakinra in patients with RA were identified. 
Two abstract reports presented limited data. 
 
Commentary on submitted model 
 
• Markov model with six month cycle time 
• There are problems associated with the structure of this model which makes its conclusion, 
that the ICER for anakinra is £16,545/QALY, unreliable 
 
Summary of the Birmingham economic model 
 
The Birmingham Rheumatoid Arthritis Model compares DMARD sequences of drugs, chosen 
to reflect current clinical practice, with and without anakinra, at different points in the 
DMARD sequence 
 
The BRAM gives a base-case estimate of the ICER of anakinra of between £106,000/QALY to 
£604,000/QALY.   
 
This model uses data from public domain trial results only.  These trials recruited a highly 
selective patient population and may well overestimate the cost-effectiveness that anakinra 
would achieve in an average clinic population. 
 
In the sensitivity analyses quite substantial variations were made in key parameters and ICERs 
were shown to be responsive. ICERs did not drop below £50,000/QALY in any univariate 
sensitivity analysis. 
 
The BRAM produces an ICER for anakinra substantially higher than those for infliximab and 
etanercept.  However, patients may respond to anakinra when they have not responded to other 
biologics, as these agents have a different mechanism of action.  Thus anakinra may produce a 
clinically significant and important improvement in some patients that they could not 
otherwise have achieved. 
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analyses of drug therapies for use in RA were also identified, both relating to the use of 
NSAIDs for example, see Gabriel and colleagues126 and DMARDs.127-130   
 
No fully published economic evaluations of anakinra treatment for patients with RA were 
identified from the literature (refer to section 3.1.1 for methodology).  Two abstract reports of 
economic evaluations, which considered use of anakinra in patients with RA, were 
identified.131;132  These abstracts contained insufficient detail to justify reporting here at 
length.  Hochberg and colleagues present a cost-minimisation analysis.  This is based on 
ACR response from placebo controlled RCTs conducted with etanercept, infliximab and 
anakinra all in combination with MTX.  Indirect comparison suggests that anakinra is 
associated with higher cost to achieve an ACR response than the TNF inhibitors.  As 
discussed previously caution is advised when interpreting data from indirect comparisons.131  
 
Brennan and colleagues developed a conceptual model of clinical pathways to compare 
therapeutic strategies; use of anakinra blind versus use in patients testing positive for IL-1A 
allele 2 (using outcome data from a preliminary study). The analysis suggested that there is 
the potential for a pharmacogenetic test to be cost effective in RA.132 
 
4.3 Report on the Amgen model 
Within their submission to NICE Amgen present an economic evaluation using a Markov 
model (see Appendix 7, page 96, for how this economic evaluation was scored using the 
checklist).  The Amgen Markov model was based on the modelling structure used by Kobelt 
et al.133;134  The Kobelt model classifies patients into six disease states by HAQ score. By 
allowing a separate set of transition probabilities for each time cycle within the model, the 
Kobelt model is able to fit any set of patient-level data to describe the progression over the 
period of follow-up of a study. This non-parametric approach has the advantage that it does 
not impose any structural assumptions on the data. However, it means that it is not obvious 
how to extrapolate time forward using the model. More importantly, the transition 
probabilities so fitted may be averages across heterogeneous groups of patients, in which case 
they would not have any meaning for particular patients. This would certainly be the case if 
the model were applied to a group of patients receiving a variety of different treatments. 
 
The published form of the Kobelt model, with only six states for live patients, is not suitable 
for assessing the impact of a strategy of using drugs sequentially, either singly or in 
combination.  The Amgen model overcomes this limitation to some extent by incorporating 
two sets of six “live” states, one set for patients on anakinra and one set for patients not on 
anakinra. 
 
It is not at all clear what population is being modelled. The statements on pages 39-40 of the 
Amgen submission appear to contradict one another. Firstly the report states that the model is 
used to estimate the cost effectiveness: 
 
“…in the treatment of patients with RA in whom conventional DMARDs are no longer 
effective.” 
 
However then it talks about patients who fail anakinra being 
 
“…maintained with conventional DMARDs.  In addition, if treatment resulted in any 
adverse event that led to withdrawal from the treatment, the patient would be 
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classified as a failure, and would be treated from then on with conventional 
DMARDs.” 
 
If anakinra is to be used as anything other than a “last resort” treatment, the patients not on 
anakinra will consist of a mixture of those still able to benefit from DMARDs and those not 
taking them.  In this case it would not be appropriate to regard these as homogeneous groups, 
applying costs and transition probabilities to the groups as a whole. Thus, if it is to be 
coherent, the model should be interpreted as applying only to the choice of anakinra as 
therapy when all others have failed. 
4.3.1 Technical aspects of the model 
 
The model was supplied in two forms, one based on study 960180 (anakinra in combination 
with MTX) and one based on study 0560 (anakinra as monotherapy). The two forms have the 
same basic structure, but differ in the data used to populate the model. The model runs to a 
cycle length of 6 months. 
4.3.2 Model Structure 
Each version of the model compares two strategies, one involving anakinra and the other not. 
For the branch not involving anakinra, there are seven states: six live states and one 
representing death.  Time-dependent transition probability matrices are used to determine the 
proportions of patients in each state at the end of each cycle.  The first cycle uses the results 
of the appropriate study (960180 or 0560), but subsequent cycles use instead probabilities 
calculated from the Early Rheumatoid Arthritis Study (ERAS) data set. 
 
For the branch involving anakinra, there are 13 states: six live states for remaining on 
anakinra, six live states for anakinra failures, and death.  Transition probabilities from the 
failure states are as for the non-anakinra arm.  For patients on anakinra, a probability of death 
is first applied; survivors may then remain on anakinra or not, and may change health state. 
The same transition matrices for health states are used for those who remain on anakinra and 
those who do not.  The transition matrices for the first cycle are taken from 960180 or 0560 
as appropriate.  The second cycle probabilities are taken from 0564, and are the same in the 
two versions of the model (except for a difference in rounding in one case).  For later cycles, 
the transition probabilities used are the mean of the probabilities in the previous two cycles. 
 
There are several problems associated with this structure. These are detailed below.  State 
numbers referred to here are for the six health states determined by HAQ score, ranging from 
state 1 (best; HAQ < 0.6) to state 6 (worst; HAQ 2.6 to 3.0).  Many of the problems are 
inherent in the structure of the model as supplied; where it is possible to test an alternative by 
changing the values of variables used in the model, the effect of such changes is quoted 
below. 
4.3.3 Overfitting 
Values from the appropriate data sources appear to have been applied exactly, with no 
evidence of any attempt at smoothing or checking for consistency.  For example, in trial 
960180, the transition probability for the improvement from state 3 to state 1 is actually 
higher for placebo than for anakinra. 
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4.3.4 Different handling of death according to treatment 
For patients still on anakinra, the probability of death is derived from UK death rates. 
However, for patients not on anakinra, death rates are included in the transition matrices 
derived from the ERAS data set.  In all cases, there are zero probabilities for death recorded 
for many cycles.  A common pattern is for non-zero probabilities to appear in alternate cycles 
only.  This suggests that survival data was only available on an annual basis, but all deaths 
have been put into the same half of successive years. 
4.3.5 Independence of transition with response status 
For patients who are on anakinra at the start of a cycle, the transition probabilities for health 
states are exactly the same for those remaining on anakinra as for those quitting.  It would be 
more reasonable to assume that those staying on anakinra would in general be in a better 
health state than those quitting the drug. 
4.3.6 Calculation of transition probabilities after the first two cycles for anakinra 
patients 
Transition probabilities for anakinra patients after the first two cycles are calculated as the 
mean of the probabilities for the previous two cycles.  Applying this process repeatedly has 
the effect that the probability for a given transition converges towards a figure ,3231 qp +  
where p is the probability for the first cycle and q for the second cycle.  This does not seem to 
be a sensible way of calculating these.  The sensitivity analysis provided includes the effect 
of fixing the probabilities for later cycles to remain at the value for the second cycle.  This is 
done separately for the probability of remaining on anakinra, and for the transition 
probabilities between health states for those remaining on anakinra.  The effect of each of 
these changes is to increase the ICER slightly.  In the model based on trial 960180, the ICER 
increases from £16,545 to £17,561 if the probability of remaining on anakinra is fixed after 
the second cycle.  It increases from £16,545 to £17,399 if the transition probabilities between 
health states are similarly fixed.  The combined effect of the two changes is not stated. 
4.3.7 Patterns of zeros in the transition matrices 
Because the studies from which the anakinra data were taken had very few patients in health 
state 6, there are many zero values in the transition matrices.  The method used to project the 
probabilities has the effect that if the probability of a particular transition is zero in each of 
the first two cycles, it necessarily remains zero thereafter.  This has the effect that in the 
model based on study 960180, it is possible to move from state 6 to state 3, but not 2 or 4, 
while in the model based on study 0560, it is possible to move from state 6 to state 2 or 4, but 
not to state 3. 
 
As a measure of the significance of the above problem, if the initial population is amended by 
changing all the starting patients in state 6 to state 5, the ICER for the model based on study 
960180 increases from £16,545 to £26,904. 
4.3.8 Costing 
Apart from the cost of anakinra, the costs for the model are based on costs for each health 
state. These costs include costs of DMARDs and associated monitoring for a substantial 
proportion of the patients in the data set from which they were derived.  Such costs cannot be 
regarded as representative of costs for patients who are not taking DMARDs.  If these costs 
are removed completely, the ICER for the model based on study 960180 decreases from 
£16,545 to £16,314.  It can thus be seen that the effect of these costs on the model is not 
substantial. 
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4.3.9 Utilities 
The model is based on utilities for each of the health states.  The base-case utilities used are 
taken from applying the EQ-5D questionnaire to a group of patients.  The numbers in each 
state ranged from approximately 25 to 40.  The mean values for each group are used, and 
appear to be reasonable. 
4.3.10 Sensitivity analysis 
A number of one-way sensitivity analyses have been carried out. These include fixing 
transition probabilities for anakinra responders as described above. Additionally, a 
probabilistic sensitivity analysis was performed which varied the cost and utility estimates for 
the various health states in the model, but no other parameters. There are some minor 
problems with the way the distributions for utility scores were determined. However, the 
purpose of probabilistic sensitivity analysis is to represent all the uncertainty together. A 
probabilistic sensitivity analysis on a limited set of variables does not meet this purpose. 
 
Crucial uncertainties which have not been tested include the following two. First, there is 
uncertainty in transition probabilities resulting from the very small numbers in certain states 
in the trials. Second, the model uses the same transition probabilities between health states for 
patients starting a cycle on anakinra, regardless of whether anakinra remains effective. The 
structure of the model does not allow this issue to be tested. 
4.3.11 Conclusion 
The results of the Amgen model must be treated with considerable caution.  
 
4.4 Methods for Economic Analysis 
The aim of this analysis is to assess the cost-effectiveness of adding anakinra to an existing 
treatment pathway for rheumatoid arthritis compared to the same pathway without anakinra. 
The costing perspective of the evaluation is NHS costs. 
 
The economic analysis was conducted using the Birmingham Rheumatoid Arthritis Model 
(BRAM). This model is a revised version of a previous model used in the assessment of 
etanercept and infliximab.39 The BRAM is an individual sampling model. A large number of 
virtual patient histories are simulated, costs and QALYs being accumulated as required. Full 
details of the means used to implement the model are to be found in a parallel report.135 A 
complete description of the model structure is given below. The basic model structure is as in 
Figure 9, page 71 
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Figure 9 Basic structure of the model 
 
Start new treatment
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activity taking a variable amount of time
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Patients are assumed to follow a sequence of DMARDs, involving starting treatment, some 
time on the treatment, quitting the DMARD and selecting the next treatment. The pattern is 
then repeated for the next DMARD. Any patient surviving all the DMARDs moves on to 
palliation. Patients’ HAQ scores are assumed to improve (decrease) on starting a DMARD; 
this improvement is lost on quitting the DMARD, which may be for reasons either of toxicity 
or loss of effectiveness. While on any treatment, patients’ condition is assumed to decline 
slowly over time; this is modelled as increases of 0.125 in HAQ score occurring from time to 
time. HAQ scores are calculated so that a unit change in disability detected by this 
questionnaire is 0.125; a patient may have a minimum score of 0 and a maximum of 3.0 (see 
Appendix 1, page 87 for details of HAQ).  All patients are followed through to death, which 
necessarily occurs while on some form of treatment (DMARD or palliation). Mortality risk is 
assumed to be dependent on current HAQ score, as well as age and sex. 
4.4.1 Strategies compared using the BRAM 
Table 12 shows the two strategies for using DMARDs considered in this report.  These 
treatment pathways were based on a systematic review of the literature on treatment of RA 
patients with DMARDs and a survey of rheumatologists in the UK in 2002.47  
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The combination of methotrexate and ciclosporin was not used if either of its components had 
been quit on the grounds of toxicity. In each case, the comparison is made between the 
strategy as shown (with anakinra “in the middle”) and without anakinra. Because of current 
supply problems with etanercept (personal communication Wyeth Medical Information 
22/1/03), each strategy was subdivided according to the use or non-use of etanercept; 
versions using etanercept are referred to as strategies 1A and 2A; without etanercept, 
strategies 1B and 2B.  Further comparisons were made moving anakinra to the end of the list, 
after combination therapy; again, the comparison in each case was between the strategy with 
anakinra last, and without anakinra. Thus a total of eight pair-wise comparisons could be 
made for any set of parameter values. 
 
Table 12: Strategies used in the BRAM for assessment of anakinra 
 
 Strategy 1 Strategy 2 
sulfasalazine sulfasalazine 
methotrexate (MTX) methotrexate (MTX) 
leflunomide hydroxychloroquine 
(etanercept) gold (GST) 
infliximab leflunomide 
anakinra (etanercept) 
gold (GST) infliximab 
azathioprine anakinra 
ciclosporin (CyA) azathioprine 
combination MTX + CyA ciclosporin (CyA) 
Sequence 
of 
DMARDs 
used 
 combination MTX + CyA 
 
(Note that neither of these strategies uses penicillamine, because our survey revealed that this 
treatment was not widely used.) 
 
4.4.2 Starting point for comparisons 
Since both treatment arms in any comparison start with the same initial drug sequence, early 
costs and QALYs are the same. Therefore, in each case, the starting point for comparison was 
the point of divergence between the two options compared. All patients in the model were 
started at the beginning of the sequence; patients who did not reach the point of divergence 
were not included in the analysis. Costs and QALYs were accumulated only from the point of 
divergence, and discounted (at 6% and 1.5% respectively) to that point. In principle, it would 
be possible to start the model at the divergence point. This would, however, require 
knowledge of the distribution of patients by age, sex and HAQ score at the divergence point, 
and thus separate starting populations for each comparison. The method used requires only a 
single data set for its starting population. 
 
The model assumes a constant risk of increase of HAQ score while on treatment and that an 
individual’s HAQ score increases gradually and in steps of 0.125, apart from the effects of 
starting and ending treatment. While HAQ can change at any stage of disease, and is known 
to be more labile in early disease, the assumption of a gradual increase in HAQ is reasonable 
for the parts of the model where comparisons are being made, as the model applies to the 
later stages of the disease. The rate of increase of HAQ was chosen to reflect the empirically 
observed increase reported by Scott et al.136 
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Notice also that, for a particular strategy, the same total sequence of DMARDs is used in the 
non-anakinra branch whether anakinra appears in the middle or last. However, the point of 
divergence is different, and so the total costs and QALYs counted will also be different. 
 
4.4.3 Data used in the BRAM for anakinra 
What follows is a list of the data used in the BRAM for anakinra. Data for anakinra are 
essentially drawn from this review; other data have been taken from the literature. 
 
Table 13 shows the initial age and sex distribution, based on Wiles et al.8 
 
Table 13: Initial age and sex distribution 
age 15 – 24 25 – 34 35 – 44 45 – 54 55 – 64 65 – 74 75 – 84 total 
male 0.6 1.2 2.3 5.8 6.4 9.3 5.2 30.8 
female 2.9 5.8 9.9 16.9 14.0 15.1 4.6 69.2 
 
The starting distribution of HAQ scores is shown in Table 14, based on Wiles et al.66  Note 
that although only three different values were used at the start, natural HAQ increases mean 
that a much greater variety applies at the point of divergence between branches in any 
strategy. 
 
Table 14: Starting distribution of HAQ scores 
HAQ 0.25 0.75 1.5 
%age 25 50 25 
 
Time spent on any DMARD is drawn from a Weibull distribution. A random variable X has a 
Weibull distribution with shape parameter a and scale parameter b if 
a
b
X 

  has an 
exponential distribution with unit mean.  The Weibull distribution is more general than the 
constant-risk exponential distribution in that it reduces to the exponential distribution when 
.1=a  If ,1<a  then the risk decreases over time, while if ,1>a  the risk increases over time. 
Parameters a and b are shown in Table 15.  For convenience, the mean of the distribution is 
also shown. 
 
For anakinra, our review gave a withdrawal rate of 23 % at 24 weeks. With no data beyond 
this point, we fitted an exponential distribution to this one point, to be varied in sensitivity 
analysis. (Although we had some information about timing of withdrawals up to 24 weeks, 
this was not felt to be a sensible basis on which to extrapolate the shape of the curve.) 
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Table 15: Times to quitting DMARD 
DMARD a b (yrs) mean (yrs) source 
anakinra 1 1.77 1.77 see text 
azathioprine 0.73 1.60 1.95 Hawley and Wolfe 137 
ciclosporin 0.79 7.62 8.71 Marra et al 138 
etanercept 0.73 12.34 15.03 Geborek et al 139  
gold 0.71 3.08 3.85 Maetzel at al 43 
hydroxychloroquine 1 3.62 3.62 Maetzel at al 43 
infliximab 0.73 5.96 7.26 Geborek et al 139  
leflunomide 0.66 1.7 2.28 Siva et al 140 
methotrexate 0.77 4.62 5.39 Maetzel at al 43 
penicillamine 0.62 1.86 2.69 Pincus et al 52 
sulfasalazine 0.71 2.76 3.45 Maetzel at al 43 
combination 1 1.74 1.74 Tugwell et al141 
Gerards et al142 
(Penicillamine appears in this table as it has the lowest value of the shape parameter a; we used this value in the 
sensitivity analysis for anakinra.) 
 
Toxicity of DMARDs was only an issue for methotrexate and ciclosporin because toxicity to 
either of these agents would mean that combination therapy with methotrexate and 
ciclosporin would not be included as a therapeutic option. For other DMARDs cessation 
because of toxicity or inefficacy has the same consequence in our model i.e. use of the 
DMARD next in sequence.  For ciclosporin it was assumed drug cessation was due to toxicity 
with a probability of 0.8 regardless of time spent on drug.143  For methotrexate, the 
probability p was set to depend on the time t years on the drug, by the formula 
,115.0362.0 457.0 tep −+=  which was derived from a comparison between the survival curves 
given in Maetzel et al.43 
 
Costs are made up of drug costs plus monitoring costs.  For all DMARDs, there are higher 
costs on starting than there are for continued use.  The total cost for time on any treatment is 
modelled as a one-off starting cost followed by a steady annual usage cost.  The only ones 
that are relevant for the comparisons in this report are for treatments that come after the point 
of divergence. For completeness, all costs are shown.  The price year is 2002 in each case.  
The unit costs of the various inputs are shown in Table 16 and Table 17.  The monitoring 
assumptions are listed in Table 18. 
Table 16: Unit costs for tests and visits 
Test  Source 
Full Blood Count 3.77 
ESR 2.91 
Biochemical Profile 3.63 
Newchurch Ltd., National Pathology Alliance Benchmarking Report: 
Haematology and Blood Transfusion 2000/2001. London: Newchurch. 2002 
Chest X-ray 14.75 Newchurch Ltd., Radiology Benchmarking Report: 1999/2000. London: 
Newchurch. 2001 
Urinalysis 0.08 Newchurch Ltd., National Pathology Alliance Benchmarking Report: 
Haematology and Blood Transfusion 2000/2001. London: Newchurch. 2002 
Visits   
GP 18.00 
Hospital OP 86.00 
Hospital IP (per day) 191.00 
PSSRU144 
Specialist nurse visit 43.00 assumed half of OP visit 
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Table 17: Unit costs for drugs (sources: Drug tariff / Mims, Dec 2002) 
Treatment Cost Assumptions 
anakinra £20.47 per day 100 mg/day 
azathioprine 3×15.2p per day  150mg per day 
ciclosporin £5.187 per day 70kg patient; 3.25mg/kg per day 
etanercept £89.38 per dose 102 doses per year 
gold £9.36 per month 50 mg amp, administered at GP 
visit 
hydroxychloroquine 11.4p per day 300mg per day 
infliximab £451.20 per vial 70kg patient, drug wastage if full 
vials not used, cost per 
administration £124 
leflunomide £1.55 per day 20mg per day 
methotrexate 11.4p per 2.5mg tablet 15mg per week 
sulfasalazine 37.5p per day 2.5g per day 
 
Table 18: Monitoring assumptions 
Treatment Pre-treatment On treatment 
palliation  OP visit every 3 months 
anakinra FBC, ESR, BCP, 4 
specialist nurse visits 
FBC, ESR, BCP monthly at specialist nurse 
visit, GP visit every 3 months 
azathioprine FBC, ESR, BCP FBC and BCP weekly for 6 weeks, then every 2 
weeks for 3 visits, then monthly 
ciclosporin FBC, 2×BCP, ESR, 
urinalysis 
FBC, BCP every 2 weeks for 4 months, then 
BCP monthly 
etanercept FBC, ESR, BCP, CXR FBC, ESR, BCP at weeks 2, 4, 8, 12, then every 
3 months 
gold FBC, ESR, BCP, 
urinalysis 
FBC, BCP, urinalysis every week for up to 21 
injections, then every 2 weeks for 3 months, 
then every 3 weeks for 3 months, then monthly. 
Treatment given by i.m. injections 
hydroxychloroquine FBC, ESR, BCP FBC, ESR, BCP every 3 months 
infliximab FBC, ESR, BCP, CXR FBC, ESR, BCP at weeks 2, 6 and every 8 
weeks (at time of infusions) 
leflunomide FBC, ESR, BCP, 
urinalysis 
FBC every 2 weeks for 6 months, every 8 weeks 
thereafter. BCP monthly for 6 months, every 8 
weeks thereafter 
methotrexate FBC, ESR, BCP, CXR FBC, BCP every 2 weeks for 4 months then 
monthly 
sulfasalazine FBC, ESR, BCP FBC every 2 weeks and BCP every 4 weeks for 
12 weeks, then FBC and BCP every 3 months 
(FBC = full blood count, ESR = erythrocyte sedimentation rate, BCP = biochemical profile, CXR = 
chest X-ray) 
 
Combining the above information leads to the model inputs shown in Table 19. It should be 
noted that palliation does not include hospitalisation, although this may be higher for RA 
patients with no DMARD options, as we could not quantify this. 
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Table 19: Treatment costs 
Treatment Start-up (£) Annual usage (£) 
palliation 0 344 
anakinra 182.31 8080.32 
azathioprine 656.71 1286.78 
ciclosporin 331.22 2963.63 
etanercept 473.61 9513.64 
gold 2538.55 1450.08 
hydroxychloroquine 96.31 426.74 
infliximab 1758.51 9867.24 
leflunomide 933.81 1124.60 
methotrexate 484.66 1156.37 
sulfasalazine 552.42 510.10 
combination 331.22 2999.20 
 
Basic mortality comes from standard life tables. A relative risk of 1.33 per unit HAQ is 
applied.145 
 
In the base case, it is assumed that there is a mean time of 4 years between each 0.125 unit 
increase in HAQ. This reflects a mean decline (increase) of 0.031/yr.136 Table 20 shows the 
improvement (reduction) in HAQ for starting each DMARD. If the patient’s HAQ score at 
the time of starting a DMARD is less than the reduction given, then the HAQ score reduces 
to zero. The reduction actually applied is used for the increase in HAQ score on quitting the 
DMARD, except that HAQ cannot go above 3. For example, a patient starting methotrexate 
with a HAQ score of 0.25 would improve to a HAQ of 0. If the same patient has a HAQ score 
of 0.125 when quitting methotrexate, the HAQ score increases to 0.375. 
 
Table 20: Improvement in HAQ for starting each DMARD 
DMARD HAQ reduction Sources 
anakinra 0.25 From this review 
azathioprine 0.25 Assumed to be at the lower end of 
effectiveness as there is no reliable data on 
which to base estimates 
ciclosporin 0.375 Zeidler HK et al 146 
etanercept 0.5 Jobanputra P et al.39  Based on meta-
analysis of available trials. 
gold 0.375 Munro R et al 41 
hydroxychloroquine 0.25 HERA study group 147 
infliximab 0.5 Jobanputra P et al.39   Based on meta-
analysis of available trials. 
leflunomide 0.375 Scott and Strand 136 
methotrexate 0.5 Wyeth Laboratories 148 
sulfasalazine 0.375 Scott and Strand 136 
combination 0.25 As for azathioprine 
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Conversion from HAQ to QALYs is by the formula HAQQoL 327.0862.0 −=  calculated 
from the data set supplied by Nigel Hurst, and reported in Hurst et al.149   We have assumed 
that start and end effects can be modelled as one-off deductions equal to 0.2 years times the 
change in QoL score. 
 
4.4.4 Results 
 
Results from the model are in the form of comparisons between two options, one containing 
anakinra (“with Ana”) and one not (“no Ana”). In each case, the mean cost and QALYs per 
patient are given. These are calculated from the point of divergence between the options, and 
discounted to that point at 6% per annum for costs and 1.5% for QALYs, in accordance with 
Treasury guidelines. The results are subject to statistical error from the sampling used in the 
model. Quasi-standard errors (Q.S.E.) are quoted for costs and QALYs. These reflect the 
sample sizes used and are given simply to show that an adequate number of replications of 
the model was made. For each option, the %age of (virtual) patients ending on palliation has 
been quoted. This shows what proportion of patients completed a sequence of DMARDs. The 
results from the two branches must be treated as unpaired data, so the square of the quasi-
standard error of the difference is the sum of the squares of the individual quasi-standard 
errors. ICERs are quoted as the ratio of mean differences, followed by an approximately 95 
% quasi-confidence interval obtained using the formula on page 91 of Armitage and Berry150 
to the reciprocal of the ICER. 
 
Unless otherwise stated, the results with anakinra “in the middle” are based on 1,000,000 
patients reaching the divergence point. For anakinra last, a much smaller proportion of the 
original population reaches the divergence point, increasing the running time for the model if 
the number of patients is fixed. However, the variation among patients is reduced 
considerably, so a sample of 100,000 proved adequate. In some cases, the run-length was 
increased in order to reduce the size of the quasi-confidence intervals; such cases are noted in 
the results tables. 
 
Strategies 1 and 2 are as defined in Table 12, page 72.  Strategies 1A and 2A include 
etanercept; strategies 1B and 2B do not. The effect of removing etanercept is that patients 
reach the divergence point earlier, and therefore tend to be younger. Since all patients are 
followed through to death, the total costs and QALYs are therefore higher than for the 
corresponding strategy with etanercept. Similarly, although the patient pathways in the “no 
anakinra” options in each strategy are the same whether anakinra is in the middle or last, the 
point from which costs and QALYs are counted is different, and the criterion for reaching the 
point of divergence is also different. 
 
4.4.4.1 Base Case Results 
 
The base-case costs, QALYs and ICERs for anakinra used in either treatment strategy, with 
and without the availability of etanercept are shown in Table 21, below.  For fuller details 
please refer to Appendix 8, page 97. 
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Table 21: Base-Case ICER Calculations 
Base-Case ICER Calculations 
   Difference in cost 
per patient (£) 
QALYs per 
patient ICER (£/QALY) 
Place in 
DMARD  
sequence 
DMARD 
sequence 
Is etanercept 
available? mean q.s.e. mean q.s.e. ICER low high 
Yes 9477   7.8 0.016 0.0030 604 000 436 000 985 000 
1 
No 9647 11.1 0.025 0.0046 379 000 278 000 597 000 
Yes 9639 16.0 0.025 0.0054 385 000 270 000 674 000 
Middle 
2 
(early 
HCQ and 
gold) No 9843 16.3 0.035 0.0059 278 000 209 000 415 000 
Yes 11508 24.3 0.088 0.0106 131 000 106 000 173 000 
1 
No 11682 17.3 0.111 0.0082 105 000 92 000 124 000 
Yes 11441 24.1 0.105 0.0100 109 000 91 000 134 000 
Last 
2 
(early 
HCQ and 
gold) No 11551 24.3 0.109 0.0110 106 000 88 000 132 000 
q.s.e.  = quasi standard error of the difference in means.  This reflects only the uncertainty due to sampling within the model, 
not the parameter uncertainty.  It can be reduced by increasing the number of virtual patients in the model and is quoted to 
show that a sufficient number have been used.  
QALY = quality adjusted life-year  
ICER = incremental cost-effectiveness ratio 
low/high = low and high ends of ~95% quasi-confidence intervals (reflecting only sampling uncertainty within the model) 
 
4.4.5 Sensitivity Analysis 
As the best base-case ICER estimate was over £100K/QALY, i.e. above that which is 
generally accepted as “value for money” within the current NHS budget envelope, we 
undertook sensitivity analyses only in the direction that would favour anakinra.  The effect of 
the following assumptions was explored: time on anakinra; start and end effects; 
effectiveness of anakinra.  A best-case scenario for anakinra was produced combining these.  
The effect on the ICER is summarised in Table 22, page 80.  Please see Appendix 9, page 99 
for full details of the simulations for the sensitivity analyses. 
 
Time on anakinra 
As noted above, the time on anakinra was based on a single time-point in the base case.  As 
an alternative to the exponential distribution, we tried the lowest value (0.62) of the shape 
parameter a for any of the DMARDs in Table 15, page 74.  (This is the most favourable to 
anakinra.)  To fit 23% withdrawal at 24 weeks requires .02.4=b  The mean of the new 
distribution is 5.80 years, compared to 1.77 years in the base case. 
 
Start and end effects 
For the sensitivity analysis the one-off loss of QALYs at start and end of DMARDs were 
omitted. 
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Effectiveness of anakinra 
To see the effect of benefit of anakinra on HAQ scores, we changed the HAQ improvement 
due to anakinra from 0.25 to 0.5.  It must be emphasised that there is no evidence to support 
this value: this is purely a “what if” analysis. 
  
Best case scenario 
We combined the estimates of the three parameters above used in the sensitivity analyses to 
produce the best case scenario.   
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Table 22: ICER Calculations for Sensitivity Analyses 
ICER Calculations for Sensitivity Analyses 
  ICER (£/QALY) 
Parameter varied 
Place in 
DMARD  
sequence 
DMARD 
sequence 
Is etanercept 
available? ICER low high 
Yes 301 000 250 000 377 000 
1 
No 245 000 209 000 295 000 
Yes 198 000 177 000 225 000 
Middle 
2 
 No 174 000 157 000 195 000 
Yes  83 000 74 000 94 000 
1 
No  85 000 76 000 98 000 
Yes 89 000 79 000 101 000 
Time on anakinra 
(mean 5.8 years instead 
of 1.77) 
Last 
2 
 No 81 000 72 000 91 000 
Yes 277 000 205 000 431 000 
1 
No 199 000 156 000 272 000 
Yes 201 000 164 000 258 000 
Middle 
2 
 No 166 000 138 000 206 000 
Yes 97 000 82 000 118 000 
1 
No 88 000 75 000 107 000 
Yes 84 000 73 000 99 000 
Start and end effects 
(there is no loss of 
QALYs at start and end 
of DMARDs) 
Last 
2 
 No 82 000 71 000 98 000 
Yes 77 000 70 000 88 000 
1 
No 72 000 66 000 80 000 
Yes 72 000 67 000 78 000 
Middle 
2 
 No 68 000 63 000 74 000 
Yes  59 000 53 000 66 000 
1 
No  62 000 53 000 75 000 
Yes 54 000 50 000 60 000 
Effectiveness of 
anakinra 
(arbitrary assumption 
that effect of anakinra 
on HAQ score is equal 
to best of other 
DMARDs i.e. 0.5) Last 
2 
 No 57 000 53 000 61 000 
Yes 50 000 48 000 51 000 
1 
No 48 000 47 000 50 000 
Yes 46 000 44 000 47 000 
Middle 
2 
 No 45 000 43 000 46 000 
Yes 38 000 36 000 40 000 
1 
No 38 000 36 000 41 000 
Yes 38 000 36 000 41 000 
Best-case scenario 
(Combining the above 
three parameter 
changes) 
Last 
2 
 No 37 000 35 000 39 000 
q.s.e. = quasi standard error of the difference in means. This reflects only the uncertainty due to sampling within the model, 
not the parameter uncertainty. It can be reduced by increasing the number of virtual patients in the model and is quoted to 
show that a sufficient number have been used. QALY = quality adjusted life-year ICER = incremental cost-effectiveness 
ratio. low/high = low and high ends of ~95% quasi-confidence intervals (i.e. sampling uncertainty within the model) 
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5 IMPLICATIONS FOR OTHER PARTIES 
The substantial economic impact of rheumatoid arthritis in terms of direct and indirect costs 
has been highlighted elsewhere in this report.  Studies indicate a great range of potential costs 
that cannot readily be explained by socio-economic or clinical factors.  However it is 
apparent that a minority of patients may account for a great proportion of the direct medical 
costs.  Costs incurred by individuals, in a cohort of early arthritis patients, are similar to costs 
incurred by health care services.  Costs incurred by family and friends in terms of forgone 
paid work, forgone leisure time and other factors greatly exceed costs incurred by individuals 
and health care services.  Clearly this could have an impact on the quality of life of patients 
and carers.  Further, physical disability resulting in difficulties in self-care, and work 
disability has implications for personal social services. 
 
6 FACTORS RELEVANT TO NHS 
Use of anakinra can be anticipated to place a demand on out-patient rheumatology facilities, 
with particular implications for out-patient nurse workload. These professionals are likely to 
take the lead in teaching patients and carers to self-administer injections, provide back-up 
support and disease and drug monitoring services. The availability of such specialist nurses in 
rheumatology varies across the NHS. 
 
There are currently no data on which to base an assessment of the potential impact of 
anakinra on joint damage in patients with RA. If a reduction in joint damage is apparent this 
has the potential to reduce the need for surgery in patients with RA. This may in turn lead to a 
reduced demand for orthopaedic services. 
 
On the basis of the evidence available the most difficult issue for professionals is likely to be 
identifying the true place in therapy of anakinra amongst other treatments for RA. 
 
7 DISCUSSION 
7.1 Main clinical effectiveness results 
Anakinra, at the higher doses evaluated, demonstrated modest efficacy compared to control, 
in terms of improving symptoms of RA, when used as both monotherapy and in combination 
with methotrexate. The effect seen was relatively consistent across the trials with a RR with 
the ‘licensed dose’ of anakinra of achieving an ACR 20 of  1.6, ACR 50 2.3, ACR 70 3.1 
with respective NNTs of 7, 11 and 33, based on the public domain data. A response was 
generally evident early (within 4 weeks) with no waning of treatment effect evident over the 
medium term  
Three of the trials evaluated ranges of doses of anakinra. Whilst a clear dose response was 
not evident across all the dose ranging studies there was a suggestion of increased response 
with increasing dose. Optimal efficacy was seen at the higher doses that are in line with the 
licensed dose of 100mg daily. No evidence of efficacy was apparent with the low doses of 
anakinra (≤ 30mg/day) studied in trial 0182.   
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For the composite endpoint ACR response benefit with anakinra was slightly greater when 
used in combination with methotrexate than when used as monotherapy. This may reflect 
differences in study designs and populations and perhaps late response to continued 
methotrexate. No subset of patients were identified who had greater or lesser likelihood of 
response to anakinra. 
 
ACR endpoint data for study 0757 a large pragmatic safety study have not been made 
available. This is of concern, due to the size and ‘real life’ design of this trial. We consider 
that this study and the ACR endpoint data collected are absolutely valid in informing clinical 
practice.  Pragmatic trials that reflect average clinical practice tend to have more external 
validity than those conducted on highly selected patient populations.  We do not believe that 
because the primary purpose of this trial was to look at safety that it is “inappropriate and 
misleading to draw any conclusions from any efficacy assessments taken from this study”?   
The key issue is whether the study design used (in this case a randomised, double-blinded 
placebo-controlled trial with before and after measurements of effectiveness outcomes) is an 
appropriate design from which to be able to draw valid conclusions about effectiveness.  It 
clearly is.   
 
Although a trial undertaken in an every day clinical setting will have more heterogeneity 
among the participants than a trial undertaken on a highly selected population with restrictive 
inclusion criteria, this does not necessarily mean that the results will be confounded.  One of 
the benefits of the randomised design is that, not only does it reduce selection bias, but it 
minimises or avoids the effects of both known and unknown confounders by ensuring that the 
groups compared have a similar distribution of baseline characteristics.  In this trial the 
patient characteristics of disease duration, concomitant medications and co-morbid 
conditions, that the company allude to as potential confounders, are randomly distributed 
between the arms, reducing the risk that they will confound the analysis.  Moreover the large 
size of this trial helps to minimise the risk of this happening by chance.  Indeed the reported 
baseline characteristics of the two groups in this trial confirm that there were no significant 
imbalances in NSAID, corticosteroid, methotrexate, or other DMARD use between the 
anakinra and placebo participants, nor in baseline demographic characteristics or disease 
status (Tables 8-7 and 8-8 of the trial report).   In the light of this an analysis of differences in 
clinical outcomes is methodologically sound and valid. 
 
Because about half the relevant data on effectiveness has been withheld and this is the data, 
which most reflects the average RA clinic population, it is difficult to make an accurate 
estimate of likely effectiveness of anakinra in actual clinical practice.  It is probable that the 
data that has been released into the public domain overestimates the effectiveness that would 
be seen in a clinic context.  In the absence of data we made an educated estimate about the 
effectiveness of anakinra seen in trial 0757 (described earlier). The derived estimate 
combined with data from earlier trials, using a random effects model, gives our best summary 
estimate of effectiveness for the ACR 20 response; RR 1.43 (95% CI 1.16 to 1.76), RD 0.11 
(95% CI 0.04 to 0.18), NNT 9 (95% CI 6 to 25). 
 
No conclusion can be made on effect on disease progression given current data.  Study 0560 
(monotherapy) suggested that treatment may be associated with a slowing of disease 
progression as measured by the Larsen score.  This endpoint was not presented for the other 
studies.  Trial 0145 evaluated disease progression using the modified Sharp score. This trial is 
now complete but full data are not yet available. We have serious reservations about post-hoc 
analyses that claim benefits in clinical non-responders especially because of the problems of 
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measurement error with radiographic outcomes.  Rheumatologists may feel justified in 
employing therapeutic agents in essence for prophylactic purposes where patients experience 
no immediate benefits.  However whether patients find this approach acceptable allowing for 
ISRs and other hazards of IL-1Ra would need to be determined.  In addition since other 
DMARDs also inhibit radiographic damage and have the potential for improving clinical 
outcomes for patients who have not previously used them it would seem appropriate for 
Rheumatologists to use untested DMARDs rather than continue with anakinra in the face of 
continued disease activity.151 
Anakinra has not been compared head to head with other DMARDs. Such trials are required 
to inform clinical practice in order to place this drug amongst other DMARDs for the 
treatment of RA. In the absence of head to head trials an adjusted indirect comparison of 
NNTs for ACR suggests that anakinra is less effective than other biologic and other 
DMARDs. This could be due to different trial conditions or populations or represent a true 
treatment difference.  
Injection site reactions were common with anakinra treatment but were generally mild or 
moderate and transient. Less than 10% of patients withdrew from treatment due to ISRs. 
These reactions may however have lead to unblinding of treatment. Only study 0145 used 
adjusted methodology to protect against this. Unblinding due to ISRs has the ability to 
influence the perceived response for subjective markers (e.g. SJC, ACR response). However 
objective endpoints (e.g. ESR, CRP) should be less subject to unblinding. Benefits with 
anakinra at therapeutic doses were demonstrated in both subjective and objective endpoints 
across the clinical trials. 
Serious adverse events were uncommon and included serious infections and neutropenia. To 
date an increase in opportunistic infections such as TB has not been reported. Increased 
incidence of malignancy was not evident but data and exposure are still limited. The BSR 
biologics register is monitoring adverse events over the longer term. 
7.2 Economic evaluation 
There are no relevant economic evaluations in the published literature.  The economic model 
included in the Amgen submission to NICE contains structural flaws that make its estimate of 
the cost-utility of anakinra unreliable. 
 
Results of the Birmingham Rheumatoid Arthritis Model: 
• The BRAM gives a base-case estimate of the ICER of anakinra of between 
£106,000/QALY to £604,000/QALY.   
• This model uses data from public domain trial results only.  These recruited a highly 
selective patient population and may well overestimate the cost-effectiveness that 
anakinra would achieve in an average clinic population.   
• Used as a last resort treatment it has a more favourable ICER than when used earlier 
in the treatment pathway.  This is because anakinra displaces cheaper drugs. 
• In the current situation, where supplies of etanercept are limited, the ICER appears to 
be slightly more favourable than it would be were etanercept readily available. 
• Although the ICER is slightly more favourable when used in drug sequence 2 (with 
early hydroxychloroquine and gold) the choice of this drug sequence is usually 
determined by the patient characteristics and disease presentation.47 
• In the sensitivity analyses quite substantial variations were made in key parameters 
and ICERs were shown to be responsive. 
• ICERs did not drop below £50,000/QALY in any univariate analysis 
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• The best-case scenario produced ICERs between £37k and £50k/QALY.  These 
figures, however, are highly improbable and are based on the generous assumption 
that doubles anakinra’s estimated effectiveness, for which there is no empirical 
evidence. 
 
Assuming that anakinra is used as a last resort DMARD, the Amgen model estimate of 
£16,545/QALY is lower than our very best case scenario and appears to be unsustainable.  
This is due to multiple inappropriate structural assumptions and errors of the Amgen model. 
 
The BRAM produces an ICER for anakinra substantially higher than those for infliximab and 
etanercept.  This finding is consistent with the indirect comparison of effectiveness for ACR 
responses (a parameter not used in the model) which suggest that anakinra has a substantially 
higher NNT.  However, it must be borne in mind that patients may respond to anakinra when 
they have not responded to other biologics, like the TNF inhibitors, as they have a different 
mechanism of action.  Thus anakinra may produce a clinically significant and important 
improvement in some patients that they could not otherwise have achieved. 
 
7.3 Assumptions, limitations and uncertainties 
A key strength of this review was the expert input received at all stages that ensured a 
clinically relevant perspective was maintained throughout.  Sensitive searches were 
conducted to maximise retrieval of relevant data. 
 
Included studies were of high quality as judged by the Jadad scale. Withdrawal from 
treatment was handled variously using last observation carried forward or non-responder 
imputation. It is not known if these method of analyses could have introduced unforeseen 
biases.  However the FDA and EMEA evaluated the robustness of this approach with 
sensitivity analyses assuming a worst case scenario.  Other than for study 0560 this did not 
alter the conclusions of the trials in relation to ACR response. 
 
The double-blind trials conducted can be considered of short duration (up to 6 months with 
the exception of 0145) for a chronic disease such as RA.  Longer term open label follow up 
studies are however available.  Evaluation of the studies is complicated by the use of a wide 
range of doses, both fixed dose and doses by body weight, across the clinical trial 
programme.  
 
Approximately 75% patients completed the trials. Reasons for withdrawal varied across the 
treatment and control groups. Generally adverse events were a more frequent reason for 
withdrawal with the higher doses of anakinra evaluated, and lack of efficacy with control.  
 
There is the potential for bias due to unblinding due to adverse events most notably ISRs. 
Only one study used additional methods to protect against this. 
 
Efficacy data were not available for the large pragmatic trial 0757.  This is a major weakness 
in evaluating the effectiveness of anakinra in patients with RA.  Given the size of this trial its 
findings are likely to overshadow those seen in the smaller studies. (See earlier comments.)  
In the absence of the published results of this trial we made an educated guess on the trials 
likely findings.  Whilst this analysis should be interpreted with caution it provides a 
sensitivity analysis around the primary outcome of ACR 20 response.  Additionally full data 
on the disease progression endpoints for study 0145 were not available. 
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No direct comparisons of anakinra with DMARDs or anti-TNFs are available. These are 
required to inform clinical practice. In the absence of this an adjusted indirect comparison 
was undertaken to help inform practice, this should be interpreted with caution and the 
findings tested in direct head to head trials. 
 
An assessment of dose response across all endpoints using individual patient data is required 
to identify whether a true dose response exists in studies 0560 and 0180. Sensitivity analysis 
assuming no dose response did not alter our findings in relation to ACR response. 
 
Anakinra is too new to be able to know about any effect, if any, it may have on the need for 
joint replacement.  Therefore joint replacement effects have not been modelled. 
 
Although mortality benefits have been included in the model, these have been assumed to 
relate solely to HAQ scores.   
   
There is very limited evidence, if any, reliably relating ACR responses to quality of life.  
Consequently the BRAM uses HAQ score changes as a predictor of QALY scores.  However 
all studies, including those for the comparator drugs, have limited data on HAQ scores.  
Therefore the model is based on crude estimates of the effect on HAQ of all treatments. 
 
Trial data is only available to 24 weeks, therefore continued benefit has been derived by 
extrapolation.  There is a very wide range of time on anakinra consistent with the current 
data, consequently there is a large degree of uncertainty in the results. 
 
The economic evaluation takes an NHS perspective and may therefore underestimate the true 
cost-effectiveness of anakinra as a considerable proportion of the cost of uncontrolled disease 
falls on patients and carers. 
7.4 Need for further research 
A number of other therapeutic approaches in RA are currently being investigated, these are 
summarise in Appendix 10, page 104. 
 
For research that has already been conducted with anakinra research needs are  
• the publication of the efficacy data from the large pragmatic study (0757) to enable the 
benefit of treatment to be fully evaluated 
• publication of the 1 year radiology outcome data from study 0180  to evaluate the 
potential effects of treatment on disease progression. It is also important to identify 
whether any benefits on radiological measures are limited to patients who demonstrate a 
symptomatic response. 
 
Current clinical trials with anakinra are of limited duration. RCTs are required to evaluate the 
efficacy, safety and cost of anakinra over the longer term in patients with such a chronic 
disease. 
 
Comparative trials of anakinra with other DMARDs and biologic modifiers are needed to 
identify the comparative efficacy of these drugs and to guide clinical practice to optimise 
patient care. Additionally trials are required to assess the role of anakinra in the treatment of 
patients who have failed to achieve a benefit whilst taking infliximab or etanercept. 
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Studies with IL-1Ra given by continuous infusion to rats with collagen induced arthritis 
produced dramatic effects on soft tissue swelling and disease progression. Blood levels 
achieved in clinical trials with once daily s.c. dosing in humans with RA were much lower 
than those seen in the animal models. It is not known whether daily s.c. administration is 
sufficient to achieve continuous saturation of IL-1 receptors. A clinical trial in which IL-1Ra 
is delivered by continuous infusion or a slow release delivery system would address whether 
this apparent difference between species is related to sub-optimal dosing in humans. 26;152 
 
Suggestions that newer biologic therapies reduce radiographic damage without necessarily 
improving clinical outcomes need to be confirmed if treatments in the absence of a clinical 
response are to be justified. 
 
Further research is required to assess the impact of DMARDs on joint replacement, mortality 
and quality of life. 
 
As the pathogenesis of RA is complex, it may not be fully suppressed by monotherapy by 
blocking a single mediator. Optimal treatment in the future may require combinations of 
therapeutic agents that inhibit more than one mediator in a complex pathogenic network. 25  
Controlled clinical trials are required in this area to inform clinical practice, before any such 
approaches are widely adopted.  
 
Further research is needed to improve the utility of radiographic outcomes in clinical trials of 
RA either by building on existing efforts with plain radiographs or through the use of newer 
imaging methods. 
 
8 CONCLUSIONS 
Anakinra offers a new therapeutic approach for the management of RA.  The clinical trials 
establish efficacy of anakinra in reducing the signs and symptoms of RA, most notably at the 
higher doses studied.  Although modest efficacy is established the degree of clinical 
effectiveness is difficult to gauge because of the absence of data from a large pragmatic 
safety study.  There are no studies of a direct comparison with other DMARDs or anti-TNF 
therapies.  An adjusted indirect comparison suggests that anakinra may be significantly less 
effective at relieving the clinical signs and symptoms of RA, as measured by the ACR 
response criteria, than TNF inhibitors all used in combination with methotrexate.  Such 
indirect comparisons should be interpreted with caution and assume generalisability of study 
results.  Whilst safety over the short-term is established duration of exposure is still limited. 
Safety over the longer term is not yet known. 
 
The independent economic model developed to evaluate the cost-effectiveness of anakinra in 
clinical practice gives a base-case estimate of the ICER for anakinra of between 
£106,000/QALY to £604,000/QALY. This ICER is substantially higher than those for 
infliximab and etanercept.  However, patients may respond to anakinra when they have not 
responded to other biologics, as these agents have a different mechanism of action.  Thus 
anakinra may produce a clinically significant and important improvement in some patients 
that they could not otherwise have achieved. 
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Appendix 1: Health Assessment Questionnaire153 
 
Patient Label          Date: 
 
We are interested in learning how your illness affects your ability to function in daily life.  Please feel 
free to add any comments at the end of this form. 
 
PLEASE TICK THE ONE RESPONSE WHICH BEST DESCRIBES YOUR USUAL ABILITIES 
OVER THE PAST WEEK 
 Without 
ANY 
difficulty 
With 
SOME 
difficulty 
With 
MUCH 
difficulty 
Unable to 
do 
 Score = 0 Score = 1 Score = 2 Score = 3 
1. DRESSING & GROOMING  
     – Are you able to: 
2.  3.  4.  5.  
-Dress yourself including tying shoelaces and 
doing buttons? 
    
-Shampoo your hair     
2. RISING - ARE YOU ABLE TO: 3.  4.  5.  6.  
-Stand up from an armless straight chair?     
-Get in and out of bed?     
3. EATING - ARE YOU ABLE TO:     
-Cut your meat?     
-Lift a cup or glass to your mouth?     
-Open a new carton of milk?     
4. WALKING - ARE YOU ABLE TO:     
-Walk outdoors on flat ground?     
-Climb up five steps?     
 
PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE 
ACTIVITIES 
 
Cane  Devices used for dressing (button hook, zipper pull, long handled 
shoe horn, etc.) 
 
Walking frame  Built-up or special utensils  
Crutches  Special or built-up chair  
Wheelchair  Other (specify)  
 
PLEASE TICK ANY CATEGORIES FOR WHICH YOU USUALLY NEED HELP FROM 
ANOTHER PERSON 
 
Dressing and Grooming  Eating  
Rising  Walking  
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Health Assessment Questionnaire - continued 
 
 Without 
ANY 
difficulty 
With 
SOME 
difficulty 
With 
MUCH 
difficulty 
Unable to 
do 
 Score = 0 Score = 1 Score = 2 Score = 3 
5. HYGIENE – ARE YOU ABLE TO      
-Wash and dry your entire body?     
-Take a bath?     
-Get on and off the toilet?     
6. REACH – ARE YOU ABLE TO     
-Reach and get a 5lb object (e.g. a bag of 
potatoes) from above your head)? 
    
-Bend down to pick up clothing from the floor?     
7. GRIP – ARE YOU ABLE TO     
-Open car doors?     
-Open jars which have been previously 
opened? 
    
-Turn taps on and off?     
8. ACTIVITIES – ARE YOU ABLE TO     
Run errands and shop?     
Get in and out of a car?     
Do chores such as vacuuming, housework or 
light gardening? 
    
 
 
PLEASE TICK ANY AIDS OR DEVICES THAT YOU USUALLY USE FOR ANY OF THESE 
ACTIVITES: 
 
Raised toilet seat  Jar opener (for jars previously opened)  
Bath seat  Long handled appliances for reach  
Bath rail  Other (specify)  
 
PLEASE TICK ANY CATEGORIES FOR WHICH YOU USUALLY NEED HELP FROM 
ANOTHER PERSON 
 
Hygiene  Gripping and opening things  
Reach  Errands and housework  
 
Scoring of HAQ 
Add the maximum score for each of the 8 sections and divide by 8 to give a score between 0 
to 3.  If aid / device or help is needed the score for that activity automatically = 2 (unless 3 
has already been ticked).  Normal function = 0, Most severely affected = 3. 
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Appendix 2 : Assessment of response to DMARDs 
 
American College of Rheumatology Response Criteria.59 
Tender joint count 
Swollen joint count 
At least 3 of: 
- global disease activity assessed by observer 
- global disease activity assessed by patient 
- patient assessment of pain 
- physical disability score (e.g. HAQ) 
- acute phase response (e.g. ESR or CRP) 
 
Response is defined as ACR20, ACR50 or ACR70 where figures refer to %age improvement 
of the clinical measures shown above. 
 
European League Against Rheumatism (EULAR) response criteria.154;155  
 
This measure is referred to as the DAS (disease activity score).  Currently the DAS28 based 
on a simplified method is favoured for use.  The DAS28 is calculated from the following 
formula: 
DAS28 = 
(0.555 x square root of tender joint count using 28 defined joints)  
+ (0.284 x square root of swollen joint count using 28 defined joints)  
+ (0.7 ln (ESR))  
+ (0.0142 x patient global assessment of disease activity on 0-10 visual   
analogue scale). 
 
Paulus response criteria156  
 
Responses in 4 of 6 selected measures are required for improvement.  Improvement by 20% 
or more in the following measures is required (the threshold for % improvement may be 
increased, e.g. to 50%, 70% as for ACR responses): 
• Early morning stiffness 
• ESR 
• Joint pain or tenderness score 
• Joint swelling score 
• Patient overall assessment of current disease severity improved by >2 grades on 5-point 
scale, or from grade 2 to 1. 
• Physician overall assessment of current disease severity improved by >2 grades on 5-point 
scale, or from grade 2 to 1. 
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Appendix 3 : Notes on radiographic scoring methods 
 
Modified Sharp Method157 
 
Radiographs of hands, wrists and feet are scored.  46 joints are scored for erosions.  Erosions 
are scored on a 6-point scale.  A score of 0 indicates no new erosion and no worsening of an 
existing erosion.  Each point increase indicates occurrence of a new erosion or 20% 
worsening of an existing erosion.  42 joints are scored for narrowing on a 5-point scale.  A 
score of 0 indicates no narrowing, 1 indicates minimal narrowing, 2 loss of 50% of the joint 
space, 3 loss of 75% of the joint space and 4 complete loss of the joint space.  Scores for joint 
space narrowing and erosions are summed to give a total Sharp score. 
 
Larsen scoring method 
 
Radiographs of the hands and wrists are scored. Fifteen areas are examined.  Dislocation and 
bony ankylosis are considered; if they are present, the scoring is based on the concomitant 
bone destruction.  Maximum score (total for both hands) is 150.158 
  
0  = normal 
1 = slight abnormality, including 1 or more of the following lesions: 
periarticular soft tissue swelling, periarticular osteoporosis, and slight joint space 
narrowing 
2 =  definite early abnormality, including definite erosion, with or without joint space 
narrowing 
3 =  medium destructive abnormality 
4 = severe destructive abnormality 
5 =  mutilating abnormality (the original articular surfaces have disappeared) 
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Appendix 4: American College of Rheumatology revised criteria for classification of 
functional status in rheumatoid arthritis159 
 
Class 1 DESCRIPTION 
 
Class I Completely able to perform usual activities of daily living (self-care, 
vocational, and avocational) 
Class II Able to perform usual self-care and vocational activities, but limited in 
avocational activities  
Class III Able to perform usual self-care activities, but limited in vocational and 
avocational activities 
Class IV Limited ability to perform usual self-care, vocational, and avocational 
activities 
Usual self-care activities include dressing, feeding, bathing, grooming, and toileting.  
Avocational (recreational and/or leisure) and vocational (work, school, homemaking) 
activities are patient-desired and age and sex-specific. 
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Appendix 5: Yield from Medline and Embase Searches 
Date: 10 Dec-2002 
Database: Medline <1966 to present> 
 
Set Search Results
1 exp Arthritis, Rheumatoid/ 64573
2 exp Receptors, Interleukin-1/ or receptors interleukin 1.mp. 2357
3 (IL-1RA or IL 1RA).mp. 1768
4 anakinra.mp.. 17
5 kineret.mp. 3
6 SIALOGLYCOPROTEINS/ 5095
7 Recombinant Proteins/ 92451
8 or/2-7 99041
9 1 and 8 494
10 randomized controlled trial.pt. 169545
11 controlled clinical trial.pt. 62509
12 randomized controlled trials/ 26378
13 random allocation/ 46502
14 double blind method/ 71756
15 single blind method/ 6954
16 or/10-15 286786
17 (animal not human).sh 2624439
18 16 not 17 273317
19 clinical trial.pt. 345108
20 exp clinical trials/ 138904
21 (clin$ adj15 trial$).ti,ab. 86668
22 (singl$ or doubl$ or trebl$) adj25 (blind$ or mask$).ti,ab. 70784
23 Placebos/ 21852
24 placebo$.ti,ab. 75840
25 random$.ti,ab. 251875
26 research design/ 40192
27 or/19-26 605915
28 27 not 17 563903
29 28 not 18 301805
30 29 or 18 575122
31 9 and 30 95
32 from 31 keep 1-95 95
 
 
Date: 10-Dec 2002 
Database: EMBASE <1988 to present> 
 
Set Search Results
1 exp Rheumatoid Arthritis/ 38527
2 Interleukin 1 Receptor Blocking Agent/ or Interleukin 1 receptor 
antagonist.mp. 
3022
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3 exp Interleukin 1/ or interleukin 1.mp. 21123
4 (IL-1RA or IL 1RA).mp. 1619
5 exp Recombinant Interleukin 1 receptor blocking agent/ 196
6 anakinra.mp. 35
7 kineret.mp. 21
8 or/2-7 22483
9 1 and 8 1129
10 limit 9 to human 990
11 randomized controlled trial/ 67095
12 exp clinical trial/ 246318
13 exp controlled study/ 1425624
14 double blind procedure/ 44637
15 randomization/ 4695
16 placebo/ 58995
17 single blind procedure/ 3771
18 ((control$ adj (trial$ or stud$ or evaluation$ or experiment$).mp. 85364
19 ((singl$ or doubl$ or trebl$ or tripl$) adj5 (blind$ or mask$)).mp. 64321
20 placebo$ or matched communities or matched schools or matched 
populations).mp. 
97807
21 (comparison group$ or control group$).mp. 93788
22 (clinical trial$ or random$).mp. 417278
23 (quasiexperimental or quasi experimental or pseudo 
experimental).mp. 
813
24 matched pairs.mp. 1325
25 or/11-24 1734786
26 10 and 25 478
27 from 26 keep 1-478 478
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Appendix 6: List of included and excluded studies for effectiveness review. 
 
Citation Inclusion? 
 
Publication type and reason for exclusion /  
comment 
 
1 Cohen et al 2002160  Yes Abstract. Trial 0180 HAQ scores at numerous 
time points 
2 Bresnihan, McCabe et al 
2001161  
Yes Abstract. Trial 0560. Modified Sharp score 
3 Bresnihan, Chan et al 
2001162 
Yes Abstract. Trial 0560. Productivity  
4 Emery et al 2001163 Yes Abstract. Trial 0560. Subgroup analysis NHP data 
5 Cohen, Woolley et al 
2001164 
Yes Abstract. Trial 0180. HAQ component parts 
6 Jiang et al 2000158 Yes FP. Trial 0560. Genant sharp scores vs Larsens 
scores 
7 Cohen, Moreland 2001105 Yes Abstract. Trial 0145.  
8 Bresnihan et al 1998102 Yes FP. Trial 0560 
9 Cohen, Hurd et al 2002104 Yes FP. Trial 0180 
10 Fleishman, Tesser et al106 Yes Abstract. Trial 0757. Safety study 
11 Emery, Wolley et al 2001165  No Abstract. Data duplication 
12 Miller et al 2001166  No Abstract. Combined analysis of 2 separate trials 
13 Cravets et al 2001167  No Abstract. Post-hoc analysis of Larsen scores from 
trial 0560 using imputed data from bootstrapping 
14 Bresnihan 200126 No FP. Review 
15 Bresnihan 1999168 No FP. Review 
16 Bresnihan 1996169  No Abstract. Data duplication 
17 Bresnihan 2001170 No FP. Review 
18 Campion et al 1996171 No FP. No comparator arm 
19 Cunnane et al 2001172 No FP. Not an RCT, endpoints not appropriate 
20 Snaith 2002173 No Abstract. Open label extension, insufficient details 
to identify study 
21 Cohen, Hurd et al 1999174 No Abstract. Data duplication from trial 0180 
22 Cunnane et al 1996175 No Abstract. Data duplication. Subgroup analysis, 
endpoint not appropriate  
23 Cunnane et al 1998176 No Abstract. Data duplication. Subgroup analysis, 
endpoint not appropriate  
24 Dayer, Bresnihan 2002177 No FP. Review 
25 Jiang et al 2001178 No Abstract. Data duplication 
26 Jiang et al 1998179 No Abstract. Data duplication 
27 Genant 2001180 No FP. Data duplication 
28 Lebsack et al 199297 No Abstract. Pharmacokinetic study 
29 Nuki et al 1997181 No Abstract. Non comparative extension of trial 0560 
30 Schiff 2000182 No FP. Review 
31 Watt, Cobby 2001183 No FP. Duplicate data 
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Citation Inclusion? 
 
Publication type and reason for exclusion /  
comment 
 
32 Drevlow et al 1996184 No FP.IL-1 receptor type 1, not anakinra 
33 Bresnihan, Newmark et al 
2000185 
No Abstract. Non comparative extension of trial 0560 
& duplicate data 
34 Bresnihan, Chan et al 
2001186 
No Abstract. Duplicate data, & data on non 
comparative extension of trial 0560 
35 Caldwell et al 2001187 No Abstract. All treatment arms contained anakinra 
36 Cohen, Nakelsky et al 
2001188 
No Abstract. Not an RCT 
37 Nuki, Bresnihan et al 
2001189 
No Abstract. Non comparative extension of trial 0560 
38 Schiff et al 2001190 No Abstract. No comparator treatment arm 
39 Genant et al 2000191 No Abstract. Duplicate data, & data on non 
comparative extension of trial 0560 
40 Wallis et al 2002192 No Abstract. Review 
41 Wallis et al 2002193 No Abstract. Review & duplicate data 
42 Yang et al 2002194 No Abstract. Pharmacokinetic study 
43 Hochberg et al 2002131  No Abstract. Cost-minimisation study 
44 Brennan et al 2002132  No  Abstract. Preliminary economic evaluation 
45 Fleischmann et al 2002195 Yes Abstract. Subgroup analysis of trial 0757 
46 Fleischmann et al 2002196 No Abstract. Duplicate data trial 0757 
47 Schiff et al 2002197 No Abstract. Sub-group analysis & duplicate data for 
trial 0757 
48 Tesser et al 2002198 Yes Abstract. Subgroup analysis of trial 0757 
49 Fleischmann 2002199 No Abstract. Duplicate data trial 0757 
50 Rooney et al 2002200 No Abstract. Duplicate data 
51 Caldwell et al 2002201 No Abstract. Duplicate data 
52 Edwards et al 2002202 No Abstract. No control arm  
53 Andrias et al 2002203 No Abstract. Juvenile RA 
54 Schiff et al 2002204 No Abstract. Duplicate data 
55 Hochberg et al 2002205 No Abstract. Review 
56 Shergy et al 2002206 Yes Abstract. Trial 0145 one year endpoint data 
57 Shergy et al 2002112 No Abstract. Duplicate data. Trial 0145 one year 
endpoint data  
58 Cohen et al 2002207 No Abstract. Duplicate data 
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Appendix 7: Scoring Using Modified Drummond Checklist for Amgen Economic 
Evaluation 
Study design  
(1) The research question is stated Yes 
(2) The economic importance of the research question is stated Unclear 
(3) The viewpoint(s) of the analysis are clearly stated and justified Yes 
(4) The rationale for choosing the alternative programmes or interventions compared is 
stated 
Stated yes, but of 
questionable 
appropriateness 
(5) The alternatives being compared are clearly described Yes 
(6) The form of economic evaluation used is stated Yes 
(7) The choice of form of economic evaluation is justified in relation to the questions 
addressed 
Yes 
Data collection  
(8) The source(s) of effectiveness estimates used are stated Yes 
(9) Details of the design and results of effectiveness study are given (if based on a 
single study) 
Yes 
(10) Details of the method of synthesis or meta-analysis of estimates are given (if 
based on an overview of a number of effectiveness studies) 
Yes 
(11) The primary outcome measure(s) for the economic evaluation are clearly stated Yes 
(12) Methods to value health states and other benefits are stated Yes 
(13) Details of the subjects from whom valuations were obtained are given Yes 
(14) Productivity changes (if included) are reported separately N/A because of perspective 
(15) The relevance of productivity changes to the study question is discussed N/A 
(16) Quantities of resources are reported separately from their unit costs Unclear 
(17) Methods for the estimation of quantities and unit costs are described Yes 
(18) Currency and price data are recorded Yes 
(19) Details of currency of price adjustments for inflation or currency conversion are 
given 
N/A 
(20) Details of any model used are given Yes 
(21) The choice of model used and the key parameters on which it is based are 
justified 
Authors outline their 
reasons but we think these 
are not justified (see text) 
Analysis and interpretation of results  
(22) Time horizon of costs and benefits is stated Yes 
(23) The discount rate(s) is stated Yes 
(24) The choice of rate(s) is justified Determined by NICE 
Guidance 
(25) An explanation is given if costs or benefits are not discounted N/A 
(26) Details of statistical tests and confidence intervals are given for stochastic data NO!  Transition 
probabilities are best 
estimates with no sampling 
variability explored. 
(27) The approach to sensitivity analysis is given Yes 
(28) The choice of variables for sensitivity analysis is justified No (see 26) 
(29) The ranges over which the variables are varied are stated Yes 
(30) Relevant alternatives are compared Only if interpreted as a last 
resort treatment 
(31) Incremental analysis is reported Yes 
(32) Major outcomes are presented in a disaggregated as well as aggregated form N/A, as model 
(33) The answer to the study question is given Yes 
(34) Conclusions follow from the data reported Not in our opinion 
(35) Conclusions are accompanied by the appropriate caveats Partially 
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Appendix 8: Base Case ICER Calculations 
 
Results with Anakinra “in the middle” 
 
Strategy 1A with etanercept(4,000,000 patients used) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 26088 6.5 5.119 0.0022 48.1 
no Ana 16611 4.4 5.103 0.0021 53.0 
difference 9477 7.8 0.016 0.0030  
ICER (£/QALY): 604 000 (436 000 – 985 000) 
 
Strategy 1B without etanercept (2,000,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 27075 9.2 6.178 0.0033 52.5 
no Ana 17429 6.3 6.153 0.0033 57.3 
difference 9647 11.1 0.025 0.0046  
ICER (£/QALY): 379 000 (278 000 – 597 000) 
 
Strategy 2A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 23498 13.1 4.109 0.0038 54.5 
no Ana 13859 9.2 4.084 0.0038 60.6 
difference 9639 16.0 0.025 0.0054  
ICER (£/QALY): 385 000 (270 000 – 674 000) 
 
Strategy 2B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 24353 13.3 4.947 0.0042 58.2 
no Ana 14510 9.4 4.912 0.0041 64.0 
difference 9843 16.3 0.035 0.0059  
ICER (£/QALY): 278 000 (209 000 – 415 000) 
 
 
 
Results with Anakinra last 
 
Strategy 1A with etanercept (200,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14171 24.0 3.149 0.0075 90.3 
no Ana 2662 3.4 3.061 0.0075 100 
difference 11508 24.3 0.088 0.0106  
ICER (£/QALY): 131 000 (106 000 – 173 000) 
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Strategy 1B without etanercept (400,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14523 17.2 3.840 0.0058 91.6 
no Ana 2841 2.5 3.729 0.0058 100 
difference 11682 17.3 0.111 0.0082  
ICER (£/QALY): 105 000 (92 000 – 124 000) 
 
Strategy 2A with etanercept (200,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14021 23.8 2.844 0.0071 89.8 
no Ana 2581 3.4 2.739 0.0071 100 
difference 11441 24.1 0.105 0.0100  
ICER (£/QALY): 109 000 (91 000 – 134 000) 
 
 
Strategy 2B without etanercept (200,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14293 24.1 3.447 0.0078 91.2 
no Ana 2742 3.5 3.337 0.0077 100 
difference 11551 24.3 0.109 0.0110  
ICER (£/QALY): 106 000 (88 000 – 132 000)  
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Appendix 9 : Senstivity analyses 
1. Time on anakinra 
The time on anakinra was based on a single time-point. As an alternative to the exponential 
distribution, we tried the lowest value (0.62) of the shape parameter a for any of the 
DMARDs in Table 15, page 74.  (This is the most favourable to anakinra.) To fit 23 % 
withdrawal at 24 weeks requires .02.4=b  The mean of the new distribution is 5.80 years, 
compared to 1.77 years in the base case. 
 
Results with Anakinra “in the middle” 
 
Strategy 1A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 34785 23.5 5.160 0.0043 40.9 
no Ana 16613 8.7 5.100 0.0043 53.0 
difference 18172 25.1 0.060 0.0061  
ICER (£/QALY): 301 000 (250 000 – 377 000) 
 
Strategy 1B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 36317 24.0 6.228 0.0047 45.3 
no Ana 17429 8.8 6.151 0.0046 57.3 
difference 18887 25.6 0.077 0.0066  
ICER (£/QALY): 245 000 (209 000 – 295 000) 
 
Strategy 2A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 32044 23.4 4.176 0.0039 46.2 
no Ana 13859 9.2 4.084 0.0038 60.6 
difference 18185 25.1 0.092 0.0054  
ICER (£/QALY): 198 000 (177 000 – 225 000) 
 
Strategy 2B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 33423 24.0 5.021 0.0042 50.0 
no Ana 14510 9.4 4.912 0.0041 64.0 
difference 18913 25.7 0.109 0.0059  
ICER (£/QALY): 174 000 (157 000 – 195 000) 
 
Results with anakinra last 
 
Strategy 1A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 24254 75.5 3.316 0.0108 77.0 
no Ana 2666 4.8 3.055 0.0105 100 
difference 21588 75.6 0.261 0.0151  
ICER (£/QALY): 83 000 (74 000 – 94 000) 
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Strategy 1B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 25086 77.5 4.002 0.0119 79.1 
no Ana 2844 4.9 3.741 0.0116 100 
difference 22243 77.7 0.261 0.0166  
ICER (£/QALY): 85 000 (76 000 – 98 000) 
 
Strategy 2A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 23725 73.9 2.967 0.0102 76.0 
no Ana 2577 4.8 2.729 0.0100 100 
difference 21148 74.0 0.238 0.0143  
ICER (£/QALY): 89 000 (79 000 – 101 000) 
 
Strategy 2B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 24635 76.3 3.600 0.0112 78.2 
no Ana 2736 4.9 3.328 0.0109 100 
difference 21899 76.5 0.272 0.0156  
ICER (£/QALY): 81 000 (72 000 – 91 000) 
 
2. Start and end effects 
 
In this analysis the one-off loss of QALYs at start and end of DMARDs was omitted. 
 
Results with Anakinra “in the middle” 
 
Strategy 1A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 26092 13.0 5.235 0.0043 48.1 
no Ana 16613 8.7 5.200 0.0043 53.0 
difference 9479 15.6 0.034 0.0061  
ICER (£/QALY): 277 000 (205 000 – 431 000) 
 
Strategy 1B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 27071 13.0 6.303 0.0047 52.6 
no Ana 17429 8.8 6.254 0.0046 57.3 
difference 9641 15.7 0.049 0.0066  
ICER (£/QALY): 199 000 (156 000 – 272 000) 
 
Strategy 2A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 23498 13.1 4.200 0.0038 54.5 
no Ana 13859 9.2 4.152 0.0038 60.6 
difference 9639 16.0 0.048 0.0054  
ICER (£/QALY): 201 000 (164 000 – 258 000) 
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Strategy 2B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 24353 13.3 5.041 0.0042 58.3 
no Ana 14510 9.4 4.981 0.0041 64.0 
difference 9843 16.3 0.059 0.0059  
ICER (£/QALY): 166 000 (138 000 – 206 000) 
 
 
 
Results with anakinra last 
 
Strategy 1A with etanercept (200,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14171 24.0 3.180 0.0075 90.3 
no Ana 2662 3.4 3.061 0.0075 100 
difference 11508 24.3 0.119 0.0106  
ICER (£/QALY): 97 000 (82 000 – 118 000)  
 
Strategy 1B without etanercept (200,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14515 24.3 3.857 0.0082 91.6 
no Ana 2838 3.5 3.725 0.0082 100 
difference 11677 24.5 0.132 0.0116  
ICER (£/QALY): 88 000 (75 000 – 107 000) 
 
Strategy 2A with etanercept (200,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14021 23.8 2.874 0.0071 89.8 
no Ana 2581 3.4 2.739 0.0071 100 
difference 11441 24.1 0.136 0.0100  
ICER (£/QALY): 84 000 (73 000 – 99 000) 
 
Strategy 2B without etanercept (200,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14293 24.1 3.478 0.0078 91.2 
no Ana 2742 3.5 3.337 0.0077 100 
difference 11551 24.3 0.140 0.0110  
ICER (£/QALY): 82 000 (71 000 – 98 000) 
 
 
3. Effectiveness of anakinra 
 
To see the effect of the benefit of anakinra on HAQ scores, we changed the HAQ 
improvement due to anakinra from 0.25 to 0.5. It is emphasised that there is no evidence to 
support this value: this is purely a “what if” analysis. 
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Results with Anakinra “in the middle” 
 
Strategy 1A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 26181 12.9 5.224 0.0043 48.2 
no Ana 16613 8.7 5.100 0.0043 53.0 
difference 9568 15.6 0.124 0.0061  
ICER (£/QALY): 77 000 (70 000 – 88 000) 
 
Strategy 1B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 27154 13.0 6.286 0.0047 52.7 
no Ana 17429 8.8 6.151 0.0046 57.3 
difference 9724 15.7 0.135 0.0066  
ICER (£/QALY): 72 000 (66 000 – 80 000) 
 
Strategy 2A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 23597 13.1 4.220 0.0038 54.7 
no Ana 13859 9.2 4.084 0.0038 60.6 
difference 9738 16.0 0.136 0.0054  
ICER (£/QALY): 72 000 (67 000 – 78 000) 
 
Strategy 2B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 24437 13.3 5.057 0.0042 58.5 
no Ana 14510 9.4 4.912 0.0041 64.0 
difference 9928 16.3 0.145 0.0059  
ICER (£/QALY): 68 000 (63 000 – 74 000) 
 
 
Results with anakinra last 
 
Strategy with etanercept (200,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14244 24.1 3.258 0.0075 90.9 
no Ana 2662 3.4 3.061 0.0075 100 
difference 11581 24.4 0.197 0.0106  
ICER (£/QALY): 59 000 (53 000 – 66 000) 
 
Strategy 1B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14531 34.2 3.930 0.0116 92.1 
no Ana 2844 4.9 3.741 0.0116 100 
difference 11687 34.6 0.188 0.0164  
ICER (£/QALY): 62 000 (53 000 – 75 000) 
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Strategy 2A with etanercept  (200,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14095 23.9 2.950 0.0071 90.3 
no Ana 2581 3.4 2.739 0.0071 100 
difference 11514 24.2 0.212 0.0100  
ICER (£/QALY): 54 000 (50 000 – 60 000) 
 
Strategy 2B without etanercept  (400,000 patients) 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 14369 17.1 3.545 0.0055 91.6 
no Ana 2745 2.4 3.340 0.0055 100 
difference 11625 17.3 0.206 0.0078  
ICER (£/QALY): 57 000 (53 000 – 61 000) 
 
 
4. Best case for anakinra 
 
Results with Anakinra “in the middle” 
  
Strategy 1A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 35071 23.6 5.573 0.0044 41.1 
no Ana 16613 8.7 5.200 0.0043 53.0 
difference 18459 25.2 0.372 0.0062  
ICER (£/QALY): 49 600 (48 000 – 51 300) 
 
Strategy 1B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 36580 24.1 6.652 0.0048 45.5 
no Ana 17429 8.8 6.254 0.0046 57.3 
difference 19150 25.7 0.398 0.0067  
ICER (£/QALY): 48 100 (46 600 – 49 800) 
 
Strategy 2A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 32347 23.5 4.557 0.0040 46.4 
no Ana 13859 9.2 4.152 0.0038 60.6 
difference 18488 25.3 0.405 0.0055  
ICER (£/QALY): 45 700 (44 500 – 47 000) 
 
Strategy 2B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 33693 24.1 5.412 0.0043 50.2 
no Ana 14510 9.4 4.981 0.0041 64.0 
difference 19183 25.9 0.430 0.0060  
ICER (£/QALY): 44 600 (43 400 – 45 800) 
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Results with anakinra last 
 
Strategy 1A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 24506 76.2 3.631 0.0112 77.7 
no Ana 2666 4.8 3.055 0.0105 100 
difference 21840 76.3 0.576 0.0154  
ICER (£/QALY): 37 900 (36 000 – 40 000) 
 
Strategy 1B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 25302 78.0 4.328 0.0122 79.7 
no Ana 2844 4.9 3.741 0.0116 100 
difference 22459 78.2 0.587 0.0168  
ICER (£/QALY): 38 300 (36 200 – 40 600) 
 
Strategy 2A with etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 24048 74.8 3.287 0.0106 76.7 
no Ana 2577 4.8 2.729 0.0100 100 
difference 21470 74.9 0.558 0.0146  
ICER (£/QALY): 38 400 (36 500 – 40 600) 
 
Strategy 2B without etanercept 
 Cost (£) Q.S.E. (£) QALYs Q.S.E. % Pall 
with Ana 24916 77.1 3.924 0.0115 78.8 
no Ana 2736 4.9 3.328 0.0109 100 
difference 22180 77.2 0.596 0.0159  
ICER (£/QALY): 37 200 (35 300 – 39 400)
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Appendix 10: Therapeutic approaches being investigated in RA 
A number of other therapeutic approaches in RA are currently being investigated many of 
these involve modulation of the cytokine network. These include receptor antagonists, 
soluble receptors and monoclonal antibodies to other cytokines eg IL-6 as well as the direct 
use of 'anti-inflammatory' cytokines eg IL-10 & IL-4, IL-11.21;208-210 
 
Further developments around TNF blockade are being actively investigated; D2E7 
(adalimumab) a fully humanised anti-TNFα monoclonal antibody and PEG sTNF-RI, a 
pegylated soluble p55 TNF receptor.211 Adalimumab has been submitted for a product licence 
in both the US and Europe.212 
 
Clinical trials of experimental IL-1Ra gene therapy in RA are also underway. The human IL-
1Ra gene is transferred to synovium by retro-viral vector. Clinical benefits in patients with 
RA are yet to be evaluated 213 
 
A novel biologic agent for the treatment of RA, CTLA4Ig, which is the first of a new class of 
drugs the ‘co-stimulation blockers’ is in phase 3 trials. This drug blocks T-cell activation and 
pro-inflammatory cytokine release. It is hoped that this drug will be launched in 2004214 
 
Other therapeutic targets being investigated are oral toleragen therapy, adhesion molecules,  
modulation of T cell activity, blockade of effector function, vaccination with T cell receptors, 
major histocompatibility complex antigens, autologous hematopoietic stem cell 
transplantation.209 
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